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ABSTRACT
Over the past few years, and with the tremendous advances in recombinant protein technology,
cytokines and other therapeutic proteins have emerged as a promising and effective strategy in
immunotherapy of cancer. As such, much of the current research has focused on many aspects of
developing new drug delivery systems which are capable of targeting and controlling the release of
cytokines for the treatment of cancer. Most of those efforts however were directed towards the systemic
administration ofcytokines which is often limited by side effects and the necessity to administer these
therapeutic proteins in a clinical setting. There are several reasons for the attractiveness of the regional
delivery approach ofcytokines in cancer therapy. It is generally recognized that loco-regional delivery
localizes the cytokines actions and activities into the vicinity of tumors, reducingthe dose required,
providing uniform delivery and can result in an improved therapeutic outcome with much less side
effects or toxicity. Different strategies have been utilized to deliver interleukin 2 (IL-2) to the tumor site
including gene therapy and polymeric drug delivery systems. Some of the polymeric delivery systems
investigated to date include liposomes, hydrogels and biodegradable microspheres made from
polylacticacid,polyglycolicacidandtheircopolymers.Anextensiveevaiuationofthedifferentdelivery
approaches utilized for IL-2 has been reviewed in chapter I. These delivery strategies have inherent
problem in maintaining the required therapeutic activity over time and/or in preserving their content of
the loadedIL-2 and lor maintaining its stability during their formulation techniques.
The main objective of our studies was to formulate a new biodegradable polymeric drug delivery
system capable of providing a constant and sustained IL-2 delivery rate. The new polymeric system will
be designed in a manner in which the IL-2 protein particles could be easily dispersed, into this
synthesized polymeric system, in a protein friendly formulation condition. This shall provide an
environment to maintain 1L-2 stability and activity while within the delivery device and prior to it being
released. On the other hand the release, which is undergone by utilizing the osmotic driven release
mechanism, shall facilitate complete release of the protein before the device eventually degrades and
becomes bioabsorbable. In addition, the use of a slowly hydrolysable copolymer would reduce or
eliminate the production of an acidic environment within the device until the vast majority of the loaded
protein is released, before any significant reduction in the mechanical properties of the biomaterial
occurs due to its hydrolysis.
These new polymeric biomaterials are based on the poly(diol-tricarballylate) (PDT)
photocrosslinked elastomers. The synthesis was carried out by the polycondensation reaction of
tricarballylic acid and alkylene diols, followed by acrylation and visible light photo-curing under
ambient temperature and solventless conditions, which is described in chapter 3. Chapter 4 describes the
in vitro evaluation of the osmotic-driven release mechanism by a release study using the papaverine
hydrochloride,asamodelforawatersolubledrug. Theexarninationsofinvitrocytotoxicity,invivo
biocompatibility and biodegradability were also conducted to assess the elastomers' biological
performance after long term contact with lung epithelial cell line and soft subcutaneous tissue of
Sprague-Dawley rats, the details of which is described in chapter 5. Eventually, different 1L-2 loaded
devices have been formed by homogenous distribution of the co-lyophilized 11-2 and
stabilizing/osmotic excipient particles throughout the acrylated prepolymer which is then
photocrosslinked. These experiments are described in chapter 6. The in vitro 1L-2 release studies in
phosphate buffer saline of pH 7.4 were undertaken to demonstrate the proposed osmotic mechanism and
to determine the time frame for the release. The activity of the released 1L-2 was also examined in vitro
using C57BU6 mouse cytotoxic T lymphocyte. Chapter 7 is devoted to "General Discussions and
Conclusions."
Overall, the results have shown that the prepared elastomers were rubbery and their mechanical
properties can be controlled through manipulations of the chain length of the diol used and the degree of
polymer acrylation. As well, the papaverine hydrochloride release rate, from 10% v/v loaded cylinder-
shaped matrices, was found to be dependent on the degree of macromer acrylation. Decreasing the
degree ofacrylation of the prepolymers resulted in reduction in the crosslinking density of the formed
elastomeric matrices. Furthermore, it was found that co-formulating papaverine hydrochloride with
trehalose increases the release rate without altering the linear nature of the drug release kinetics. The
results also have demonstrated that these elastomers, with different degrees ofacrylation, showed
promising non cytotoxicity results with MvlLu cells and received reasonably consistentresultsbetween
the two common cell viability assays (MTT and 3H-thymidine incorporation). The in vivo implantation
results showed that no macroscopic signs of inflammation or adverse tissue ceactions were observed at
implant retrieval sites. We have shown in vivo justification to confirm the potential of these elastomers
as soft-tissue friendly materials as well as the candidacy of these elastomers as biodegradable
biomaterials for long term application. We have also demonstrated that elastomer selection can be
tailored to achieve the desired implantation period and release rates. Promising results regarding
osmotic-drivencontrolled IL-2 release have been demonstrated via typical zero-orderreleasekinetics.
The increase in the device's surface area and the incorporation of trehalose in the loaded lyophilized
mixl\jte increased the IL-2 release rate. As well, it was shown that the decrease in the degree of
prepolymer acrylation of the prepared devices increased the IL-2 release rate. Cell based bioactivity
assay for IL-2 over a release period of28 days showed that the released IL-2 retained more than 94% of
its initial activity.
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ABSTRACT
Despite the fact that different administration routes and delivery systems have been used for
interleukin-2 (IL-2) delivery, little has been reported regarding the most efficient strategies used to
deliver IL-2 in a non-toxic, efficient, stable and safe manner. Systemic IL-2 administration has always
been associated with rapid clearance and severe toxicity as a result of its narrow therapeutic index.
Loco-regional IL-2 delivery however, is used to locaIizeIL-2 actions and activities into the vicinity of
tumors and can result in an improved therapeutic outcomewithmuchlesssideeffectsortoxicity. The
purposeofthischapteristoreportonthedifferentpropertiesandaspectsofIL-2,includingi15
mechanism of action, physicochemical properties, and structure which have an impact on the activity,
stability and formulation of IL-2 dosage forms and delivery systems. In addition, advantages and
limitationsofthecurrentlyavailabletechniquesandstrategiestodeliverIL-2willalso be covered.
1.1. BACKGROUND
Interleukin-2 (lL-2) is a cytokine messenger protein which activates parts of the immune system. It
is one of the members of the interleukins family that was discovered in early 1976.1 Although members
of this family are structurally similar, IL-2 demonstrated an extraordinary unique contribution to the
concept"~f immunotherapy as a whole and to cancer therapy in particular. IL-2 is particularly important
as it regulates both inflammatory and immune responses by stimulating the growth of blood cells in the
immune system.2 Many studies established IL-2 as the Iymphocytotropic cytokine responsible for
signaling helper T-Iymphocyte (CD4+ T-cell) proliferations.2,3 It was in 1983 that the immuno-
therapeuticpotentialofIL-2alone,withoutanyadoptivetransferofcytotoxicT-celis, was introduced in
thetreatmentofcancer.4
In comparison with other cytokines, IL-2 has been found to be more effective against many types of
tumors when it is administered alone. ' In addition to being an essential factor forthegrowthofT-cells,
IL-2 also enhances various T-cells and natural killer (NK) cell functions. IL-2 activates lymphokine-
activated killer (LAK) cells which have the ability to destroy tumor cells and improve the recovery of
immune function in certain immunodeficiency cases. Furthermore, IL-2 is considered to be the most
importantcytokine in the generationofmemoryT-cells, which are able to undergo secondaryexpansion
upon their second encounter to an antigen.6 Although IL-2 and interferon-a 2b in the early-1990swere
both approved by the United States Food and Drug Agency (FDA) for treatment of cance~·7, IL-2
proved to have more applications in the treatment of both hematological malignancies and immunogenic
tumors. In fact, IL-2 would offer an alternative approach to the traditional adoptive immunotherapy by
its use to stimulate lymphocytes to proliferate in vitro which will help the patient in avoiding the
exposure to humanantigens.8
Therapeutically, IL-2 has been reported to have applications in the treatment of a number of different
types of cancer diseases. These include but are not restricted to metastatic melanoma,9 kidney
carcinoma,1O lymphoma, II hepatocellular carcinoma,12 colorectal carcinoma,13 head and neck
carcinoma,14 bladder carcinoma,IS nasopharyngeal carcinoma,16 mesothelioma,17 gastrointestinal
cancer,l8ovariancarcinoma,19lungcancer,2omalignantpleuraIeffusions,2landbasaIcellcarcinoma.22
Table 1.1 summarizes some of clinical trials conducted to investigate the aforementioned applications of
IL-2:' -,
Also, IL-2 was found to be effective in experimental mice with surgical minimal residual tumor
disease after cancer resection surgery,23.240r the use ofchemotherapy.2S.26It was reported that short-term _
preoperative IL-2 immunotherapy abolishes postoperative immunodeficiency and can induce
immunological control of the growth of minimal residual disease.27 It can also inhibit the growth of
tumor residue and metastases in mice after chemotherapy with cyclophosphamide,2sifosfamide26 and
imiquinod.28
It was not until 1987 that IL-2 was fust approved by the FDA to be used alone or in combination
with LAK cells as an anticancer agent. This FDA approval was mainly for treatment of advanced
melanoma, advanced kidney cancer and as an adjuvant for vaccines.s Recombinant forms ofIL-2 are
now sold with different brand names such as Proleukinl>, Teceleukinl>, Ontakl>, Aldesleukinl> and
Interkingl>. Proleukinl> injection was the first IL-2 therapy approved by the FDA for patients with
metastatic melanoma in 1998.9Currently, and due to the fact that deficiency of functional IL-2 plays a
pivotal role in the pathogenesis of many chronic viral infections, IL-2 is under clinical trials for the
treatment of human immunodeficiency virus (HIV) and hepatitis C viral infections.29,Jo
Table 1.1 Therapeutic effects of free IL-2 on human cancer patients.
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• CR: complete regression, PR: partial regression, SD: stable disease, PD: progressive disease
II A1thoughIL-2 has been extensively investigated and approved for the use in the treatrnentofabroadrange of diseases, it still possesses many limitations and properties that restrict its full clinical use.
Systemic IL-2 therapy, which is the main route of administration, is reported to be complicated by life-
threatening toxicities some ofwhich are similar to those seen with other cytokines. Flu-likemalaise, low
blood pressure, fevers, nausea, vomiting, diarrhea, chills, swelling, weight gain, confusion, skin rashes,
andchangesinbloodchemistryarecommonlyseeninpatientsreceivingsystemiclL-2injections.31 In
additiontotheabovesideeffects,reversiblehepaticdysfunctioncharacterizedbyhyperbilirubinaemia
and "vascular leakage syndrome" which is an increase in the vascular penneability and a decrease in
vascular resistance, are considered two of the major complications resulting from the systemic IL-2
therapy which may result in hypotension and increase in the body weight of up to tenpercent due to
extravascuiarfluidaccumuiation.31 .J2
With the purpose of finding solutions to the aforementioned complications and limitations that
accompaniedlL-2 systemic administration, many researchers investigated alternate modes andstrategies
for delivering this cytokine with the goal of achieving less toxicity and optimal clinical outcome. In this
chapter, emphasis will be placed on the different means of optimizing the anticancer therapy oflL-2by
utilizing an understanding of its immunological action, structure, pharmacokinetics, and relating all of
this knowledge to the different strategies used in delivering this cytokine to its site of action.
1.2. MECHANISMS OF ACTION
Although most of the issues relating to how IL-2 exerts its effect are fairly clear, the exact cellular
mechanism of action oflL-2 is still not yet fully understood. Several theories were proposed on
explaining the cellular mechanism of IL_2,',33,34 however, the most acceptable theory today states that
IL-2 is taken by activated CD4+ T-cells which express IL-2 specific receptors.3l Those receptors are
reported to be composed of three subunits: IL-2 receptor alpha (IL-2Ra), beta (IL-2RP), and gamma (IL-
2Ry). The low-affinity alpha chain (CD25) is a unique and specific marker for the IL-2 receptor,
whereas the medium-affinity beta chain (CDI22) is common to both the IL-2 and IL-15 receptors, but
the high-affinity gamma chain (p64-CD132) is common to all cytokine receptors.36 The binding of IL-2
with IL-2R, beta and garnmachains in specific, is responsible for signal transduction through activation
of several signaling molecules such as Janus Kinase 3 (JAK 3),3' protein tyrosine kinases (pTK),38
signal transducers and activators of transcription 5 (STAT 5) protein,39 the mitogen-activated protein
kinase (MAPK)33 and phosphatidyl inositol3-kinase (pI3K) pathways.40
The generated signals from the subsequent interaction of IL-2 with its receptors then result in
alteration in cell behavior that was seen through five event signals: stimulation of tumor specific
act~te;!.. cytotoxic T-cells growth;41 generation and differentiation of LAK cell activity and
augmentation of NK cell mediated cytolysis of tumor cell;41 activation of the endothelium and up-
regulation of adhesion molecules on T-cells, which results in enhanced migration of T-cells to the
tumor; enhancement ofmajor histocompatibility complex (MHC) expression on tumor cells and antigen-
presenting cells; and proliferation of immunoglobulin in B-cells and cytotoxic macrophages.42 Figure
1.1 shows a representation of the proposed mechanism ofactionofIL-2.
All of the signals transmitted by IL-2provide the rationale for using this cytokineforthetreatment
of cancer. The mitogenic effect of IL-2 on T-cells, LAK and NK cells can provide the organ of tumor-
Figure 1.1 A proposed mechanism of action ofIL-2.
bearing individuals with an expanded pool of effector cells and the cytotoxic effect which isdirected
against malignant, but not normal cells in the body: I
1.3. PHYSICAL PROPERTIES AND STRUCTURE
The structure and the physicochemical properties ofIL-2 are important aspects in understanding the
function, activity and in designing the optimal thempeutic stmtegies and delivery systems for this
cytokine. IL-2 is a member ofa four-helical bundle family of proteins. Ithasastructure similar to that of
human growth hormone and has been reported to have an isoelectric point (PD of 7.9. It is susceptible to
deamidation of the aspamgine amino acid, at position 88 of its amino acid sequence, upon its stomgein
aqueous solutions (pH 5.0 at 25 0c) for periods exceeding two months. Thisdeamidation occurs ina
much accelerated fashion at 40°C compared to 25 °C but reported not to occur at tempemtures below 5
°C.43 The biologic activity of IL-2 is sensitive to acidic conditions as it forms a compact denatured state
atpHof2.l or lower with subsequent loss ofactivity.44.4s Furthermore, it is heat sensitive and undergoes
irreversible thermal denaturation and aggregation in solution at tempemture exceeding 44 0C.44- 46
Natural human IL-2 (hIL-2) is an amphipathic 15.5 kDa globular giycosylated protein with a various
degreeofglycosylation, as estimated from gel filtmtion. It is glycosylated at position 3 by the amino
acid threonine.47 Its primary structure is represented by 133 aminoacids,whichshowsnosignificant
homologies in the primary structure with other cytokines.48.49 Recombinant human IL-2 (rhIL-2), which
is produced by recombinant protein technology, maintains the native amino acid sequence andbiological
activity of hIL-2 but, as with many recombinant proteins, possesses some differences in its
glycosylation.Itisrecognizedthat,incontmsttothenaturailyoccurringhIL-2,rhIL-2Iackspartia1IY,or
completely, the carbohydmte moieties attached to its structure.so To improve the pharmacokinetic
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properties and the half-life ofrhIL-2, modification of this cytokine with various carbohydratemoieties
(glycosylation) was studied. As with many proteins, both degree ofglycosylation and the glycan moiety
used in its glycosylation have tremendous impact on the biological activity, hepatic metabolism, and
renal elimination of this cytokine.S2
The IL-2 molecule contains one intramolecular disulphide bridge, as determined by a combination of
peptide mapping and protein sequencing, linking between cysteine amino acids at positions 58 and 105.
Both of these cysteine residues and the presence of the critical disulphide bond are important for
maintaining the stability of the tertiary structure oflL-2 which is essential forthebiological activity of
IL_2.s2.s3 The carbohydrate moiety present in the structure oflL-2 molecules, added after translation of
the IL-2 gene, has no effect on its bioactivity, but has an increase in hydrodynamic size sufficient to
increase its systemic duration of action.54 1bis carbohydrate moiety represents the molecular
heterogeneity of natural IL-2, and it can be speculated that this moiety has some functions duringthe
intra-cellulartransport ofIL-2 molecules.54 The similarities in the structural and functional properties
suggest that IL-2 derived from humans, rats, mice and apes are anaJogous to each other and have similar
bioactivity. The only difference between human and murine IL-2 is a unique repeating of 12 consecutive
glutamineresiduesatN-terminalofmaturemurineIL-2.ss
Tl!e X-ray crystallographic analysis of the three dimensional structure of IL-2 molecules showed it
to be composed ofacompact bundle of four antiparallel a-helices with short hairpin loops between
helices and without any spatial correspondence between sequential helices (see Figurel.2for
reference).S51bis·suggests that one portion of these molecules forms a structural scaffold, which
underlies the receptor binding-facets of the molecules.s6 The receptorcontact sites have been localized
with the N-terminal and C-terminalportionofIL-2 molecules.55
Figure 1.2. Human IL-2 crystalline structure (reproduced from Ref. 55).
1.4. PHARMACOKINETICS
The rate and extent at which the maximum IL-2 concentration is reached in the bloodstream depends
mainly on its physicochemical properties (molecular weight, size, and degreeofglycosylation), the
dosage fonndesign, and its route of administration. As it is the case with all the other acid-sensitive
protein drugs, IL-2 faces many stability and physiological challengeswhengiven orally. This explains
the reason for it being mainly given by alternative routes of administration. For most patients, the
primary route of administration ofIL-2 is subcutaneous (sc) injections under the skin.57 Intravenous(iv)
injections, on the other hand, whether given as a bolus or in infusion form, 57 are more commonly used
for patients under close clinical monitoring as this is considered an intensive patient treatment that is
usually given in intensive care units. Other less traditional delivery routes used to administer IL-2
include: intrapleural,5s intrathecal,59 intraventricular,60 intravesicular,15 intrasplenical (is),62
intralesional63 intraeranial,64 intrahepatic7andby inhaIation.65 Oependingon the route ofadministration
used, different concentrations at the tumor site were usually obtained with the highest being always
achieved after localized injections ofIL-2, which also proved to result in complete tumoreradication.66-
Following ivadministration, thepharmacokinetic profile ofrhIL-2 is characterized by high piasma
concentrations that decline in a bi-modal exponential fonn. The initial elimination phase of IL-2, which
is mainly due to extraeellular-distribution and renal elimination was reported to have a plasmabalf-life
(tll2) of7-14 minutes.57.66 The second phase of elimination, which is attributed solely to excretion via the
kidneys,isslowerandwasestimatedtohaveatenninalplasmatll2of85minutes.66Itiswell established
that more than 80% of the amount of IL-2, which is cleared from the circulation and presented to the
kidney, is metabolized to amino acids in the cells lining the proximal convolutedtubules.69 The initial
volume of distribution (Vj) ofrhIL-2 in mice following iv bolus injection of 500 I1g1kgwas reported to
be39rnl/kg while its steady state volume of distribution (V,,) is 87 rnl/kg with an area under the curve
(AUC) of I.51h111g1m1 and a clearance rate of330 mllh/kg.70 Similarly, continuous six-hour iv or ip
infusionofIL-2 resulted in detectable steady state serum levels after two hours foilowed by a rapid drop
in the plasma level when the drug infusion stopped.66 With respect to im injections of IL-2, it was
reportedthatsuchadministrationroutesresultedinplasmalevelsthataretypicallylOtolOOtimes lower
than those obtained following iv injections but with a more extended effect. On the otherhand,whenIL-
2 was administered subcutaneously, it was detectable in the plasma within fifteen minutes and achieved
a half-life of 2.4 hours and a 100 % bioavailability relative to iv dosing.69 It was also demonstrated that
the presence of soluble IL-2 receptor decreases the AUC of IL-2 in patients with metastatic renal cell
carcinoma.7I Therefore, the sc route of administration was looked at being more preferred over iv
injections since sc injections form depots in the subcutaneous tissues and result in sustained released IL-
2 concentrations which are sufficient to bind to more than half of the high-affinity IL-2Rs that are
expressed by antigenactivatedT-andNK cells.7o
AnotherparameterthatmighthaveanimpactonthepharmacokineticsofIL-2administrationbythe
systemic route is the plasma level of soluble IL-2Rs preceding the treatment. Clinical studies showed
that soluble IL-2Rs in tumor-bearing patients is 3- 8 folds higher than in normal individuals (1315 U /00
in which each 3U is equivalent to I pg of purified protein).n The a chain is thought to be released from
the cell membrane of activated T cells by proteolytic cleavage. The presence of the soluble IL-2Ra is
therefore thought to reflect the state ofT cell activation in this patient's population.7J As such, the
failure to saturate all the soluble plasma IL-2Rs could be the reason for variations in the bioavailability
of IL-2. Although there are no studies that report on the effect of these soluble receptors on the
distribution and other pharmacokinetics parameters ofIL-2, the high affinity oflL-2 to the soluble IL-
2Rs will decrease the amount oflL-2 which reaches the interstitial fluid in the relevant tissue site.n.74
During systemic administrationofrhiL-2 in humans, elevated soluble IL-2 receptor levels havebeen
found. 7s The soluble IL-2Rs differs from its membrane-bound counterpart with respect to size, binding
capacity and ligand specificity. The soluble form of the human IL-2 receptor is a glycosylated protein
with a molecular weight between 35 and 50 kDa.76 It binds to IL-2 with low affinity (Kd: 10 nmoVL)
which is comparable with the affinity to the membrane bound a-chain of the IL-2 receptor? The a-chain
is expressed on activated Tcellswhichcombineswiththe~-and'Y-chainstoconstituteahigh-affinity
IL-2R with a lOOO-fold higher affinity to IL-2 than presented by the soluble IL-2Rs .77-80 It has been
hypothesized that the competition between the membrane-bound and the soluble receptor for IL-2
causes inhibitionoflL-2 dependent mechanisms. So far, no data are available on the exactinfluenceof
slL-2Ron IL-2 pharmacokinetics.
The preceding discussion illustrates that systemic administration of IL-2 results in unequal and
unpredictable distribution and rapid clearance from the body. As such, smaller amounts will reach the
tumor cells. Inaddition,thepresenceoftheendogenoussolubleIL-2Rsadversely afi'ects the amount of
IL-2thatis free and penetrates the tissues and the organs.71 Also, toobtainlL-2 in concentrations high
enoug!l to saturate those high-affinity soluble receptors, at least 20 mgoflL-2 must beadministered,n
as the total extra-cellularspace in a normal adult is approximately 14 liters. This relative large dose is
enough to evoke all thelL-2 systemic side effects.
1.5. LOCO-REGIONAL VERSUS SYSTEMIC DELIVERY
Although systemic injections (iv, im,and ip) are reported to be the most commonly used routesfor
delivering 1L-2 when used in cancer immunotherapy,31.62 the intratumoral and loco-regional
administration strategies of this cytokine have been reported to be more successful and demonstrate
much effectiveness against a broad range of cancers, specifically those associated with solidtumors.82
This mode ofIL-2 administration provides many advantages over systemic administration. First, local
1L-2 adrninistrationmore often involves the use of lower doses, which results in the absence of the
major side effects and toxicities that usually accompany the use of systemic adrninistration.67 Second,
localized tumors that are resistant to chemotherapy and irradiation, such as tumors located inthehead
and neck regions, brain tumors, breast tumors and urinary bladder carcinomas, can be efficiently
eradicated by loco-regional 1L-2 immunotherapy.83.84 Similarly, tumors which are often localized close
to body surfaces and are not amenable to surgery or conventional therapy, such as malignant melanoma,
couldbesuccessfuilytreatedwithlocalIL-2adrninistration.8s Third,loco-regionaideliveryofIL-2
simulates its normal physiologica1 paracrine release pattern and results in less unequal and unpredictable
distribution of1L-2 throughout the body tissues and fluids that are usually common in systemic
injections. In this manner, side effects and toxicity will decrease tremendously.86.87 It is well known that
systemically injected1L-2 creates a response that follows the endocrine release pattern ofcytokines
which usually occurs in response to immune stimulation in which the cytokine diffuses out of the
microenvironment to the blood stream where it becomes highly diluted and rapidly eliminated from the
body.66Furthermore,dosetolerabilityfollowingsystemicadministrationofhighdosesofIL-2therapyis
a well~ported phenomenon where the response rate ofIL-2 may decrease down to 10% less than that of
the most frequently applied doseS.88.89 1bis has typica1lyresulted in a subsequent gradual increaseofIL-
2 dosing regimen during the maintenance therapy, with a significant increase inthesystemictoxicity.
Fourth,althoughthe regional andintratumoral IL-2 administrations will result in limited diffusion of the
IL-2 into the blood stream, nevertheless, the immune cells (T and NK cells) after being stimulated
locally (in the microenvironment) by IL-2 would diffuse through the extracellular fluids to neighboring
cells in the surrounding region and also travel in the circulation, producing defensive mechanisms
against other tumors without the need for the cytokine itself to circulate.90 Additionally, it was also
fouiid thiilthe systemic deliveryoflL-2 to patients with malignant tumors in the central nervoussystem,
such as tumor in the spinal cord, the cerebrum, the cerebellum, and the brain stem, was not effective as
IL-2 was unable to cross the blood brain barrier.56 Finally, local delivery sustains the immune effect and
prolongs the half-life of the injected IL-2 in the area of the growing tumor as well as in the circulation.91
The effect of local IL-2 therapy was reported to be through the induction of local massive edema in
the vicinity of the tumor cells. 1his edema is due to the induced vascular leakage and causes extensive
tumor necrosis owing to the accompanied interstitial pressure that causes collapse 0 fcapillariesand
difficulties of nutrients and oxygen reaching tumorcells.92 In addition, local IL-2 inducesangiogenesis
in the normal connective tissue around the tumor, allowing infiltration of leukocytes (mainly
macrophages). The infiltrating macrophages will form granulomatous lesions at the site of the tumor and
willultimatelyresolvethetumor.93
Various studies have been aimed at investigating the effectiveness and safety of loco-regional
deliveryoflL-2 and other similar cytokines. One of the first studies on the therapeutic efficacy and
safetyoflocaladministrationofIL-2incancertherapywasreportedinI983.Bubeniketa/.,showedthat
peritumoral IL-2 injections could inhibit the growth of the experimentally induced fibrosarcoma tumors
inpreclinicalBIO male mice models: In this study, groups of3-month-old mice receiveddosesof5x
104 MCII tumor ceUs sc at day 0 and were then given either repeated injections of IL-2-containing
supernatants from rat spleen cultures or control preparations in 0.5 mI amounts of medium at days I, 3,
5,7,9, II, 13, 15, 17, and 19. The injections were given subcutaneously around the site of the tumor
inoculum. Treatment of tumor-bearing mice with IL-2 preparations differing in the concentration ofIL-2
revealed that IL-2 concentrations higher than I Ulmi were necessary to produce a significant tumor-
inhibitory effect. It was also concluded that the tumor-inhibitory effects were dependent on the
concentrationofIL-2andtherepeatedinjectionsofthesupernatants. This study represented one of the
first few preclinical attempts in the therapeutic utilization of local IL-2 alone, without being
acC;;inp~edbytheadoptivetransferofcytotoxicT-ceUsinthetreatmentofcancer.Furtherevidence
for the efficacy of local IL-2 administration has been provided by the positive results of the preliminary
clinical trials that were conducted using local administration ofIL-2.
Pizzaetal., found that repeated intratumoral injections of 1969-4046 Uofbovine IL-2 over 7-54
days lead to almost complete regression of the urinary bladder carcinoma.89 They concluded that the
dose-dependent antitumor immunological effects were mediated by IL-2 activity alone and not
dependent on the level of foreign bovine protein contained in the preparation. Also, itwas concluded
that in none of the patients treated were any early or late adverse clinical side effects observed. In
anotherstudy,Yasumotoetal.,carriedoutaninvestigationontheeffectofintrapleuraIadministrationof
rhIL-2 in II patients suffering from malignant pleurisy due to solid tumors in their lungs.2o The 6
patients who were subjected to surgical resection of the primary tumor were given IL-2. Clinically,
malignantcellsinthepieuraIeffusiondisappearedin90fli patients4to 10 days after the start of the
treatment. Recent studies conducted by Caporale etal., on rats also demonstrated the efficacy of loco-
regional IL-2 therapy in colon carcinoma.94 Furthermore, promising results were reported with many
other studies that investigated the advantages of loco-regional IL-2 over its systemic administration
includingbutnotrestrictedtointralperi-lesionallocalinjection,9I,95 intra-cavityinfusiOn,96 intra-vesicle
administration97 and inhalation,65 all of which suggest that local IL-2 therapy is more effectiveinraising
an antitumor action against transplanted tumor, as well as spontaneous tumor of various origin and
immunogenicity, than any systemic applications,98 Tables 1.2 and 1.3 list more details regarding pre-
clinical and clinical studies conducted in that regard including those discussed above,
In addition to the above, local IL-2 therapy was always superior to the systemic treatment in all the
studies in which a direct comparison was made between systemic and local treatment.95-97 Also, it was
reported that in some cases, local IL-2 was even more effective in treating distant tumors than systemic
administration of the cytokine,95,99,looJacobsetal.,recentlyconcludedthat local IL-2 is more effective
~s;;emic application in patients with nasopharyngeal carcinomal6 The researchers combined
standard irradiation therapy with local IL-2therapy. During the 5 years of the study, the resultsrevealed
that 63 % of the patients showed a disease free survival; whereas no response was observed with chiet
al., who applied single modality systemic IL-2 therapy,lOI
It can be concluded from the above discussion that local IL-2 administration restores paracrine
pattern of release of IL-2 upon lymphocytes stimulation rather than simulating its endocrine release
pattern under immune stress or stimuli. As well, the regional mode of administration of IL-2 and the
limited diffusion ofthisparacrine IL-2 to blood strearn would minimize the exposure of many othercell
and organs that do not need to be switched to the immunostimulated state. In this manner, side effects
and toxicity would be decreased. It has also been observed that lymphatic cells and other cytokine
activated by IL-2 locally would travel in the circulation, producing defensive mechanisms, without the
Table 1.2. Summary of representative pre-clinical animal studies demonstrating the efficacy and toxicity
of using different routes ofadrninistration and dosing schedules ofIL-2.
Table 1.3. Summary of representative clinical studies demonstrating the efficacy and toxicity of using
different routes of administration and dosing scheduIes ofIL-2.
peri-Iesional
intrapleural
progressing
patients.
need for the IL-2 itself to ciroulate.99 In other words, the beneficial effect ofIL-2 administration is
consistentlymaximizedbylocalizeddelivery.Consequently,itcanbeconcludedthattherecentresults
suggest that the regional administration might provide the best strategy for IL-2 immunotherapy of
1.6. SUSTAINED (CONTINUOUS) VERSUS INTERMITTENT RELEASE
In view of the discussion above, the following questions come to mind: What is the maximum
concentration required in the local microenvironment? Do we need an intermittent or continuousrelease
ofIL-2? Although several recent studies described the application ofIL-2 and the superiority of its
regional delivery over its systemic administration in the treatment of different tumors,101.102 little has
been reported regarding the most efficient and least toxic mode of delivering this cytokine to its site of
action. It has been established in almost all reported cases that a single IL-2 injection, in whatever
manner local or systemic, is not sufficient for completing the tumor eradication and there is a
requirement for frequent repeated injections of IL_2. IOJ The already approved IL-2 cancer therapy
protocol requires a dosing schedule of intravenous administration every eight hours for five days,
followed by another five-day course after day nine. lo. In the same manner, the standard local
immunotherapywithIL-2 includes local injections for five consecutive days. Thisintermittent mode of
administration during treatment is characterized by relatively high frequency of dosing, whichrequiresa
healthcare professional and may be inconvenient to the patient. In addition, most of the tumor
localization strategies prevent repeated injections for technical and ethical reasons.67 In the meantime,a
simpler alternative continuous delivery strategy offers a better approach to maintaining the therapeutic
tissue level,avoidingthe imperfections of recurrent administration methodology. ObviousIY,itwilibea
great step forward if patients can be treated with only a single injection ofa slow delivery system, in
which IL-2 is gradually released during certain consecutive days, for maintaining a long-lasting
therapeutic level at the site of the growing tumor. lOS The important issue that should be addressedinthe
intermittent mode of administration is that the T-cells are exposed to a throb or wave of the deliveredIL-
2,whichis characterized by a time and concentration dependent decline in the action.106
ThismodeofIL-2deliverywasthefocusofresearchconductedbyOtterandhiscoworkers. 13 This
research group explored the consequent outcome of massive intermittentperitumoral IL-2 injection on
transplanted murine colon carcinoma. Although after four IL-2 injections more than 45% of the mice
were cured, it was perceived that there was a possibility of tumor re-growth while the IL-2level
declined. In another study, Da Pozzo et af., examined the toxicity and the immunologic effects of
localized prolonged infusions of low dose rIL-2 in dogs. 107 The results demonstrated that continuous
regional infusion with relatively low doses of IL-2 was able to stimulate peripheral blood LAK cells
effect. ThisstudynotonIyprovedthatcontinuouslocalizedadministrationisasafemethodofIL-2
delivery with the absence of major side effects, but also confirmed its higher ability to selectively
increase the number and activity of NK cells when compared to the intermittent mode. Additionally, a
study was done by Naito etaf., to examine the difference between intermittent and continuous delivery
ofIL-2 into tumor bearing mice. 106 In this study, they compared the antitumor effect of continuous
infusion (iv, ipand is) versus a single daily dose of the sarne injection route. The results manifested that
for all routes of administration, continuous infusion prolonged host survival, and was vastly superior in
anililu= efficacy than bolus doses. They also reported that uninterrupted IL-2 concentration at the
tumor site had augmented the CD8+ T-cell inductiOn. I06 Many other studies aimed at studying the
advantages of sustained release of IL-2 including the use of minimum osmotic pumps,108 liposomal
formuiations lO9 and polymer based release systems have been conducted. 110 Ail these studies concluded
non-tumor or non-infected tissues are exposed upon administering this potent cytokine. Currently,
the therapeutic outcome, in extending its half-life in plasma and in decreasing the amount to which other
that the continuous delivery represented the method of choice as it enhances lL-2 efficiency in
immunotherapy against the tumor by increasing the mean residence time (MRT) of the lL-2 and
decreases the number of injections.
Based on the discussion just presented, it can be concluded that maintaining localized lL-2 doseata
low and continuous ievel in the tumor vicinity is important, as it results in avoiding side effects which
accompany intennittenthigh lL-2 dosing regimen, preventing the cytokine level at the tumor site from
fluctuation, augmenting the antitumor immuno-stimulatory performance of this cytokine and increasing
the patient compliance.
1.7. DELIVERY SYSTEMS AND DOSAGE FORMS: ADVANTAGES AND
LIMITATIONS
Since its discovery in 1976, different delivery systerns and strategies have been exploredto
formulate and deliver lL-2 while at the same time trying to achieve two major goals. The first is to
deliver and target lL-2 specifically and safely to its site of action to maximize its therapeuticefficacy
while minimizing its toxicity. The other is to overcome stability issues during the preparation of dosage
forms containing this cytokine, and to help in maintaining its stability during storage of the dosage form
and after administration to the body. Work in this area is ongoing.
With respect to IL-2, which is acid sensitive and which possesses other stability problerns, early
studM:sfQcused mainly on achieving a localized and/or sustained/controlled release to help in increasing
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studies concerning how efficient the methods and strategies used to formulate IL-2 to achieve the two
mentioned goals are running in parallel with efforts to use it in the treatment of different neoplastic and
As with other protein therapeutics, administering IL-2 by the oral route has been a challenge and an
elusive target since its discovery. The major barriers in developing oral formulations for IL-2 include but
are not restricted to poor intrinsic permeability, luminal and cellular enzymatic degradation, rapid
clearance,andchemicalandconformationaiinstabilities. 111
Inspiteoftheobstaclesdescribedabove,manyresearchersattemptedtoinvestigate the use of the
oral route for IL-2 delivery. For example, Koren and Fleischmann studied the myelosuppressive effect
of IL-2 orally administered to mice. I 12 They demonstrated that oral administration of IL-2 was shown to
exert systemic effects by suppressing both the peripheral white blood cell counts andthebonemarrowin
a dose-dependent manner. Those observations suggested that the induction of systemic effects by orally
administered cytokines may be a general phenomenon. Moreover, Tothetal.,reportedadoubleblind
study in which they evaluated the effect of orally administered IL-2 on the hematologicalvariablesin
feline leukemia-positive cats. 1I3 Their results revealed that oral administration of 400 IV of rIL-2
decreased the mean corpuscular hemoglobin concentration after 7 days in cats which returned to the
control level by 14 days. Other researchers have also demonstrated that IL-2 delivered to the oral cavity
can transfer signals through the mucus membranes and as such induced systemic responses. I 14
In spite of the above encouraging results, conventional approaches to address those barriersfacing
IL-2 oral delivery, which have been workable with traditional, small, organic drug molecules, have not
readily fully translated into effective IL-2 formulations yet As such, the development of a clinically
effective and approved oral formulation of IL-2 is still something to be materialized. Currently, the
researchconductedtoovercometheobstaclesfortheabsorptionofIL-2fromthe gastrointestinal tract
includes the co-administration of enzyme inhibitors and/or absorption enhancers, the encapsulation in
liposomes,micro-emulsions,theuseofbiodegradablemucoadhesivenanoparticles,andthemodification
of the cytokine structure through the attachment ofchemical moieties. I IS
Among the other systems which are extensively investigated for delivering IL-2 are inhalers.
Administering IL-2 via pulmonary inhalation is currently receiving enormous attention due to its
applications in both regional and systemicIL-2 delivery in cancer therapy. Potentialadvantagesoftltis
delivery route for protein-containing drugs like IL-2 include a greater extent of absorption due to an
absorptive surface area of approximately 140 m2 and high volume of blood (5000 ml/min in the human
lung) flowing through the lungs which result in high IL-2 bioavailability.1I6 Lack of some form of
peptidaselprotease activity when compared with the gastrointestinal tract and lack of first-passhepatic
metabolism of absorbed compounds adds to the potential benefits of protein drug administration via
pulmonary inhalation.
A local immunotherapy using high-dose IL-2 inhalation therapy was clinically scheduled by Huland
et al., to 116 patients with metastatic renal cell carcinoma The results obtained throughout the duration
of six years ofinhalatory IL-2 therapy concluded that progressive pulmonary metastases responded
dramatically in the 15 % of patients for a median of 15.5 months and were stabilized in 55% of patients
for a median of 6.6 months.6S Many other studies also reported the therapeutic potential and the
advantages ofinhalatory delivery of IL-2. 117·120
Based on the encouraging results obtained to date and the rapid advances being made in IL-2
inhalation therapy, it can be anticipated that additional fonnulation approaches such as the different
aspects of aerosol technology might be developed to this delivery technique in the near future. By
applying aerosol technique, we could achieve more unifonn distribution with greater extent of
penetration into the peripheral or the alveolar region of the lung. Although pulmonary deliveryisvery
attractive because of the large absorption area and avoidance of first-pass metabolism in the Iiver,goals
such as de~~e~tiveness,ease of use, and low cost, as well as dosage reproducibility, sustained drug
release, rapid tissue uptake, optimal targeting, and reduced side effects, are still ratherelusive. Also, the
relative inefficiency and volume limitations of inhalation delivery currently limit this approach to
molecules of relatively high potency like IL-2. Nevertheless, in light of the fast growing drug-delivery
market, the pharmaceutical industry and medical device companies seek technical solutionsto these
problems to meet the demands of investors, stockholders, healthcareproviders,andpatients.
In general, the delivery systems developed for IL-2 were divided into two main categories. The first
~tegoryaimedatincreasingIL-2therapeuticoutcomethroughextendingitshalf-life.1biscategory
includes but is not restricted to gene therapy,I22.123 liposomes,124.125 polymeric microspheres,126.64 thenno
responsive synthetic polymers,127 hydrogels,128 and biodegradable elastomericdevices. 132 It is important
to state here that the above used references are only representative citations for research work conducted
on those IL-2 delivery systems and do not constitute a comprehensive list of all the work done in that
area. In the following section, the advantages and limitations of each of these fonnulationstrategiesand
delivery systems will be examined individually. Table 1.4 lists more details regarding some of these
controlled/sustained delivery systems.
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Several approaches have been investigated to increase IL-2 plasma half-life by decreasing its body
clearance. One of those successful approaches is to increase the molecular weight ofIL-2 bybindingit
with PEG derivatives like monomethoxy polyethyleneglycol in a process named PEGylation. 130 The
addition of PEG molecule to IL-2 resulted in an increase in the hydrodynamic radius of IL-2 molecule,
which in tum decreased its glomerular filtration rate and reduced the renal clearance up to 130 fold in
comparison to the free non-PEGylated IL-2 molecule. 131 As well, the covalent attachment of PEG to IL-
2 proved to improve its water solubility, thermal and physical stability and protected it against
enzyrnaticdegradations.Onthenegativeside,althoughthisapproachsucceededinincreasingthehalf
life oflL-2 ~tI1~_~oodstream, the addition of this hydrophilic moiety to IL-2 resulted in a significant
decrease in IL-2 lipophilicity which leads to a decrease in its absorption via the lymphatic system and
subsequent reduction in its lymphatic concentration. In addition, IL-2 activity was found to be heavily
influenced in a harmful way by the degree and the site of its PEGylation. 132 Inconclusion, the use of
PEGylation technology to IL-2 allows the dosing interval to increase, resulting in improved patient
convenience and enhances quality of life. However, it rnight decrease the clinical effectivenessoflL-2
for the aforementioned reasons and could increase the level of undesirable side effects oflL-2 which is
related to the high and prolonged plasmaconcentration.13o Another approach to prolong IL-2 in vivo
half-life, in order to extend its therapeutic efficiency, was the genetic fusionoflL-2 molecule with
human serum albumin. An example of using this albumin fusion technology is "Albuleukin~' which is a
long-acting form of IL-2 approved for cancer. Albulekint' has the advantageous pharmacokinetics
properties of albumin and it can distribute between vascular and extravascular tissue of the body.69 The
pharmacological andpharmacokinetic profiles of Albuleukint' following a single iv injection tornice
Table 1.4. Summary of the polymeric controlled/sustained release delivery systems used for IL-2.
Liposomes
Hydrogel.
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gelatin and diffusion and 80"10 within the 52 days not reported improved the Rhinesetal."
chondroitin sulphate degradation fl!St7days animal survival
was reported to have a longer plasma half-life than free IL-2 with activity exerted 0vera longer period
oftime.69 This continuous immuno-stimulation supports the antitumor effect oflL-2 and requires less
administrated doses for successful therapy.61.67 Similarly, IL-2 was fused with another human pro-
apoptotic protein with the name 'Bax'. This fused protein complex, "IL-2-Bax", provided more effective
elimination of the tumor and improved survival rate while less frequent administration than regular IL-2
therapy was needed. 110
Denileukin diftitox (Ontak*), was the first IL-2 fusion protein to be approved by the FDA for
therapeutic use. 133 It is a recombinant protein composed of the amino acid sequences for diphtheria toxin
followed by the sequences for IL-2. Ontak~ represents an example of a fused protein that targets cells
bearing high affinity IL-2 receptors internalized via receptor-mediated endocytosis in an acidified
vesicle. It is proteolytically cleaved within the endosome liberating the enzymatically active portion of
the diphtheria toxin. This diphtheria toxin fragment is released into the cytosol inhibiting the protein
synthesis and leading to malignant cell death.
In spite of the advantages seen from the above protein fusion technologies, however,
immunogenicity and formation ofantibodies is one of the major reported problems that were faced when
the used protein was obtained from biologically contaminated sources. In addition, the antitumor action
of this form ofIL-2 was only limited to highly perfused organs (liver, spleen, and lymph nodes) where it
was highly localized. 134
The use of IL-2 gene therapy has been extensively explored to obtain a sustained local IL-2
concentration to minimize its systemic toxicity, while retaining its immunobiological efficacy. The
transfectionofIL-2 gene into tumor cells, both in vitro and in vivo, had shown to produce a specific
immune response with reported tumor reduction. There are several molecular approaches for introducing
IL-2 gene directly into the tumor to allow local productions ofcytokines. These included the use of
tumor cells that have been genetically altered in vitro to secrete IL-2,13S.136 the use of adenovirus vectors
expressing IL_2,137.138 the use of plasmid DNAllipid complexes for the in vivo direct delivery of IL-2
cDNA into tumors139•140 and by using non-viral vectors like polymers and liposomes. 141 The possible
utility of the approach has been demonstrated in many clinical trials. In one study,142 a total of21
patientsreceived107 -109 plaqueformingunitsofintratumoraiinjectionsofaretroviralvector
containing IL-2 gene. Treatment was well tolerated with only minor adverse effects; however, only vey
low levels of IL-2 mRNA were detected in tumor biopsy samples taken from patients.
Gene therapy has potential; however, there are some unresolved issuesandproblems surrounding it.
First, it is reported that viral vectors could elicit immune reactions and acute toxicities resulting from the
infusion of the foreign materials; humoral immune responses against the gene products; and cellular
immune responses against the transduced cells.143.144 Besides, some of the integrating viral vectorsstill
have a potenua:ri1Sk of insertional mutagenesis. Also, it cannot be overlooked that two cases of death
have been previously reported inhuman gene therapy usingadenoviral andretroviral vectors. l44 Second,
as noted in the aforementioned example, in vivo transfection rates, particularly fortumorcells, are low.
This lowtransfection rate necessitates harvesting cells such as tumor infiltrating lymphocytesortumor
cells and treating them to express increasedcytokines. 14S The cell population is then established in vitro
and returned to the patient. Tumor cells are irradiated before being returned to the patient, to prevent
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reintroduction of replication competent tumor cells. 13S This process is labour intensive, and difficult to
achieve. Most human tumors are difficult to establish as in vitro cell lines, and extensivesubcloningand
in vitro replication might alter the original antigenic composition of the prirnary tumor. 108 Moreover, it
may take several months to transduce a tumor cell. Such patient-individualized therapy is therefore very
cost intensive. Finally, this approach is fraught with ethical issues.
Liposomal formulations have been extensively used by researchers for formulating IL-2 loaded
sustained-release delivery systems. As non-toxic and biodegradable carriers, liposomes can incorporate
IL-2 in its lipid bilayer. In many of these studies, IL-2 has been found to be efficiently incorporated
when formulated by using negatively charged liposomes.I46-ISO The results from those studies show that
IL-2 consistently adsorbs onto the surface ofliposomes, due to electrostatic interaction between the
positively charged IL-2 and the negatively charged liposomal components, and not in the aqueous
interior. As such, the encapsulation efficiency of IL-2 within the liposomal structure was always low
and was found to be influenced by the density of negatively charged lipid in the liposomes. Specifically,
it ranged from 25% for liposomes composed of egg phosphatidylcholine and 20% egg
phosphatidylglycerol or cholesteryl hemisuccinate to 80% for liposomes composed of egg
phosp~ati~ylcholine only.149 In one study conducted by Koppenhagen et 01.,149 although it was
concluded that no differences in the protein structure were observed using the circulardichroismscans
offreerIL-2 and rIL-2 adsorbed to the liposomepreparation,the in vitro activity assays demonstrated
that rIL-2lipOsOnies possessed only 47% activity when compared to free rIL-2. 146 Furthermore, the
release period of IL-2 from liposomal formulations were always short. For example, in a study
conducted by Neville et 01., ISO it was demonstrated that up to 60% ofthe total loaded rIL-2 was released
as a burst within the first two hours while all the rIL-2 was released from the liposomal preparations by
24 hr. lbis behavior has been noted with other proteins, such as interferon-gamma,l5I in which 75% of
the initially loadedcytokine was released within the first 8 hours.
Liposomes have the distinct advantage of easy administration by injection. However,theyalsohave
distinct disadvantages. As a result of short tenn stability, they produce relatively short drug release
durations necessitating additional painful injections, and release rates are neither sustained nor
controllable. Thus, they do not appear to be optimal for sustained, local delivery.
Hydrogels have also been used as carriers for localized and sustained release oflL-2 using polymers
from both natural and synthetic sources.IOl.Il2.IS4 For example, De Groot et al., developed IL-2-
containing macroscopic cylinder-shaped non-biodegradable methacrylated dextranhydrogelsbyredox
initiated polymerization reaction using potassium peroxy-disulfate. ll2 The in vitro release studies
showed that within the first 2 days, almost 30% of the encapsulated IL-2 was released withatotalof
40% released in the first 5 days. lbis5-dayreleaseprofilerevealedthatthishydrogelmightbeableto
mimic the current treatment protocol with free IL-2 for 5 consecutive days. Additionally, two months
following the intraperitoneal injection implantation of cylinders of this hydrogel (loadedwith5xl06 ru
IL-2) in experimental mice model with lymphosarcoma showed that 87.5 % of the treated mice (7 of the
8 mice) survived longer time than the control tumor mice and 62% cure rate (5 of8 mice) was
achie~d.~2
Hiemstra et al.• developed a PEG-(poly L-lactide) and PEG-(poly D-lactide) hydrogels in which the
rhlL-2 was loaded by mixing it with aqueous solutions of these copolymers. 101 The release of IL-2 from
thiscolloi~;;I;asconstantandsustained,andthetherapeuticeffectinthetreatmentoflymphorna
was retarded up to 2 weeks in comparison with free rhlL-2. The zero order release kinetics and
effectiveness of the released IL-2 indicated that PEG-lactate hydrogels was a promising platform for
sustained delivery of IL-2. A more recent study was conducted by Qiao and coworkers to demonstrate
the feasibility of long term sustained-release of IL-2 from injectable thermosensitive hydrogels
synthesized by bulk copolymerization of DL-lactide, glycolide and PEGl500 (see Table 1.4 for
details).155
As seen from the aforementioned examples, the advantages of hydrogels as delivery vehicles are that
they areas soft as body tissue, and thus are considered to be very biocompatible and can be designed to
be biodegradable.105.128.152 However, they possess few limitations. First, for most protein drugs,
hydrogels possess drug stability issues with storage because of the presence ofalarge degree of water in
the device; second, hydrogelsmade from natural materials like collagen and gelatin are frequently
immunogenicl56.157 and are more difficult to manipulate or process than synthetic polymers; Finally,
hydrogelsmade from natural materials like dextran are typically characterized by weaknessintheir
mechanical properties, batch-to-batch variations and the release rate was not controlled.
On the other hand, although hydrogels made from synthetic polymers can be reproducibly and
reliably manufactured, their chemical modifications can be easily made to tailor their properties and
mechanical strengths to a specific application, and their sterilization is often easier. They possess few
lirnitations.First,manyofthosepreparedhydrogelsareeithernotbiodegradableorpossess very low
biodegradability and so a surgical removal step would be required; Second, as seen in the
aforementioned examples in the above discussion, the constant release achieved was always short with
high percentage of release achieved in the first few hours or days; Third, in chemically crosslinked
hydrogels formulation, crosslinking agents are needed, which most often are toxic and may damage the
incorporated proteins andpeptides. On the other side, physically crosslinked hydrogels depending on
hydrophilic interactionlSS may also lead to denaturation of the loadedcytokine.
Polymeric microsphereslnanospheres have also been developed which are designed to deliver
constant amounts of encapsulated 1L-2 in a controlled and/or sustained manner. Such formulations
provide-one of the most promising localized delivery systems for cytokines to tumors. The
microsphereslnanospheres are reported to be typically made from a biodegradable polymeric material
like polylactide-co-g1ycolide (pLG),IS8.IS9 polylacticacid (PLA),I60.161 chitosan,l62 a1ginatelchitosan,l63
dextran,I64.16S andgelatin!chondroitin-6-sulfate.64.166
Microspheres made from PLG and PLA in which 1L-2 is loaded as discrete solid particles typically
release the drug in three phases: an initial burst; diffusion controlled release; anderosioncontrolled
release. The initial burst is due to protein particles adsorbed onto the microsphere surface, while the
diffusion controlled release is a result of dissolved protein diffusing through the water-filled pores and
channels within the microspheres.167.168 To obtain a constant release rate from PLG or PLA
microspheres, the diffusion phase must overlap with the erosion release phase such that new pores or
channels are created. Polymeric microspheres have the advantages of not only providing a constant
release, but of being easily injected to the target site, providing a long term release duration,consisting
of proven biocompatible materials, having a reasonable shelf-life and degrading to completely
bioresorbable compounds. They thus appear to be a very promising formulation.
The main problem with PLG and PLA microspheres is maintenance of protein stability. The activity
of a protein molecule is determined by its conformation in solution. Proteins are susceptible to
aggregation, denaturation and adsorption at interfaces, deamidation, isomerization, cleavage,oxidation,
thiol disulfide exchange, and p elimination in aqueous solutions. The major factors affecting these
changes are mechanical forces such as shear, the presence ofsurfactants, buffers, ionicstrength,the
presence of oxidizers such as ions, radicals and peroxide, light, pH and temperature. Thus, protein
denaturation and aggregation rnay result in a loss of potency and the conforrnation changes in the protein
molecule may make the protein immunogenic. 169
As It is the case with protein drugs, IL-2 possesses a number of stability problems. Firstly, IL-2 is
susceptible to loss of activity under acidic conditions due to the disruption 0 fthe cysteine bond integrity,
which is the key to IL-2 activity as a result of protonation. Loss of cysteine bonding has been correlated
to activity loss of at least 50%.13,170 Furthermore, at low pH, unfolding takes place for IL-2 resulting in
the formation of compact denaturated hydrophobic clusters that facilitate the aggregation ofprotein.46
Various means of stabilizing proteins in solution have beendeterrnined. These include the addition of
compounds such as polyols, inorganic salts, and amino acids. l7I
The problems of using the PLG rnicrosphere formulation involve both acidic protein degradation,
and denaturation at an organic solvent-water interface. The bulk erosion characteristics of this polymeric
system can allow water infiltration and swelling in the matrix prior to release. This will result in the
accumulation of the carboxylic acid based monomers and oligomers (lactic acid and glycolic acid) in the
core of the PLG rnicrospheres which has been found to decrease the pH in the pores and channels of the
device to as low as 1.5. 172 As explained above, at this pH, IL-2 is certain to lose the majority of its
activity. In addition, IL-2-loaded rnicrospheres are typically prepared using a water-in oil-in water
(w/o/w) emulsification procedure in which the protein is dissolved in the aqueous phase.
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preparation procedure has also been found to result in protein denaturation due to the contactofthe
protein with the polymer solvent at the solvent-water interface. 159.173
There are few reports in which IL-2 has been incorporated in PLG and PLA microspheres and its
activity after release studied.15s.161 Sharma etal. l60 used phase inversion encapsulation to loadIL-2 into
PLA. They demonstrated that PLA nanospheres are able to release IL-2 for 30 days with 25% released
between days 1-3. They also reported that the bioactivity of day I rIL-2 released samples (post-release
activity) was only 40%. In a similar approach, Egi/mez et al., also loaded rIL-2 into PLA nanospheres.161
They demonstrated an encapsulation efficiency of 7I% and release of 22% within the first 3 days. The
totJifrIf-2 release process lasted for 7 days and the composite bioactivity of all rIL-2 released was
approximately 50%.
Thomas et al.,159 reported the use of double emulsion (DE) and single emulsion (SE) methods to
prepare PLG (50/50) based microspheres. Both microsphere systems demonstrated sustained release
behavior over a period of almost 30 days. The SE prepared particles showed a 10-15% burst in the initial
36hoursfollowedbyaslowerlinearreleaseratethatlastedthroughdayfive.Subsequently,therewasa
phase of induction followed by another period of release. The DE prepared spheres exhibited a similar
overall time course of release, although the magnitude was larger in terms of the percentage of total
content released. Both SE and DE prepared microspheres demonstrated reduction in activity over the
delivery period. The bioactivity of IL-2 released from microspheres prepared by DE was around 80% for
the first 5 days, and then rapidly dropped to less than 40% by day 10. On the other hand, the bioactivity
of IL-2 released from microspheres prepared by SE was around 85% for the frrst 4 days, and then
rapidly dropped to less than 50% by day 7. Thus maintaining the stability of IL-2 within PLG
microspheres is still a problem. This stability problem may be overcome by changing the design of the
microspheres surface geometry to permit the complete release oflL-2 via diffusion beforesignificant
degradation takes place. One possibility of doing so is through the use of microporous microspheres
wherein the cytokine is loaded completely into the pore and not surrounded by polymer. IL-2 release
would then proceed via diffusion through the tortuous channels, which may proceed ata faster rate than
polymer degradation. 17• A study to demonstrate this concept was conducted by Hora el a/.,ISS They
reported that PLG microspheres only delivers very limited amounts of the encapsulated PEG-IL-2 daily.
However when IL-2 was co-encapsulated with human serum albumin in the same polymer, an initial
burst of 8-10% was observed with an increase in release rate oflL-2 to about 2-3% per day ina
bioactive form continuously over a 20- to 30-day period. This was mainly attributed to the porous
structure formed upon using human serum albumin with PLG.
Alternatively, a different release mechanism could be employed. It has been demonstrated that a
constant drug release rate is achievable from a rubbery polymer matrix in which the drug is distributed
as discrete particles. Due to osmotic water penetration, ruptures occur in the polymer and dissolved drug
solution is forced out of the device. 17S.176 Accomplishing this type of release mechanism with
microspheresusingnovelelastomericmaterialsiscurrentlyunderinvestigation.177
In an attempt to avoid the harsh effect on IL-2's stability and bioactivity caused by using organic
solvents in the preparation of IL-2 microspheres, other aqueous-based polymers and preparation
methods were introduced. IL-2 loaded dextranl64.16s and gelatin-chondroitin-6-sulphate based
microspheres64.166 are typical examples of such microsphere formulations.
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The use and tissue reaction of subcutaneous injections ofIL-210aded dextran microspheres was
investigated in rats by Cadeeetal.,I64 In their study, microspheres based on methacrylateddextran(non-
degradable), dextran derivatized with lactate-hydroxyethyl methacrylate, or derivatized with
hydroxyethyl methacrylate (degradable) were prepared. The tissue reaction over a period of 6 weeks of
the injected dextran microspheres was compared to similar injections of PLG microspheres. They
showed that both dextran-based microspheres were well tolerated and are suitable candidates forIL-2
slowreleasesysterns.
Dextran-based microspheres are promising; however, they possess few limitations which make PLG
microspheres a more favorable system. First, the use of non-degradable dextrans like methacrylated
dextran microspheres requires a second visit to the site of injection for the removal of the depleted
microspheres. Second, although this study shows that both non-degradable and degradable dextran-
based microspheres are well tolerated after subcutaneous injection in rats, PLG microspheres were
overall less cytotoxic and showed lower numbers of infiltrating granulocytes compared to both
degradable and non-degradable dextran based microspheres.I64,165
Other promising aqueous-based microsphere formulations that do not necessitate the use oforganic
solvents in their preparation are the gelatin-chondroitin-6-sulphate based microspheres. These
microsphereformulationswere investigated for the purpose of intratumoral and sustained deliveryofIL-
2 for experimental brain and liver tumors and for treatment of experimental malignant glioma in mice
and rats.64•166 The results demonstrated the ability of those carriers to stimulate long acting antitumor
immunity that provided an avenue for their use as a method of treating a variety of cancers. In one
study, Rhinesetal.,64 investigated the encapsulation, release kinetics, and the bioactivityofIL-2from
gelatin-chondroitin-6-sulphatebasedmicrospheres. The study revealed that the encapsulation efficiency
was approximately 88.5%. The release profile was characterized with a rapid release rate (almost 80%)
within the first 7 days followed by a much slower release over a total period of approximately52 days.64
The in vitro bioassay studies conducted by the same team in a previous study using the same
formulation approach demonstrated that IL-2 retained only a total of approximately 50% of its original
bioactivityoveratotalreleaseperiodof2weeks. l66
Gelatin-chondroitin-6-sulphate based microspheres have potential. However, gelatin based
preparations face the same challenges and limitations discussed underhydrogels-forming preparations.
In addition, there are other specific issues that should be addressed. First, as seen from the
aforementioned examples, one disadvantage of gelatin microspheres is that drug reiease rates are usually
very rapid; therefore, these microspheres may not be useful if a controlled and constant slow release
rate is required in the diffusion phase of the release period.178 Second,gelatinas amaterialpossesses
poor mechanical properties which is one of the reasons for the initial rapid release rate. l79 Third,
glutaraldehyde which is a crosslinking agent that has been thoroughIyexamined for its use ingelatin-
based systems and found to significantly improve the mechanical and thermal properties of gelatin
hydrogelsiscytotoxic, and biodegradation of glutaraldehyde cross-linked materials in vivo has the
potential to release cytotoxic agents. 180 Since gelatin is more readily degraded than fibrillarcollagen,
release of glutaraldehyde and its reaction products would be more likely fromhydrogels than from
glutaraldehyde cross-linked collagen-based preparations. As such, g1uteraldehyde crosslinking still
remains as a potential problem in clinical application of gelatin although quenching strategieshavebeen
developed to reduce that effect. Finally, although coacervation methods for preparing proteinloaded
microspheres are simpler to perform than suspension crosslinking methods and the particles are less
toxic, a disadvantage is that the particles are not particularly stable and aggregate easily t0 fonn larger
microspheres.lthasbeendifficult,todate,tousecoacervationmethodstoprepareproteinnanospheres
around 200 nm or less for potential use as injectable preparations. 181
Chitosan microspheres have also been investigated to deliver constant amounts ofencapsulatedIL-2
in a controlled and/or sustained manner. In a study conducted by Ozbas-Turan et al., 162 IL-2 loading of
chitosan microspheres was made by using two different methods; rIL-2 was either added to the sodium
sulfate solution during the preparation, or it was adsorbed onto the surface of empty microspheres. In
this study different parameters such as amount and addition method of protein, concentration of
chitosan, volume of sodium sulfate solution, and incorporation or not of the glutaraldehyde were
investigated. In addition, encapsulation efficiency, release kinetics, and the bioactivity ofIL-2 were also
reported. In general, rIL-2 encapsulation efficiency in these microspheres was high (75-98%). The
release profiles were biphasic, characterized by an initial protein burst followed by slow protein release
which continued for 200 days. The study showed that adsorption of rIL-2 onto the empty chitosan
microspheres caused a remarkable delay on the release of the protein. In a previous study,II I
chitosan/alginate polyelectrolyte complexes which were prepared by inducing the gelation of sodium
alg~at~olution with calcium chloride were also used to prepare porous microspheres. The pores
fonned in the microspheres result as a consequence of the lyophilization process since during
crosslinking, the polysaccharide swell in a continuous liquid phase, which is removed during
lyophilization. More than 95%ofIL-2 was loaded into the alginate/chitosan microspheres and the in
vitro releaseofIL-2 in phosphate buffer saline occurred in 5 days with almost 75% released in the first3
days. The investigators concluded that almost 100% of the active IL-2 was recovered in the release
medium but without specifying the methodology used to access the activity ofIL-2.
Chitosan is a polymer with outstanding properties for drug delivery: it is biodegradable,
biocompatible, bioadhesive and has permeation enhancing properties. It has also been reported that it
has a biostimulating activity on the immune system. l82 However; one major disadvantage of chitosan is
its limited solubility in water. Chitosan requires dilute acidic solutions for dissolution. The low pH of
chitosan solution tends to denature most proteins including IL-2.As foralginates, 0 neoftheirmajor
disadvantages is their uncontrollable in vivo degradation behavior due to their weak mechanical
properties which make them not suitable for controlled release delivery systems when a burst free and
initial slow release is needed. l83 1bis was evident in the aforementioned example in which all IL-2
loaded in the chitosanlalginate microspheres was released within 5 days at avery high rate.
Further, the polymer based strategy that is currently available to produce injectable polymeric
controlled release systems, is the incorporation of IL-2 into synthetic polymeric formula followed by
direct injection into the tumor site. There are two popular strategies developed for this technique. One is
composed of mixing IL-2 with sterile aqueous solution of polylactide-co-glycolide and PEG tri-block
polymer (ReGel~ and subsequently injecting the mixture locally into the tumor site. 127 Upon entering
the tissue and in response to body temperature (above 30 0 C) the blend quickly transforms into a
biodegradable gel depot. Samlowski et 01., examined the release profile of IL-2 from this polymeric
deP.2!.I~The preparation resulted in a release pattern that was sustained for up to 96 hours with initial
burst release. 127 The in vivo results of this technique were also examined by the same research group.
They demonstrated that peritumoral injection of ReGe1/IL-2 induced a significant regression in tumor
growthandimprovedsurvivalofthetreatedanimals.1bisdrugdeliverytechniquepossessesalotof
advantages including: easy fabrication and preparation; avoidance of the use of organic solventsor
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surfactants; biocompatibility with the body tissue and achievement of high loading capacity. While at
the same time, and in the manoer like PLG polymer, this tri-block polymer breaks down by bulk
hydrolysis and liberates acidic monomers that causes a drop in the pH inside this gel before complete
release of the protein, resulting in a compromise in the stability and bioactivity of the loaded protein. IM
The other strategy involves the use of Medusa I~ nanospheres for delivery of IL-2. The Medusa IT
consists of a-tocopherols (hydrophobic moiety) which are grafted to the L-glutamate unit to
thermodynamically undergo self-assembly into hydrophobic nanodomains in a water medium, which
result in the aggregation of the hydrophilic L-glutamate chains, forming a colloidal suspension of the
nanoparticles.
The release from these nanoparticles is based on displacement of IL-2 by endogenous proteins
present in physiological fluids and the reversible interaction with the polymer.185 Apharmacokinetic
study was carried out to compare the sc injections of Medusa II-based IL-2 withrhIL-2 (proleukin~on
differentanirnal models. 185 This study revealed that the release from this formulation extended one or
two days over the rhIL-2, with decrease in the relative bioavailability. Additionally, a clinical trial
conducted on renal carcinoma patients confirmed the presence of IL-2 in the blood of the patients who
received a sc injection of Medusa 11- based IL-2 but not with those who received free rhIL-2. 186
Although Medusa II is a protein-friendly delivery technique in maintaining the IL-2 stability, the
detection of IL-2 in the serum following release of IL-2 from this system may contribute more to the
systemic side effects ofIL-2 in patients. Furthermore, this technique is new and there are still the
undetermined effects of the delivery vehicle and long term storage on the stability of proteins and
peptides.
Other delivery systems used in localized cancer immunotherapy are the biodegradable elastomeric
matrices which utilizes the osmotic pressure-driven delivery approach. Biodegradable elastomeric
--------------=-1
I
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I
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devices loaded with interferon-y, vascular endothelial growth factor and IL-2 have been investigatedand
reported lately for their suitability as controlled release drug delivery systems.129·I86.176 These polymeric
devices were prepared by UV photocrosslinking of an acrylated star-poly(e-caprolactone-co-D,L-
lactide) macromer. The controlled release mechanism was achieved by distributing the protein as
lyophilized particles within the matrix and relied on the osmotic activity of the enclosed excipientsto
compel the protein out of the matrix. In this study, the release rate was constant and the releasepaltem
was nearly zero-order with minimal burst effect.186.176 Unlike PLG microspheres, osmotic-driven
mechanism of IL-2 releases most of the drug before significant polymer degradation becomes the
predominant controller of the drug release process. Having said that, there is still a number of issues
~hichhaveanirnpactonthestabilityprofileofloadedproteinsthatshouldbeaddressedinthisstrategy.
Mainly, the use of organic solvents during the device preparation may change the protein conformation.
In addition, the use of ultra-violet radiation during the photocuring of this elastomerwasreportedto
denature proteins and consequently destroys their biologica1 activity. 187 To date, there are no preclinica1
or clinical study on the in yiyo therapeutic efficacy of this new delivery system. Such investigations and
studies are required to examine its ability to fit in the IL-2 delivery systems pipeline. Table 1.4 lists and
summarizes some of the most commonly investigated polymeric controlled delivery systems for IL-2.
1.8. CONCLUSIONS
The following conclusions can be drawn from this review. First, continuous and loco-regional
deliveryoflL-2 in the vicinity of the tumor site is a desirable mode of delivery as it closely reflects the
cyt~naturaIreleasepattemandresuitsinamoreeffectivetreatrnentwithfewersideeffects.Second,
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long-acting formulations such as PEGylation and protein fusion techniques, prolongs IL-2 action but do
not adapt with IL-2 localization concept. Third, of the examined localized IL-2 sustained release
strategies, biodegradable polymeric vehicles would be able to circumvent theproblems associated with
short-term stability of liposomes and other similar delivery systems. However, controlling the
microclimate pH of the delivery system and avoiding the use of organic solvents in the preparation and
drug loading steps are among the biggest challenges that are faced to stabilize IL-2 in any biodegradable
polymeric carrier. Finally, an area of future investigation, is the use ofsolventiess drug loadingand
more protein fiiendly crosslinking techniques to overcome the limitations associated with the
preparation and use of UV photocrosslinked star-poly(e-caprolactone co D,L-Iactide) elastomers which
utilizes osmotic-driven delivery mechanism. Encouraging results regarding stability of peptidomimetic
drugs have been achieved now with the use of novel biodegradable elastomers utilizingsolventIessdrug
loading methods and less destructive visible light crosslinking techniques. However, the stability and
bioactivity of therapeutic proteins likeIL-2 and Endostatins from these novel elastomers has yet to be
investigated.
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CHAPTER 2
Photocrosslinked Polymers: New Emerging
Biomaterials for Controlled Drug Delivery and Other
Biomedical Applications
The content of this chapter is to be submitted to the Journal ofTherapeutic Delivery
Mohamed A. Shaker and Husam M. Younes.
ABSTRACT
Photopolymerization has been widely used in several biomedical applications includingtherapeutic
delivery, tissue engineering and cell encapsulation as it combines the properties of both the
photopolymerizable precursors and the photocrosslinked networks. Nowadays, photopolymerization
technology has expanded to show promising applications and uses in protein and gene delivery as well
as other drug delivery designs and technologies. The present chapter aims to provide an in-depth review
on the latest advances in the utilization of photopolymerization technology in the drug delivery field
with discussions on the properties and the compatibility of the photocrosslinked biomateria1sused. The
discussion will mainly emphasize on the potential use of photopolymerization intargeted,controlled,
and sustained drug delivery systems.
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2.1. BACKGROUND
The history of photopolymerization, which is an irreversible light-induced polymerization reaction,
can be traced back to the ancient Egyptians who used this technique in mummification. The mummied
were wrapped· in cloths which were soaked in lavender oil. The oil was then dried and photopolymerized
into a protective polymer upon exposure to sunlight.) Since then, the use of photopolymerization
technology has significantly expanded into many biomedical applications. This is because
photopolymerization is able to provide a rapid conversion of liquid prepolymers to gels or solid
crosslinked polymers resulting in polymer networks. Not surprisingly, the research in this field has
attracted great attention for its tremendous uses and applications in the engineering ofsofttissueandin
drug delivery systems as well.2•7
A significant number of current controlled drug delivery strategies are based on the design and
fabrication of synthesized biodegradable photopolymerizable vehicles. Compared to other materials,
polymers have occupied a central status in the fabrication of implantable systems as they can meet
several criteria such as biocompatibility and reproducibility, furthermore, a polymeric matrix can be
slowly degraded allowing for the controlled release of pharmaceutical agents from amedicaldevice.2""'
This chapter is aimed at covering the recent developments from a biomedical and drug delivery
applications point of view, covering the photopolymerizationtechniques.
Photopolymerization is a flexible polymerization process and enjoys several advantages over the
conventional (thermal and solution) polymerization techniques. Firstly, the spatial and temporal control
can be easily achieved during the photopolymerization processthrough controlling the exposure area and
the time of light incidence, hence precise control of polymerization can be achieved. Secondly,
photopolymerization can take place very rapidly at room temperature, in a matter of few seconds to
minutes. Thirdly, the process can be conducted at a temperature and pH that resemble the physiological
ranges during fabrication which can allow easy and rapid production of complex matrix devices.2.J.7 In
addition to the above, photopolymerizable formulations can be typically solvent free henceminimizing
volatile organic omissions. Also, the biomaterials can be created in situ in a minimally invasive manner.
In situ fabrication of polymers is attractive fora variety of biomedical applicationsasitcanallowoneto
form complex shapes that adhere and conform to tissue structures. It is not surprising then that the
utilization ;;r'~h~~;;"polymerized polymer networks has been suggested in drug delivery system and
otherbiomedicalapplication?.J·8
2.2. PHOTOINITIATORS AND PHOTOPOLYMERIZATION
In general, there are two main steps in photopolymerization namely, photoinitiation and
polymerization, as illustrated in Figure2.1. Photoinitiation utilizes photoinitiators which are molecules
responsible for initiating the reaction of polymerization by producing reactive species upon light
absorption?.J Frequently used sources of electromagnetic radiation comprise electron beam radiation,
ultraviolet (UV) light and y-radiation. Increasing use is being made of deep UV light « 200 nm), visible
light, near infrared radiation and microwaves.
There are two types of photoinitiators: cationic and radical. Cationic photoinitiators act upon
molecules containing epoxies or molecules which undergo polycondensation reactions. This type of
photoinitiator is not compatible with biological systems since its reactivity is inhibited by water and
hence will not be dealt with further in this chapter. Radical photoinitiators on the other hand are water-
compatible and act on molecules containing an acrylate or styrene group. The range of wavelengths
used is typically near UV (300-400nm).
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Figure 2.1. Schematic representation of the photoinitiated polymerization
When the system is exposed to appropriate light, the photo-sensitizers, which can be regarded as
photo-catalysts, absorb the energy and transfer it to the photoinitiators and/or act withphotoinitiators,
which then cause the photoinitiatorto break into primary reactive species, usually free radicals.Reactive
species then generate the polymerization in subsequent steps. Some photopolymerization system can be
irradiated without using photoinitiators such as inulin-methacrylic anhydride which can be
photocrosslinkedbylongtimeUVirradiation.9
Over the last decade, various photoinitiators have been explored forphotopolymerization (Table
2.1). Sincephotoinitiators are reactive molecules, that may even in trace amounts cause darnageto
human tissues, only those photoinitiators with stringent characteristics and criteria can be utilized for
drugdeliveryandotherbiomedicaiapplications.2•1O•II Firsl,photoinitiatorsshou1d be completely stable
and when dissolved in reactive monomers should not initiate spontaneous polymerization. Second, when
irradiated,photoinitiators should undergo photolysis with high quantum efficiency and without
liberation of by-products that inhibit polymerization or degrade the quality of the final product. Third,
photoinitiators should have as low toxicity as possible, both locally and systemically. Fourth,
photoinitiatorsshouldbebiocompatiblewithcellsormoleculesentrappedwiththeforming polymers,
and also with cells and tissues in the vicinity of implantation or injection site. Finally,thesynthesisof
the prospectivephotoinitiators should be reasonably straightforward and inexpensive. Apart from for
the above criteria, the final choice of initiators is frequently based upon similarly reportedsysternsinthe
literature or prior experience. 12
Table 2.1. Examples of different photoinitiators with their structures.
photoinitiators Structure
Irgacure 2959 (2-
hydroxy-I-[4-(hydroxyl
ethoxy) phenyl)-2-
methyl-I-propanone)
Irgacure 184 (1-
hydroxycyclohexyl-I-
phenyl ketone)
Irgacure 369 (2-Benzyl-
2-(dimethylamino)-4'-
morpholinobutyrophenon
e) o IN ____
4-Benzoylbenzyl-
trimethylammonium
chloride
Irgacure 907(2-Methyl-
1[4-(methylthio)phenyl)-
2-morpholinopropan-l-
one)
Irgacure 6512 (2, 2-
dimethoxy-2-phenyl
acetophenone) [DMPA)
Irgacure 819 bis(2,4,6-
trimethylbenzoyl)
PhenYIPhOSPhineOXide~'o~
(BAPO) ~
I :: ~ ~ I
Lucirin TPO
diphenyl(2,4,6-
trimethylbenzoyl)phosphi
neoxide
diphenyl iodonium
hexafluorophosphate
diphenyl iodonium
chloride
Camphor (1,7,7-
Trimethylbicydo[2.2.1]h
eptan-2-one)
Camphorquinone(IR,4S-
1,7,7-trimethyl
norbronane-2,3-dione)
Eosin Y (disodium 2-
(2,4,5,7-tetrabromo-6-
oxido-3-oxo-xanthen-9-
yl)benzoate)
Isopropylthioxanthone
According to their mechanism of action, radical photoinitiators are divided into two generalclasses.
The first (type I) undergoes a uni-molecular bond cleavage upon irradiation to yield free radicals. The
majority of these types include aromatic carbonyl compounds containing suitable groups which facilitate
direct photo-fragmentation.13 Whereas, the second (type II) are subjected to binJolecular reaction, where
the excited photoinitiator interacts with photo-sensitizer to generate free radicals. The polymerization
pathways of this type II are two: hydrogen abstraction and photo induced electron transfer, followed by
fragmentation. I)
Photoinitiatorshavealsobeencategorizedaccordingtothetypeoflightusedtoinducephotoinitiation
process into Ultraviolet (UV), visible and laser photoinitiators. 14 The only difference between them is the
difference in light energy absorption capability at the appropriate wavelength. The UV photoinitiators in
tum include various classes and over the last decade, most of them have been reported to be used for drug
delivery purposes. One of the most inJportant groups of UV photoinitiators used in biomedical
applications includes ketones as functional groups. The reactive radicals in this group can be formed
through a photo-cleavage ofabond to the carbonyl group. Differentkindsofketonesphotoinitiatorswith
different reactive side chains are reported such as a-hydroxy ketone, a-amino ketone, and amino aryl
ketone, such as Irgacure 2959 (2-hydroxy-l-[4-(hydroxyl ethoxy) phenyl]-2-methyl_l_propanone).I0,I4-16
IrgacureI84(I-hydroxycyclohexyl-l-phenylketone)17 isthemostcommonlyusedketonephotoinitiators
in tissue engineering. AJso,ithas been investigated for the purpose of crosslinking pH-sensitiveglycol
polymers for oral drug delivery systems, IS An acetophenone derivative 4-Benzoylbenzyl-
trinJethylammonium chloride is another group of UV photoinitiators used in drug delivery, The 2, 2-
dinJethoxy-2-phenyl acetophenone (DMPA) is one example of an acetophenone that has been significantly
used as a photoinitiator for photopolymerization of PEG to form hydrogels for use in biomaterial
studies.3.19.2IIrgacure6512(2-dimethoxy-2.phenylacetophenone),was also used to fonnhydrogels from
PEG derivatives in several other studies.2,21,22 Also, phosphine oxides such as monoacylphosphine
(Lucirin TPO), bisacylphosphine (lrgacure 819) as well as iodonium salt such as diphenyl iodonium
hexafluorophosphate have been used in biomedical studies.
Photoinitiators having absorption capabilities in the visible light energy range are based on dyes,
quinines, diketones, and heterocyclic chemical structures. Camphor compounds such as
camphorquinone (CQ), camphor and amine compounds such as triethylamine and triethanolamine2,23,24
and compounds such as isopropyl thioxanthone (lTX) and ethyl 4-N,N-dimethylamino-benzoate
(EDMAB)2,23,25 have also found use as photoinitiators for tissue engineering, drug delivery and cell
capsulation. In addition, eosin Y have a broad use such as interfacial photopolymerization of PEG
diacrylate26-2l and photocrosslinked pluronic hydrogel forplasrnid DNA release.26 Also, metal10cene
compounds such as Irgacure 784 have been used in drug delivery.
The main differences between UV and visible light cured materials are in the use of a photoinitiator
that absorbs the appropriate wavelength of light energy. UV photoinitiatorsofbothclassesareavailable.
However, visible lightphotoinitiators belong almost exclusively to the second class of photoinitiators.
Visible light contains about five percentUV light.
2.3. PHOTOCROSSLINKABLE POLYMERS
Various polymers have been explored for photopolymerization as drug delivery matrices, from
which the drug can be gradually released. The development of novel drug delivery system is a very
active part of biomedical industry due to obvious therapeutic and econornic advantages in the method of
drug administration. Considering the application, biodegradable biomaterials are most commonly
used.29 Almost all the photopolymerizable biomaterials commonly have a photopolymerizable moiety in
their backbone, located atone or both ends of the molecules. Acrylateormethacrylate moieties are the
most commonly used moieties; they can be covalently crosslinked with the excitation of radical
genemting photoinitiators. The use of photocrosslinkable biodegradable polymers for the fabrication of
biomedical applications offers two major advantages. First, the elimination ofa surgery steptoremove
theimplantedprosthesisafterthehealingofthetissues.Second,thepossibilityoftriggeringandguiding
the tissue regenemtion via degradation of the material. A list of selected examples of biodegradable
polymers and their biomedical applications are illustmted in Table 2.2.
Polyethyleneglycol is widely explored for biomedical applications due to its excellent
biocompatibility and degradability. Several derivatives have been explored including acrylate or
methacrylate derivatives, poly(propylenefumamte-co-ethylenegiycol) 30 and PEG fumamte.31 PEG
diamethacrylates and PEG urethane-dimethacrylates are also studied and showed good biocompatibility,
theyhavebeensuccessfullyused,bothin vivo and in vitro, by several groups as scaffoldmaterials.32
PEG-diacrylamide is also an interesting new derivative for in vivo photopolymerization. Although
acrylamide is very toxic,PEG-acrylamide should not be toxic due to its high molecular weight and
hydrophilicity,whichwill restrict access of the polymer to the cell's interior. Additionally, it undergoes
mpidfree-radicalpolymerizationandiseasilyattachedwithpeptidesviaaconjugateadditionreaction.8
Polyvinylalcohol (PVA) has been shown to be protein non-adhesive, thus PYA offers the potential
for cell selectivity through incorpomtion of bioactive moieties. The number of cross-linkable groups on
thePVAchaincanbewidelyvaried,permittinggreatermanipuiationofhydrogelmechanicaiproperties.
Additionally, the pendant hydroxyl groups on PYA provide many more available sites for the
Table 2.2. Selected examples of synthetic photocrosslinkable biodegradable polymers and their
biomedical applications.
Pitarresi et aI. 3~
Baeetal. 51methiiC late
Dextran and glycidylmethacrylate
polyaspartamide
Poly(e-caprolactone- acrylate
co-D,L-Lactide)
I hos hoester acIT=la;:..e__ """"~~~""-_'OL-'C:i""cg.-.:.:e'"':'.?aI:-.5__
Fumurate-based diacrylate Kaietal.~3
unsaturatedpoly(ester
amide) and
poly(ethyleneglycol)
__ I
attachment of bioactive molecules.4 Furthermore, PYA hydrogels have been studied as great candidate
of protein-releasing matrices.33 Jennijer etal., investigated the use of photoactive PVA derivatives that
form crosslinked hydrogels in the presence of cells and tissues functionalized with the cell-adhesive
peptide RODS (Arg-Gly-Asp-Ser) and are found to support the attachment and spreading of fibroblasts
in a dose-dependent manner.4 Pluronic polymers are block copolymers of polyethyleneoxide and
polypropylene oxide exhibit such a thermal gelling property. Photocrosslinkedpluronichydrogelshave
beelrustd as delivery systems for several proteins and genes including IL-2, urease,34 rat intestinal
natrituretic factor.33.Jl Poly(2-hydroxyethylmethacrylate) (poly(HEMA» was also used as a drug carrier
due to its ability to release entrapped drug in aqueous medium as well as its good compatibility.7
Hyperbranched polyglycerol (HyPO)yl methacrylate, which was derivatized with glycidyl methacrylate
also showed great potential for drug delivery and for tissue engineering purposes.22
Naturally occuring biodegradable polymers such as dextran, inulin,36 collagens,37.J8 hyaluronic
acid,37andpolyphosphester,ll whosedegradability in the body is well known, have been also broadly
explored for photopolymerization use. Among the natural materials for photopolymerization,
polysaccharidesrepresentgoodcandidatestopreparebioerodiblehydrogelsusedfordrugdelivery
systems. Polysaccharides are readily available and can be degraded by hydrolysis, or enzymatically
degraded in certain cases. Besides their compatibility and biodegradability, they possess hydroxyl-
functional groups that can be used for the chemical modifications leading to crosslinking and the
formation of hydrogels, these hydroxyl groups can also be used for the covalent attachment of drugs or
other therapies to the hydrogel backbone.36.J8 Several groups have demonstrated the release of drugs
from polysaccharides matrices. Dextran is another natural polysaccharide that finds wide use in the
pharmaceutical field.39,40 Photocrosslinked dextran derivative containing methacrylate moieties
represents a simple and reproducible procedure to obtain networks able to swell in aqueous medium.
2.4. BIOCOMPATmILITY OF PHOTOCROSSLINKED POLYMERS
Any biomaterial intended for final conversion to a biomedical device or drug carrier must undergo
rigorous processing and characterization as well as comprehensive safety testing. A biocompatible
material must demonstrate appropriate interaction with the host in specific applicationandimplantsite
and biocompatibility reflects the interaction that may be influenced by a number 0 ffactors related to the
material, such as surface topography, charge, and chemistry. Similarly, biocompatibility is also
influenced by properties of the host tissue, includinglocalpH,bloodtransportrate, andpresenceoflipid
and tissue type. Absorbable materials may be shaped into very diverse device forms, thus the ensuing
discussion on toxicity and biocompatibilitywill be focused on the chemical as well asphysicalinfluence
of the bulk material or device and its degraded product on the host tissue:1 Moreover,factorssuchas
the energy of the polymerizing light, the heat and the radical species produced .during the
polymerization, the degree of monomer conversion and the toxicity of photoinitiators / monomers can
influence cytoxicity of the photopolymerizable biomaterials. However, it was found that these
pararneters may be controlled by changing the type of photoinitiator and lightintensity.2 His well
known that in vitro cytotoxicity testing evaluates lyses, growth inhibitionandotherimpactoncellsby
medical devices.42 However, the current testing guidelines set for the assessmentofcytotoxicityarenot
suitable forhydrogels, because it is difficult to place hydrogel in contact with cells and then remove the
material without causing darnage to the cells. Consequently, separatemethodologieshave to be used for
testing the hydrogel in the presence of cells. Transwell inserts, which contain the hydrogel and
polymeric solutions, were developed as an outstanding technique for an indirect contact testing.37
It is also important to consider cell interactions here since the most of materials discussed are
commonly used for in vivo purposes. These biomaterials must be tested by the use of cell viability test.
There is either direct or indirect method to test cell viability. For direct test, as the name suggests, cells
are placed in direct contact with the materials and for indirect testing samples are extracted in the
medium used to culture the cells and the extract is then placed in prepared cell culture.37 In addition to
cell viability tests, the ability of photoinitiated materials to promote or inhibitcell adhesion has been
investigated. For examples, the hydrophilic polymers such as PEG can inhibit cell adhesion whereas
hydrophobic copolymers such as polystyrene promote cell adhesion""3 Moreover, attaching bioactive
molecules to those biodegradable photopolymers, such as cell adhesivepeptides, can change the cellular
behavior. Inbrief,whenbiologicalmoleculesareconjugatedwiththebiomaterial,thecellswillrespond
only to the incorporated ligand,substantially unafIected by spuriously adsorbedproteins.27 Hubbellel
al., studied the application of a novel hydrogel prepared by PEG diacrylate derivatives. They modified
the hydrogel by binding it with Arg-Gly-Asp (RGD-eontaining peptide). The results revealed that the
modifications promoted fibroblast spreading.2UI Also, Hem el aI., showed that PEG can also be
functionalized with bioactive peptide molecules to promote cell adhesion.4s Inaddition,poly(lactide-co-
lysine) 46 and PYA 4 polymers had been modified with RGD peptide to enhance cell attachment and to
support the spreading of fibroblasts in a dose dependent manner.
2.5. PHOTOPOLYMERIZATlON IN TISSUE ENGINERRING
Photopolymerizationhas been used in a wide range of biomedical applications and is still considered
an attractive approach for a variety of further biomedical investigations. A variety of biomedical
applications have been used in medicine such as scaffold and tissue fabrication,47 blood vessel
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adhesives,44 adhesion prevention barriers,27 fabrication of biomaterial used as joint replacement,48 teeth
restoration,49.So and in cell encapsulation for tissue replacement strategies.slInthispartofthereview,
some of the main utilization of photopolymerization in the biomedical and drug delivery field are
discussed in detail.
2.5.1. Scaffold and tissue fabrication
The field of tissue engineering has witnessed new trends with advances in photopolymerization
technologies. As in vitro models of living tissue, these techniques may be useful indevelopingtherapies
for replacing lost tissue function. Replacing physiological functions lost in damaged organ can be
obtained-by combining of cells and tissues to form a three-dimensional structured tissue. Researchers
have been able to fabricate tissue engineering scaffolds with complex three-dimensionalarchitectures,
usingstereolithographyandphotolithographymethodsaswellaspolymerchemistry.Stereolithography
is a three-dimensional photopolymerization technique that uses an ultraviolet laser beam to photo-
crosslink the photopolymerizable polymer. Laser beam is directed into a layer of liquid polymer,
causing cross-linking to the exposed area and after covering with anew layer of polymer the process is
repeated. Cooke et al.• demonstrated the application of stereolithography for the production of
biodegradable three-dimensional structure tissue.47 On the other hand photolithography method is
potentially used for the production of both single and multilayerbiomaterials. The feasibility of using
photolithography process to build and control the fabrication of polymer scaffolds has successfully been
demonstrated, and a photolithographic method ofpatteringdried2-hydroxyethyl methacrylate, which is
later rehydrated before cell seeding, is also reported.S2 Also, Jejfrey etal., developed a simple yet rapid
method of creating various shapedpattemed surfaces usingphotocrosslinkablechitosan. They reported
the prepared chitosanpattemed surfaces (cardiac fibroblasts, cardiomycoytes and osteoblasts) to be
stableforuptol8days.53
An alternative method for hepatocyte transplantation is the implantation of tissue engineered
hepatocyte spheroids (hepatocytes on biodegradable polymer). Spheroids have a liver-like morphology
and preserved specific metabolic function and may serve as an in vivo substitute for lost liver function.
Valerie et aI., have fabricated a hepatic tissue by using a multilayer photopatteming platform. They have
used a photopolymerizedable PEG hydrogel which is able to support hepatocyte survival and liver-
specific function. Specifically, they incorpomted adhesive peptides able to ligate integrin on these
adhesion-dependentcells.5\
Anseth et 01., investigated a new class of methacrylate anyhydride monomers such as methacrylated
seblRlic'llcid, methacrylated 1,3-bis(p-carboxyphenoxy) propane and methacylated 1,6-bis(p-
carboxyphenoxy) hexane for orthopedic applications54 They successfully used suchmonomersinatibia
bone defect and preliminary histological evaluation showed good adhesion of the polymer to the cortical
bone and medullar cavity. Furthermore, to secure metallic orthopedic implants, bone cements based on
methyl methacrylate have been used to form rigid polymers.56
2.S.2.CeUeocapsulatioo
In cell encapsulation, transplanted cells are protected from immune rejection by artificial semi-
permeable membrane; such encapsulation can be achieved using biodegradable polymer. The photo-
polymerized polymer should potentially allow allo- or xeno-transplantation without the use of
immunosuppressive. Several photo-polymeric encapsulation systems have been developed,52,56 or are
currently being tested in clinical trialS.57
Diabetes is one of the most significant areas of current research for encapsulation of cells,
specifically the islet cells of the pancreas that produces insulin,Cruiseetal,, 16 investigated a method of
xeno-protection toward abio-artificial endocrine pancreas. They illustrated the importanceofinterfacial
photopolymerization to form polyethylene glycol (pEG) membranes for encapsulating islets of
langerhans. The results from this study illustrated in vitro and in vivo function of the photo-encapsulated
porcine islets and the capability of this membrane to prevent immune rejection in a discordant xenograft
model. Moreover using static glucose stimulation and perifusion assays the encapsulated isletswere
shown to be glucose responsive.S2 Additionally,E/isseeffetal., have suggested that the feasibility of
photopolymerizing system provides an efficient method to encapsulate cells, They described the
encapsulation of bovine and ovine chondrocytes in a poly (ethylene oxide)-dimethacrylateandpoly
(ethylene glycol) semi-interpenetrating network using aphotopolymerization process.56
A new concept for cell encapsulation was proposed by Hoe et 01., who developed
photopolymerizable beads with methacrylated hyaluronic acid and N-vinyl pyrrolidone. They directly
injected viable cells into the beads by usingmicroinjection technique. The results indicated that the cells
could proliferate well within these beads and beads could be potentially used as injectable cell delivery
vehicles for regenerating tissue defects.57
2.6. PHOTOPOLYMERIZAnON IN THERAPEUTIC DRUG DELIVERY
Targeted delivery of drug molecules to organs or special sites is one of the mostchallengingresearch
_---------------------===-1
areas in the pharmaceutical sciences. By developing photocrosslinked delivery systems such as
hydrogels,elastomers,andnanoparticlesanewfrontier is opened for improving drug delivery.62.7o Drug
release can be controlled through spatial and temporal control ofthephotopolymerizable matrix to
achieve sustained delivery. This can be achieved when a photopolymerizable polymer is combined with
a drug in such a way that the active agent is released from the material in a predesigned manner to yield
more effective therapies; while eliminating the potential forbothunderandoverdosing. Usually a drug
dissolvedordisperseduniformlythroughoutthephotocrosslinkeddevicessothatthereleasefromsuch
matrix systems is governed mainly by the diffusion process. The uniformly dispersed drug exhibits
release rates that continuously diminish with time as a result of the increasing diffusion resistanceand
decreasing area due to geometry limitations. On the otherhand,the release of the active agent may be
designed to be constant over a long period by utilizing the osmotic-driven release mechanismusing
osmotic excipient. or it may be triggered by the environment or other external events. Hence, methods of
using geometry factors and the surface erosion-controlled 60 and swelling-controlied mechanisms have
been utilized for constant rate drugrelease.61
~o.n:over, photopolymerized biomaterials are also opening up new opportunities in implantable
drug delivery systems in a minimally invasive manner. This is often preferable to the use of an injectable
drug. In silU polymerizable polyesterpolyol were prepared with succinic acid and polyethyleneglycolof
different molecular weights by Tammishetti's research group, as well as examining the in vitro release of
entrapped sulfamethoxazole from this cross linked matrices.'8 the results of this release studies
suggested that they can also be used for controlled delivery of antibiotics over a shortperiodoftime.
Meanwhile, Langer et 01.. hypothesized that light may cause a photopolymerization through the
penetration of skin. They chose to inject polyethyleneoxide as a model polymer hydrogel system to test
the penetration ofUV and visible light through the skin. Successfully, they obtained the polymers
through photopolymerization. This result came up with ''trans-dennal photopolymerization" that can be
applied to both minimally invasive implantation and drug delivery.8 Additionally, photopolymerizable
drug derivatives can be used for achieving sustained release drugs to improve the efficiency ofdrug
therapies. This approach was illustrated when Lawson et al., synthesized a photopolymerizable PEG-
acrylate derivative of vancomycin, which could be covalently attached to a titanuium implant alloy to
fonn a bactericidal surface which prevented infections in the setting of orthopedic hardware.l9 This
technique allows a loading dose several thousand times larger than that achieved with
photopolymerizable polymer coupling approaches and holds promise for the treatment of orthopedic
infections.
2.6.1PhotopolymerizedHydrogels
Photopolymerizedhydrogelsare a three-dimensional network of hydrophilic polymers held together
by association bonds such as covalent bonds and weaker cohesive forces suchas hydrogen, ionic bonds,
and intennolecularhydrophobic associations. They have gained popularity as controlled release carriers
fordrugsandproteinsduetotheirhighwatercontent,goodbiocompatibility,andconsistencysirnilarto
soft-ti~. Moreover, they have high penneability to oxygen, nutrients and other water soluble
metabolites.J,42 Although, their use in prolonged and controlled drug delivery has been widely
investigated,there is still need for the development of hydrogels using feasibIe methods still exists.J8
Degradation of the photopolymerized hydrogel matrix not only allows a customized release of entrapped
molecules but also evades the removal of the device from body.J8,39
There are two general methods for loading drugs into photocrosslinked hydrogel. One method
requires the monomer to be mixed with drug, initiator and cross-linker and is photopolymerizedto
entrap the drug within the matrix. In the other method, a preformed photopolymerized hydrogel is
allowed to swell to equilibrium in a suitable drug solution..4o Drug diffuses from the photopolymerized
hydrogel when it is placed in an environment causing it to swell and increases the mesh size. It is also
important to ensure that the polymeric system is notover-crosslinked as the drug will not be able to
diffuse out of the system. At the same time, the drug must be investigated to ensure that it can withstand
the polymerization and will not react with the monomers in the system. Peppas et oJ., developed a
kinetic experiment to study the effect of solute on the polymerization process, and found that the
presence ofa solute results in a more heterogeneous material,adelay inthe gel point and in greater
microgel regions. Aditionally, their study also revealed that presence ofalowmolecularweightsolute
increased the rate ofpolymerization.S6
Some photopolymerized hydrogels can be prepared at physiological pH and room temperature in the
presence of a nontoxic photoinitiator upon exposure to UV light. The rapid photopolymerization process
allows cells to be seeded homogeneously with the hydrogel with minimal exposure to UV light under
biologically compatible conditions. Furthermore, gelation can be controlled both temporally and
spatially by altering prepolymer concentration, photoinitiator concentration andexposuretoUVlight.4
Photocrosslinkedpolyanhydrides have highly predictable drug release profiles thatdependonthe
polymer-erosion rate and implant geometry in many biomaterial applications where drug release would
be beneficial. 1O•71 •72 Amphiphilic block copolymers can be used as stimuli-sensitive synthetic hydrogels
that shows a reversible sol gel transition behavior at a certain temperature range. These Hydrogels, such
as pluronic hydrogels, were paid more attention for their unique properties including thermo-
sensitivity.7l.77
Photopolymerized hydrogels are attractive for use in localized drug delivery as they can be
crosslinked in situ and thus adhere and conform to the targeted tissue.3 Due to an enormous number of
drugs and proteins used for various types of therapies, the applicationsofphotopolymerizable hydrogels
are countless. These applications include sustained DNA delivery,78.79 controlled release of cytokines,73
mucoadhesive delivery systems,80 and live vaccine ballistic delivery.81 For example, photocrosslinked
pluronichydrogels have been used for a sustained delivery of therapeutic genes for wound healing and
tissuegeneration.78 SimilarlY,ParketaJ., successfully synthesized photocrosslinked hyaluronic acid
(HA)/pluronic hydrogels for sustained release of proteins. When DNA was loaded in the hydrogel for
sustained delivery, various release profiles were attained by varying UV irradiation time and modified
HA amounts. This shows that the pluronic hydrogel can be utilized as a potential candidate material for
in vivo sustained gene delivery after fine-tuning various formulationparameters. 79
The main objective of using photopolymerizable hydrogels is the control of drug release, which has
been studied extensively. Theopylline,38 gentamicin 82 and live vaccine 81 were released in a well-
defined release pattern from different photopolymerized hydrogels. Also, photopolymerized hydrogel
was used for the delivery of highly potenl, but relatively toxic, anticancer drugs without inducing side
effects. This was revealed when KaietaJ., synthesizedpaclitaxel loaded biodegradable hydrogels by the
photopolymerization of two precursors: a fumurate-based unsaturated poly(ester amide) and PEG
diacrylate.Sustainedpaclitaxelwasreleasedoveratwo-monthperiodwithoutaninitiaiburstrelease
froIfi'tl!i! hydroels.83 Furthermore, Dimitrios et oJ., prepared doxorubicin encapsulated polymeric
hydrogel nanoparticles by photopolymerizaton of PEG and poloxamer 407, in which the drug was
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released in a sustained manner, with a minor burst, over a period of one week.82 Site specificdeliveryof
drugs is another example of photopolymerized hydrogel applications. This was shown when Peppas et
aJ., modified poly(acrylic acid) with PEG onto their back bone chains to developed novel acrylic-based
hydrogel used as amucoadhesive delivery systems.80
The aforementioned applications of hydrogels usually involve a single layer in which the drug is
uniformly dispersed. However, it is difficult to obtain a single layer that possesses all the properties
required fora specific application.9 Some applications may require the matrix to possess a diverse range
of properties such as pH sensitivity, high water absorption, and constant drug release. Although
sometimes these properties can be attained with a single material, it is difficult to obtain multiple
properties ina single layer that can satisfy the intended application of the materia1ordevice. Thus,the
~pability to construct multiple layers of varied composition in a single membrane or device would
increase the range of applications of these systems. Hydrogel multilayers may provide more precise
properties when a single material cannot meet the requirements for the application. For example, Anesth
et aJ., investigated the use of photopolymerization of multi-laminated poly(HEMA) to create layered
matrix devices with nonuniform concentration profiles with the goal of controlled drug release. They
state that the polymerization conditions are sufficiently mild to be carried out in the presence of
biologicalmaterials.9
Many approaches, as well,havebeenexploredto improve the efficiency of gene delivery by using
the photocrosslinked hydrogels as non vira! vectors.66•67 One area of research is focused on identifying
photocrosslinked polymer matrices to deliver DNA to cells in vivo, where they have been shown to
inc!!,asc:..DNA resistance to degradation by nucleases,lO increase plasmid DNA uptake compared to
bolus delivery methods,I0,26 and provide controlled dosing. In addition, sustained DNA release can
prolong foreign gene expression,26.66 thereby reducing the need for repeated dosing, which is a
significant advantage for long-term gene therapy. 10
Several types of polymer matrices have been explored for DNA delivery, with biodegradable
hydrogel systems being the most common.The first example of this was demonstrated in the design of a
photopolyrrier platform that enables simultaneous encapsulation of plasmid DNA by Anseth et aJ. They
first protected the DNA from the effects of photoinitiating conditions (ultraviolet light andphotoinitiator
radicals) and then plasmid DNA was photoencapsulated and the quantity and quality of the released
DNA was assessed. The results showed that encapsulated plasmid DNA was released in active forms
(supercoiled and relaxed plasmids) with an overall 60% recovery. Therefore, this photopolymerization
platform allowed for the creation of engineered tissues with enhanced control ofceII behaviortbrough
the spatially and temporally controlled release of plasmid DNA. IO In another work carried out by the
same research group, photopolymerized PEG-based macromolecules with various degradation rates to
control the DNA release profiles were prepared. These photocrosslinked hydrogels were designed in a
manner to release DNA for periods of 6-100 days with either nearly linear or delayed burst release
profiles while maintaining biological activity.66
Controlled DNA release was also achieved by loading plasmid DNA in a photopolymerizable di-
acrylated pluronic (water soluble tri-block copolymers ofpolyethyleneoxide-b-polypropyleneoxide-b-
polyethyleneoxide) in the presence and absence of vinyl group-modified HA. Various release profiles
were attained by varying UV irradiation time and modifying the ratio of hyaluronic acid. The released
DNAwasnotchemicallyaffectedduringthereleaseperiodandsubstantiailymaintainedthefunctional
gene expressionactivities.26 In addition, WieJandetaJ., investigated the photocrosslinking ofacrylated
PEG-hyaluronic acid as a controlled release vehicle for gene therapy vectors. The release from these
hydrogels was dependent on the physical properties for both the hydrogel and the vector. The polymer
content and relative composition of HA and PEG influenced the transport of the vector through the
hydrogel by modulating the swelling ratio, water content, and degradation rate. The release study also
revealed that the majority of the release occurring during the initial 2 days and the cumulative release
increased -with decreasing PEG or increasing HA content. Therefore, these studies demonstrated the
dependence of non-viral vector release on the physical properties of the hydrogel andthevector,
suggesting~t.Qr__andhydrogeldesignsformaximizinglocalizeddeliveryofnon-viralvectors.67
However, with PEG-hyaluronic acid delivery vehicles, DNA encapsulation efficiencies are low which
can be improved by introducing amphiphilic molecules. More important, though, is the DNA damage
that has been observed as result of degradation. Degrading PEG-hyaluronic acid produces acidic
degradation products that accumulate and are thought to damage encapsulated DNA. Researchers are
investigating more porous structures to reduce accumulation of degradation products in the implant
interior, thereby mitigating damage to pH sensitive molecules like DNA.
Some applications may require the matrix to possess a diverse range of properties such as pH
~ensitivity, high water absorption, and constant drug release. The swelling or shrinking of stimuli-
responsive photopolymerized material in response to small changes in pH or temperature can be used to
control drug release. For example, the development ofa glucose sensitive insulin reIeasing system for
diabetes therapy was developed by using a pH responsive polymer. The polymer can be mixed and
compressed with glucose oxidase, bovine serum albumin, and insulin. When the photopolymerized
matrix was exposed to glucose, it was oxidized to form gluconic acid. As the hydration state was
changed by a decrease in the pH, then insulin was released.42 On the other hand, a maleic and/or
succinic anhydride derivative of insulin are suitable candidates to avoid the release ofibuprofen(the
model drug) in the gastric region, due to their low swelling and a great resistance insimulated gastric
fluid (pH = 0.1). These crosslinked polymers showed very little release of ibuprofen in simulated gastric
fluid and a great release in simulated intestinal fluid. This pH sensitive photopolymerized insulin
derivative was approved to be a suitable candidate for non steroidal antiinfalmatorydrugs(NSAIDs)or
other drugs with a potential irritating effect on the gastric mucosa, susceptible of acidic degradation or
with a specific activity in the intestine.36 Also, Peppas et al., synthesized a novel pH responsive polymer
containing grafted PEG chains by photopolymerization as oral protein delivery carriers. In acidic media
(pH =2.2), insulin release from the hydrogel was very slow. However, as the pH of the medium shifted
to 6.5,arapid release of biologically active insulin took place as a strong indication of their potential as
a matrix fOJ.l\ll_.oraJ formulation of insulin and as a model to avoid the release of drugs in the gastric
region.68
Temperature sensitive vehicles were synthesized by photopolymerization of vinyl group modified
hyaluronic acid (HA).16 The synthesized HAl pluronic gradually collapsed with increasing temperature
over the range of 5--40 °c, suggesting that the pluronic component formed self-associatingrnicellesin
the hydrogel structure, revealing that the protein stability events such as aggregation andnonspecific
release rate could be controlled by modulating the adsorption. Poly(N-isopropylacrylarnide) based
·polymers are explored as a topic of various smart biomaterials since it undergoes a reversible
tempreture-sensitive phase transition in aqueous solutions at approximately 32°C. Nguyen etal., have
investigated composite hydrogels with temperature-sensitive properties usingphotocrosslinking. Their
novel composite materials are composed of nanoparticles made of poly(N-isopropylacrylamide). The in
vitro bovine serum albumin (BSA) release studies from these hydrogels demonstrated that these
nanoparticles were embedded inside the PEG polymeric matrix and the composite material was able to
release BSA in response to changes in temperature. These nanoparticle hydrogel networks have
advantages in applications of controlled drug delivery systems because of their ternperature sensitivity
and their ability of in situ photopolymerization. 16.69
2.6.2. Pbotopolymerizable Elastomen
Over the past 15 years, the literature on biomedical applications for elastomers has grown
considerably and reports have appeared regularly. Elastomers owned for its broad uses in biomedical
applications: The exhibition of mechanical properties as soft as body tissues make them attractive for the
implantation in the highly challenged non static part of the body. Their elasticity can be utilized along
with osmotic pressure to generate linear release profiles for water soluble compounds in drug
delivery.62·~SlmlRl1 types of biodegradable elastomeric matrices have been explored for drug
delivery.62.64 The rationale behind these elastomers is the use of non-toxic, readily available and
inexpensive monomers. In addition, the availability of various molecular weights of similar monomers
provides flexibility to tune the mechanical and degradation characteristics of the resulting elastomers.
Lifetimes of such biodegradable material could be successfully adjusted by varying the molecular
weight of the polymer, degree ofcrystallinity and crosslinking density.62
The photopolymerizable elastomers exemplify an ideal carrier for prolonged delivery of
thermosensitive drugs. Thermosentitive drugs such as protein and peptides are to be incorporated into
the device as solid particles which require the polymer to cure near ambient temperature. The
photocrosslinked biodegradable elastomers can undergo free radical polymerization upon exposure to
UV or visible light at room temperatures and process rapidly. 81 There are many photocurable
monomersloligomers that can be photocrosslinked to fonn elastomers such as methacrylated star-poly(&-
caprolactone-eo-D,L-lactide),88 poly(&-eaprolactone-eo-trimethylene carbonate),89 poly(&-caprolactone)
by end-functionalization with maleic or itaconic anhydride, 90 poly(&-eaprolactone) chain extended with
4,4(adipoyldioxy) dicinnamic acid.91
Most of the therapeutic proteins require long tenn and site localized delivery, although, most of them
are administered via multiple injection regimens. In addition, the self storage stability and low patient
compliance have also hampered their translation to clinic.62-64 As a result, an extensive amount of
research has gone into the development ofphotocrosslinked elastomers as a more effectivemeansof
administering protein drugs. This was demonstrated when aphotocrosslinked biodegradable elastomer,
starpoly(&-caprolactone-co-d,l-lactide) was designed in an attempt to deliverbioactivecytokinessuchas
interferon-y (IFN-y), interleukin 2 (IL-2), and vascular endothelial growth factor (VEGF). Younes el a/.,
chose &-caprolactone and D,L-Iactide as monomers, which have good compatibilities and a star polymer
architeclure"1ii'tJretr-elastomer scince the physical properties of the final network can be easily altered on
the basis of the number of anns in the star copolymer (e.g., crosslinking density).86 Moreover, a
comparison of elastomers prepared from linear versus star (3-isocyanatopropyl) triethoxysilane
terminatedpolylactide demonstrated that better mechanical properties were achieved with the star-
polylactide.87 This result was attributed to the higher crosslinking density achievable using a star
prepolymer architecture. Depending on the osmotic pressure release mechanism IFN-y was released
from the optimum fonnulation at a constant rate of 23 nglday over three weeks.62 A cell-based assay
showed that over 83% of released IFN-y was bioactive. Also, a constant release rate for lL-2 and VEGF
was achieved as the mechanical properties maintained during the release period.62 However, the
bioactivity profile for VEGF show a marked drop after the first week of release as a result of hydrolytic
degradation and acidic monomer accumulation inside the elastomers (pH< 5). Furthennore, it was
demonstrated that bovine serum albumin and trehalose co-lyophilized with the cytokine were released at
the same rate as the protein drug. Thus, this delivery fonnulation may be clinically useful for sustained,
local delivery of acid resistant proteins. However, there are still a number of issues which may have an
impact on the stability profile of loaded proteins that should be addressed in this strategy. For example,
the use of organic solvents during the device preparation may change the protein confonnation. Also,
the use of ultraviolet radiation during the photocuring of this elastomerwas'reported to denatureproteins
and consequently destroys their biological activity.62 To date, there are no in vivo preclinical or clinical
studies on the therapeutic efficacy of this new delivery system.
Beside that, another elastomer was developed by Chapanian et al., to provide the delivery of
vascular endothelial growth factor (VEGF I6S) and hepatocyte growth factor (HGF) by preparing a dual-
layere,2 c~inder, in which VEGF I6S was in the outer layer and HGF in the inner layer.92 This elastomer
is based on trimethylene carbonate (TMC) since it degrades without producing potentially harmful
acidic degradation products, and its mechanical properties can be tailored by copolymerizing withd,l-
lactide (DI::J:A)iiiia t-caprolactone (t-CL) and by controlling the crosslinking density. VEGF I 6S and
HGF were lyophilized separately or together with trehalose, rat serum albumin (RSA) and NaCI and
their bioactivities after released were assessed in vitro. They revealed that TMC based elastomer
combined with an osmotic mechanism to release acid sensitive growth factors in bioactive fonn, alone
or in combination, controlled rates and sequences. The prepared cylinders were able to provide a
sustained release of highly bioactive VEGF I 6S and HGF for more than IOdays. When released in
combination from the same device, VEGFI6S and HGF were released at similar rates. A constant release
of VEGF alone was first obtained, followed by overlapping and constant release of the two growth
factors after a period of4days. Having said that, the use of organic solvents and ultra violet radiation
during the photocuring are issues that should be addressed, since they have an impact on the stability
profile of loaded proteins. Also, more in vivo investigations and studies are still required to examine its
ability to fit in the protein delivery system pipeline.
Shalrer et al.• have demonstrated the ability to rapidly form elastomeric structures from acrylated
poly(diol-tricarballylate) (pOl) using visible light crosslinking in the presence of camphorquinone (eQ)
as a biocompatible photoinitiator and under solvent-free conditions.93 The tricarballylic acid and the
alkylene diol were selected as building blocks for the construction of the new elastomers since
tricarballylicacidisabundantlypresentinfoodproductsandpossessesstructuralsimilaritytosevera!
biologicalactivecompoundssuchascitricacidandaminoacid.93 0ntheotherhand,aliphaticdiolsare
reported to be biocompatible intermediate compounds used in the synthesis of polymeric systems
including, polyester elastomers, coatings, adhesives, and polymeric plasticizers. Diols as well, add many
high performance characteristics to the final structure of the elastomer such as hydrolytic stability,
incre~edJlexibility, improved adhesion, and surface hardness. The avoidance of UV photocrosslinking
drawbacks, the solvent-free preparation process, and the controllable drug delivery,94 as well as
biocompatibility properties95 of these biodegradable polymers make them excellent candidates for use in
thermosens~rapeutic protein and peptide delivery. A release study for loaded IL-2 elastomer
utilizing the osmotic driven release mechanism done by the same research group. The results show this
elastomer was able to control the IL-2 release over a period of 28 days and the increase in the
elastomeric devicc's surface area and the incorporation of trehalose in the loaded lyophilized mix
increased the IL-2 release rate. As well, the results showed that the decrease in the degree of prepolymer
acrylation of the prepared elastomeric devices increasedtheIL-2 release rate. Alsothe data showed that
the released IL-2 retained more than 940/0 of its initial activity. More details regarding the release and
bioavtivity results ofloaded protein with this elastomer is descriped in chapter 6.
2.7. CONCLUSIONS
Photopolymerization technology is the reaction of monomers or oligomers to form a linear or
crosslinked polymer structure by light induced initiation. It is a very promising multidisciplinary
technologythatcouldbeusedtoproducepolymericnetworksforbiomedicalapplications. Well defined
photoinitiated polymers such as hydrogels and elastomers can be formed with varying polymer
formulations in three dimensional patterns and they can also be designed to degrade via hydrolytic or
enzyrnaticprocesses. Furthermore, they can also be modified with biofunctional moieties within their
structure to manipulate cell behavior since have been widely explored for and become more attractive
for future research. For drug delivery applications, some "smart" photopolymerizable biomaterials have
generally been synthesized through modification of some molecules which are sensitive to circumstance
parameters such as tempemture and pH. These can become potential candidates for controlled drug
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CHAPTER 3
Synthesis, Characterization and Cytocompatibility of
Poly(diol-tricarballylate) Visible Light
Photocrosslinked Biodegradable Elastomer
The content of this chapter was published in the Journal of Biomaterial Science 21 ,4,507-528(2010).
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ABSTRACT
The synthesis, characterization and in vitro cytocompatibilityofanew family of photocrosslinked
amorphous poly(diol-tricarballylate) (pDT) biodegradable elastomeric polyesters are reported. The
synthesis was based on the polycondensation reaction between tricarballylic acid andalkylenediols,
followed by acrylation. The formation of PDT and its acrylated derivatives (APDT) was characterized
by means of Fr-IR, IH_ NMR, GPC and DSC. Liquid to solid photo-curing were carried out by
exposing the APDT to visible light in the presence of camphorquinone as a photoinitiator. The thermal
properties, mechanical characteristics, the sol content, long-term in vitro degradation and
cytocompatibility of the prepared PDT elastomers were also reported. The mechanical and degradation
properties of this newphotocurable elastomer can be precisely controlled by varying the density of
acrylate moieties in the matrix of the polymer, and through changes in the prepolymer chain length. The
use of visible Iightcrosslinking, possibilityofsolventless drug loading, thecontrollablemechanical
properties and cytocompatibility of these new elastomers make them excellent candidates for use in
controlled implantable drug delivery systems of protein drugs and other biomedical applications.
\-
3.1. INTRODUCTION
In the past decade, biodegradable elastomeric polymers have gained considerable attention due to the
renewed interest in their applications in the fields of biomedical tissueengineering l'3 and implantable
drug delivery systems.4-9 Elastomers can be regarded as one of the best biomaterials for such
applications because their mechanical properties can be manipulated in a manner that makes them as
soft as body tissues. They have the ability to recover and withstand the mechanical challenges upon
implantationinamobilepartofthebodyandtheyarealsoprovedtobewellsuitedfordrugcontrolled
drug delivery applicationsY
Biodegradable elastomers reported in the literature have been synthesized as one of two types:
thermoplasticl()-I2 or thermoset elastomers. I.ll,14 While thermoplastics offer the advantage of ease of
fabrication, they degrade heterogeneously due to the mixture of crystalline and amorphous regions. This
can lead to rapid loss of mechanical properties as well as large deformation as the material degrades.
Conversely, although thermoset polymers are not easily fabricated by heat, they outperform
thermoplastics in a number of areas, including uniform biodegradation, mechanical properties, and
overall durability, This makes thermoset elastomers better suited for controlled drug delivery
applications.
One of the common approaches reported earlier to prepare thermoset elastomers is to first prepare
multi-arm star condensation polymers by subjecting biodegradable monomers to ring-opening
polymerization in the presence of polyoIs asinitiators:,II.IS.18 The prepared star-shaped condensation
polymers are then crosslinked using thermal or non-thermal approaches. Some of the thermal
crosslinkingapproaches reported involved the preparation of polyurethanes that contain the 4,4'-
methylphenidate diisocyanate which degrades to toxic and carcinogenic products and raises issues of
biocompatibility.IJ.19 Other elastomers were prepared by thermal free-radical curing of terminal
methacrylated oligomers which involved the use of incompatible catalysts and solvents.14 Some of the
compatibility issues of crosslinkers used were overcome by using bis-lactone crosslinkers.2o These
crosslinking agents were previously reported in crosslinking lactides, E-caprolactoneand dioxepanone
monomers21 -24 and lately in crosslinking star polymers made of E-caprolactone and DL-lactide using
glycerol as initiator.I,2~ One of the disadvantages in the polymers prepared from E-caprolactone and
lactides is that they will only be composed of hydrophobic segments that contribute to their long and
slow bioabsorption and decreased biocompatibility. This made such polymers more susceptible to
proteinadsorption26-21 and fibrous tissue formation around the implant which eventua1ly resu1t in device
failure.29.JO On the other hand, the acrylated UV crosslinked version of the same thermally crosslinked
polymers involved the use of organic solvents like tetrahydrofuran and dichloromethane to incorporate
the drug into the pre-crosslinked mass. This raises issues with regard to compatibility and evenstability
ofloadedbioactiveagents.JIFinally,thepreparationstepsinvolvedinpreparingthe above described
elastomers required high temperatures (120-l40°C) and took at least 3 or more days to obtain thefinal
preparations. I.4,32
Another approach to prepare elastomeric polymers was also reported through polycondensation
reactions betweendi- and tri-carboxylic acids and diols which were further subjected to thermal or
photocrosslinkingprocess. Elastomers based on tartaric acid, citric acid and sebacic acid monomersand
their copolymers were reported earlier.JJ·J7 Some of these reported elastomers either required long
curing times ranging from a few days to weeks to prepare, or the elastomers prepared were tough and
brittle with some inconsistency in their final physical properties. In addition, high crosslinking
temperatures were needed for their crosslinking which restricted their use in drug delivery of thermally
sensitive therapeutic agents. Recently, UV photocured elastomer prepared from acrylated poly(glycerol
sebacate) was reported.33-39 The elastomer's mechanical properties demonstrated dependence on the
degreeofacrylationandthepercentageofPEGdiacrylateadded.A1thoughthiselastomerdemonstrated
to be promising, the nonacrylated prepolymers used in its photocrosslinking required almost two dayst0
prepare. In addition, the prepolymers possessed a high polydispersity index (",3.5), therefore, the
elastomer may demonstrate non-linear degradation profiles once long term degradation studies are
conducted. There remains a need for biodegradable and biocompatible elastomeric polymers that can
cirCWnVent some of those aforementioned limitations.
Herein, we demonstrate the ability to rapidly form e1astomeric structures from acrylated poly(diol-
tricarballylate) (POn using visible light crosslinking under ambient and solventless conditions. We
selected tricarballylic acid and the alkylene diol as building blocks for the construction of the new
elastomerssincetricarballylicacid(propane-I,2,3-tricarboxylicacid)isoneofthesinJplestclassesof
aliphatic acids; it is abundantly present in food products and possesses structure similarity to severa!
biological active compounds such as citric acidandaminoacid.40 0ntheotherhand,aliphaticdiolsare
biocompatible intermediate compounds used in the synthesis of polymeric systems including polyesters
elastomers, coatings, adhesives and polymeric plasticizers. Oiols add many high-performance
characteristics to the final structure of the elastomer such as hydrolyticstability,increased flexibility,
inJprovedadhesion,andsurfacehardness.Wealsoexploredthevisiblelightphotocrosslinkinginthe
presence of camphorquinone (CQ) as a photoinitiator. We selected camphorquinone because of its
cylocompatibilityandhistoryinbiomedicalvisiblelightphotopolymerization.4I
The main objective of this work is therefore, to report on the synthesis and characterization of PDT
photo-eured biodegradable elastomers. In addition, we report on the effect of varying the density of
acrylate moieties in the matrix of the polymer as well as varying the polymer chain length on the
mechanical properties and degradation behavior of the newly prepared elastomers.
3.2. EXPERIMENTAL
3.2.1. Materials
Tricarballylic acid, 1,6-hexanediol, 1,8-octanediol, 1,IO-decanediol, 1,12-dodecanediol, stannous 2-
ethylhexanoate, 4-dimethylamino pyridine, acryloyl chloride, triethyl amine, sodium suiphate,triethanol
amine, and champhore-quinone were purchased from the Aldrich-Sigma chemical company. Acetone
and chlorofonn were purchased from the Caledone chemical company. All chemicals were analytical
grade and used as received without any further purification.
3.2.2. Synthesis ofPoly(diol-tricarbaUylate) PrepoIymen
PDT prepolymers were prepared by solvent-free step growth polymerization.33 A representative
synthesisprocessofpoly(l,8octanediol-eo-tricarbailylate)isdescribedhere.Into a three-neck 250 mI
round-bottom flask equipped with a condenser, a nitrogen inlet and a magnetic stirrer, was added9.504
gofl,8 octanediol (0.065 mole), 7.05 g oftricarballylic acid (0.04 mole) in the presence of stannous 2-
ethylhexanoate as a catalyst (lxlO-4 mol). The mixture was heated to 140 ·C under continuous stirring
for 20 minutes. After that, the reaction was continued for 10 more minutes under vacuum to remove the
fonned water. The prepared crude prepolymer was then purified by dissolving in acetone and
precipitation in cold anhydrous ethyl ether. The prepolymer formed was then dried under vacuum
overnight. The following PDT prepolymers were synthesized: poly(hexane diol-co- tricarballylate)
(PHl), poly(octane diol-co- tricarballylate) (pOT), poly(decane diol-co- tricarballylate) (pOET) and
poly(dodecane diol-co-tricarballylate) (pOOT).
3.2.3. Aerylation of Prepolymer
Acrylation of the prepared PDT prepolymers was carried out by reacting acryloyl chloride (ACRL)
with the terminal hydroxyl groups of the prepolymers in the presence of triethylamine (TEA) and, 4-
dirnethylaminopyridine which acted as a catalyst. One mole of ACRL was used to react with every one
mole of OH in the prepolymers identified based on end group analysis. The following procedure
describes the methodology to acrylate POT. Figure 3.1 shows a schematic representation of the synthesis
pro;ss-:-Into a 250 mI round-bottom flask equipped with a magnetic stirrer, 10 g of POT prepolymer
was dissolved in 60 mI of acetone to which 10 mg of 4-dimethyl aminopyridine (DMAP) was added as a
catalyst. The flask was sealed, flushed with argon and then immersed in a 0 ·C ice bath. A stepwise
addition of 2.37 mI of ACRL (2.92 mmole) with 4.05 mI of TEA (equimolar amounts) to the prepolymer
solution was carried out over a period of 12 hrs. The equivalent molar amount of TEA was used to
scavenge the hydrochloric acid formed during the reaction. The reaction was continued at room
temperature for another 12 hrs. The final solution was filtered to remove triethylamine hydrochloride
salt formed during the acrylation reaction. The acrylated prepolymer solution was then dried at 45 ·C
under vacuum using a rotary evaporator and then dissolved in chloroform. Further purification was
carried out by washing this chloroformic solution several times with deionized water and then drying it
OH
O~ +HO-(C~)nQ1
OH alkylenedlol
o n=6,B,lOcr12
Q1
Tricarballylicacid
Figure 3.1. Schematic illustration of the synthesis, acrylation and photocuring of poly(diol-
tricarballylate).
over anhydrous sodium sulphate. Chlorofonn was then evaporated at 45 ·C under vacuum using a rotary
evaporator and the acrylated prepolymer was left in the vacuum oven over night at room temperature for
complete removal of solvents. The final purified product was then subjected to chemical and thennal
analysis to confinn the chemical structure and the final product's purity and thennal properties. The
acrylated POOT prepolymers were prepared following the same procedure as described above but using
varying reactant ratios that would achieve the preparation of prepolymers with 100%,75% (POOTo.7S)
and 50% (POOTo.s) theoretical degreesofacrylation.
3.2.4. Photoeuring of the Aerylated Prepolymen
The photocuring process was carried out in a dark fume hood equipped with a sodium lamp. On a
watchglass,51l10flO%ethanolicsolutionofbothcamphorquinoneandtriethanolamine(equivalentto
0.01% (w/w) photoinitiator) was added to 5 grams of the acrylated prepolymer. The mixture was then
left at 40 ·C under vacuum for 4 hr to ensure complete removal of any traces of alcohol from the
photoinitiator solutions. The dried mixture containing the acrylated prepolymer and the initiator was
then poured into a Teflon mould using a spatula The mould was then exposed to a visible light source
(450-550 nm at a 40 mW/cm2) filtered from a 50 Watt tungsten-halogen lamp (Taewoo Co., Korea) for
10 minutes at a distance of 10 cm to fonn the elastomer which was then removed from the mould for
further testing.
3.2.5. Chemical and Thermal Characterization
Fourier transfonn infrared (FT-IR) spectra of the prepared prepolymers, acrylated prepolymers and
photocured elastomers were obtained at room temperature using a Broker Tensor 27 infrared
spectrometer equipped with a MIRacle attenuated total reflection accessory unit, over the wavelength
range of 4000-400 cm- l . The spectra were collected with a resolution of 4 cm- l and a scan number of 32
using a mercury cadmium telluride (MCT) detector. Proton nuclear magnetic resonance eH-NMR)
spectra for the octane tricarballylate prepolymer and acrylated octane tricarballylate prepolymer were
recorded at room temperature on a Broker Avance-500 MHz NMR spectrometer. The sample was
dissolved in chlorofonn-d (CDCl3 containing 0.1 % (v/v) tetramethylsilane) in a 5 mm diameter NMR
tubes. The chemical shifts in parts per million (ppm) for the lH_ NMR spectra were referenced relative
to tetramethylsilane (TMS, 0.00 PPM) as the internal reference. The signal intensity of the methylene
groups ofdiols (1.3-1.7 ppm) and the acrylate groups' intensities (5.8-6.4ppm) were used to calculate
the degree of acrylation in the polymers. Molecular weights and molecular weight distributions were
determined using a Waters gel penneation chromatography (GPC) system (Waters, Milford, CT)
equipped with 410 Waters differential refractometer(RI Detctor) and on-line multiangle laser light
scattering (MALLS) detector (pD 2000 DLS, precision detectors, MA). The column configurations
consi~ed.i>f an HP guard column attached to a phenogel (2) linear 51! column (300 x 7.8 mm2). The
mobile phase consisted of anhydrous tetrahydrofuran (THF) at a flow rate of I mllmin at 35°C. The
sample concentration was 20 mglml and the injected volume was 75 I!I. The absolute MWts determined
by MALLi;;;~--; dnldc value of 0.172 mIIg calculated from the RI detector response and assuming
100% mass recovery through the column. Data were collected and handled using Precision
AcquirelDiscovery software package. End group analysis was conducted to determine the hydroxyl
number of the prepared prepolymers by catalyzed acetylation.42 Briefly, in a 125 ml conical flask, I
gram of the prepared prepolymer was dissolved in I ml acetone. Five milliliters of 2 % (w/v) 4-
dimethylaminopyridineinpyridinefollowedby2mlof25 % (v/v) acetic anhydride inpyridine,were
transferred to the solution in the flask and mixed well. After 20 minutes, 25 ml of distilled water was
added to the mixture followed by the addition of three drops of I% phenolphthalein solution. The
solution in the flask was then titrated against 0.5 N sodium hydroxide until the end point is reached
indicated by pink color formation. A blank control experiment was also carried out following the exact
procedure but without the addition of the prepolymers. The number of millimoles of hydroxyl group
present in the prepolymer samples is given by N (Vb-V.J, where Vb and V, are the milliliters of sodium
hydroxide solution ofN normality required to titrate the blank and the prepolymer sample, respectively.
The results of this end group analysis were compared with those estimated from weight average
molecular weight analysis using GPC. The thermal properties of the polymers were characterized using
Q200 differential scanning calorimeter (DSC) equipped with a liquid nitrogen cooling system. The
measurements were carried out at a heating rate of 10 ·C/ min. In order to provide the same thermal
history, each sample was heated from room temperature to 150·C and rapidly cooled down to -100 ·C,
then the DSC scan was recorded by heating from -100 to 150 ·C.
3.2.6. Mechanical Properties and Sol Content Measurements
Tensile mechanical testing was conducted on an Instron modelln-Spec 2200 tester with Merlin Data
Management Software. The tensile tester was equipped with 500 N load cell. Dog-bone shaped samples
of 30 mm in length, 3 mm in thickness, 5 mm in width at the narrow section and 15 mm in width at the
gripping section were used for that purpose. The sample was pulled at a rate of 1.0 mm/sec and
elongated to failure. Five specimens of each elastomer were measured, and the mean and standard
deviation were calculated. All specimens were tested at room temperature. Values were converted to
stress-strain and plotted. Young's modulus was calculated from the initial slope of the stress-strain
curve. The crosslink density (p.) was calculated according to the theory of rubber elasticity following
thc'eqlllitlon: Px = F1 3RT, where Px represents the number of active network chain segments per unit
volume (mole I m\ E represents Young's modulus in Pascal (pa), R is the universal gas constant
(8.3144 J/mol K) and T is the absolute temperature (K). Soxhlet extraction with dichloromethane as a
solvent for 24 hours at 45 DC was used to determine the sol content of slab samples of the elastomers (20
x 20 x 3 mm3) with weight (WI). Samples were then dried to constant weight in vacuum oven (W2).
These measurements were done in triplicate for each elastomer sample. The sol content was calculated
from the equation: S% = [(WI-W2) I WI] X 100.
3.2.7. In vitro Degradation
Dog-bone-shaped samples of known weights (Wi), which were 30 mm in length, 3 mm in thickness
and 5 mm and 15 mm in width at the narrow and gripping section, respectively, were placed in 40 mI
vials each containing 35 ml ofO.! M phosphate buffer saline (PBS) pH=7.4 and 0.01% of sodium azide.
The vials were attached to a glas-col's rugged culture rotator. The rotator was set at 20% rotation speed
and placed in an oven at 37·C for up to 12 weeks. The buffer was replaced daily to ensure a constant pH
of 7.4. After 1,2, 3, 4, 6, 8, 10 and 12 weeks, the swollen weight (W2) and dried weight (W3) were
measured after wiping the surface water with filter paper and after vacuum-drying at 45 ·C for 2 days,
respectively. The water absorption & weight loss were calculated as follows:
-weight loss % = [(Wi-W3) I WJ]X 100.
Water absorption % = [(W2-W3) I W3] X 100.
The tensile properties of the degraded samples at these intervals were also measured. The results were
reported as the mean and standard deviation of three measurements.
3.2.8./n viJro Cytocompatibility and CeU Proliferation
Murine fibroblast cell-line (AKR-2B) was grown in T-75 tissue culture treated flasks using
Oulbecco's Modified Eagle Medium (DMEM; Invitrogen) supplemented with 10% (v/v) fetal bovine
se~ ;t-:37· C in a 5% C02/air atmosphere. Cells were plated in 24 well plates (Falcon), at a density of
40,000 cells/well, in I mJ of medium and allowed to attach for 24 hours prior to the initiation of
experiments. Photocuredpoly(diol-tricarballylate) films were prepared by visible light polymerization
on 22 mm cover-glasses. The film was then cut into pieces of approximately 100, 200 and 300 mg and
sterilized by autoclaving. Film pieces of different mass were added directly into triplicate wells
containing attached cells and incubated for 24 hrs at 37°C. After 24 hrs phase contrast
photomicrographs were taken using an inverted microscope (Diaphot, Nikon) equipped with digital
camera (Coolpix4500, Nikon,). Cytotoxicity, expressed as relative cell density, was assessed
spectrophotometrically using a modified neutral red dye staining assay.43 Briefly, after 24 hrs
incubation, elastomer pieces were removed and each well was washed twice with 500 f1l of phosphate
buffer saline (PBS). Following removal of wash buffer, 250 III of 0.15 0/0{ w/v) Neutral Red, in PBS,
was added to each well and placed on an orbital bench top shaker for 30 min. Excess dye was removed
with two washes of 500 f1l PBS and cell associated dye solubilized with 250 III of lysis buffer(50%v/v
ethanol in PBS) by shaking for 30 minutes. From each well 200 f1l was transferred to acorresponding
well of a 96-well plate and absorbance was read at A= 492 nm in a Polarstar, Optima plate reader (BMG
Scientific). The differences of cell density between the four different poly(diol-tricarballylate)
elastomeric films were compared to that of untreated cells. Results reported were the mean ± SO from
three independent experiments each done in triplicate. Differences were evaluated with 2-way ANOVA
using Graphpad Prism software.
3.3. RESULTS AND DISCUSSION
Thegoalofthisresearchworkwastopreparevisiblelightphotocrosslinkedpoly(diol-tricarballylate)
elastomers. As shown in Figure I, the elastomers were prepared in three main steps. First, tricarballylic
acid was reacted with excess diol to produce low molecular weight prepolymers. To obtain low
molecular weight prepolymers, the reaction was stopped after 30 minutes. The obtained prepolymers
were colorless or clear light yellow viscous liquids. The second step involved the conversion of the
terminal hydroxyl groups in the resulting prepolymer network into vinyl groups by an acrylation
process. The obtained acrylated prepolymers were also colorless or clear light yellow viscous liquids.
Both the acrylated and un-acrylated prepolymer did not dissolve in water but were soluble in most
organic solvents. In the final stage, visible light photocrosslinking of the acrylated prepolymers was
conducted which resulted in the formation ofelastomeric crosslinked networks. Thephotocrosslinked
elastomers were stretchable and rubbery and swelled but did not dissolve inorganic soIvents.
3.3.1. Chemical and Thermal Characterization
The molecular weights of the prepolymers as measured via OPC are listed in Table 3.1. As expected,
the molecular weights of the prepared prepolymers increased upon increasing the number of methylene
groups in the backbone of the used diol. The OPC analysis also showed that the prepared prepolymers
demonstrated narrow distribution in molecular weights withpolydispersity indicesapproachingunity
I
II
Table 3.1. Results ofGPC and end group analysis ofpoly(diol-tricarballylate) prepolymers.
Mw:weightaveragemolecularweight.
(1.04-1.39). Also, the results of chemically detennined millimoles oftenninal hydroxyl groups which
are listed in Table 3.1, were very close to those estimated from OPC analysis which indicated that the
polymerization step proceeded as estimated. End group analysis for the prepared prepolymers was
important to detenninethe number ofhydroxyl groups available for further acrylation reaction (extent of
acrylation) and to ensure that all the prepolymers reacted with the optimum amount of acryloyl chloride
during the acrylation process.The POT purified prepolymer, acrylated prepolymer and elastomer were
all characterized using FT-IR analysis. As shown in Figure 3.2, the IR spectrum of the purified POT
prepolymer (Figure 3.2A) showed a broad absorption band at 3600-3400 cm,l that was attributed to the
hydrti~yl stretching vibrations, The broadening in the band was attributed to the intermolecular
hydrogen bond formation. The absorption bands at about 2930 cm,l and 2857 cm,l were attributed to C-
H stretching_yibra~ons of the methylene group. The carbonyl group of the formed ester appeared at
about 1710 cm,l. The bands from 1300-1000 cm,l were attributed to CoO stretching vibrations. In the
spectrum of the acrylated prepolymer (Figure 3.2 B), the disappearance of the broad OH band and the
appearance of two new bands at around 1635 and 813 cm,l was an evidence that the incorporation of the
tenninal acryloyl moieties was successfully achieved. The first band at 1635 cm,l corresponds to the
C=C bond stretching, while the band at 813 cm,l corresponds to C=C bond twisting vibrations. These
two bands are related only to the acrylatedgroups and known not to be present in the FT-IRofacryloyl
chloride. The same two bands at 1635 and 813 cm,l completely disappeared after photopolymerization
took place (Figure 2 C). This was attributed to the crosslinking process which consumed the C=C
tenninal bonds in the free radical initiated reaction. As illustrated in Figure 3.1, a free radical was
formed by the decomposition or oxidation of the photoinitiator in the presence of light. This free radical
initiated abstraction of one hydrogen atom of the double bond -CH=CH2 of the acryloyl moiety. The
acrylated free radical then attacked a double bond in an adjacent polymer chain. Figures 3.3aand3b
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Figure 3.2. FfIR analysis of POT, A: before acrylation, B: after acrylation and C: after photocuring.
(a)
(b)
Figure 3.3. 'H NMR spectrum of (a) poly(octane-tricarballylate) prepolymer, (b) acrylated poly(octane-
tricarballylate)prepolymer.
show the IH_NMR spectra of POT and the acrylated POT prepolymers respectively. The incorporation
oftheterrninal acrylated groups was confinnedby the appearance of three peaks at 5.8, 6.1 and 6.4 ppm,
which were attributed to the presence of vinyl group. The decrease in the integration of the overlapped
peaks, which appeared at about 3.63 ppm, was due to the disappearance of the terrninal OHproton.
The thermal behavior of the prepolymers, acrylated prepolymers and photocured elastomers are
shown in Figure 3.4 and summarized in Table 3.2. The thermal analysis of the prepolymers showed that
PHT and POT were both amorphous while PDET and PDDT were both crystalline. The reported
crystallinity of the PDET and PDDT were calculated from the heat of fusion assuming proportionality to
the experimental enthalpy. The reported enthalpy of fusion of 1,10 decanediol (249.6 JIg) 44 and 1.12
dodecanediol (234.8 JIg) 45 were respectively used as references for 100% crystalline PDET and PDDT.
Following acrylation the T10fPHT and POT increased. PDET became amorphous while the Tm and MI
of PDDT decreased to 0 °C and 31 JIg, respectively. After photopolymerization all the crosslinked
elastomers were amorphous with Tg's below 37· C which indicated that all elastomers were in a well
rubbery state at body temperature. The thermal behavior of the prepolymers, acrylated prepolymers and
photocuredelastomers can be explained as follows: First, as the number of methylene groups in the
polymer chain increased, the molecular weight also increased resulting in an increase in both the Tg and
the degree of the polymer crystallinity. This is consistent with the fact that Tg and crystallinity for an
aliphatic polyester increases with an increase in the number of methylene groups in their chain length.46
Second,the incorporationofacryloyl group at the terminals of the prepolymers led to an increase in the
T1 as well as a decrease in the crystallinity compared to those of the unacrylated prepolymers. This
behavior has previously been observed for some polyester elastomeric networks.4.47 ThischangeinTg
ranged from II to 6· C for PHT and POT, respectively. It was also noted that the acrylation process
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Figure 3.4. Differential Scanning Calorimetry thermograms ofpoly(diol-tricarballylate) (A)
prepolymers, (B) acrylated prepolymers and (C) elastomers.
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Table 3.2. Thermal properties of poly(diol-tricarballylate) prepolymers, acrylated prepolymer and
elastomers.
POET -36 -9 32 12.8
POOli ----- 26 55 23.4 31 13.2
'Degree of crystallinity was calculated from the equation, MJI~WxIOO, where ~H is the enthalpy change of the each
compoundand~Wisthatofasinglecrystalofcorrespondingdiol.
--
diminished the crystallinity of POET and POOT due to the fact that the acrylated domain's rigidity
disrupted the regularity of the prepolymers and decreased the ability of the crystal lattice in the polymer
from regularly arrange. Third, crosslinking resulted in additional increase in T1 and decrease in the
crystallinity compared to those of the uncrosslinked acrylated prepolymers. In particular, crystal
formation of acrylated POOT was remarkably diminished by the photocrosslinking reaction, thus the
POOT networks became completely amorphous. This is also explained by the fact that crosslinking
suppressed the mobility of molecular chain and prevented chain rearrangement as a result ofwhichan
obstruction of crystal formation took place.41
3.3.2. Mecbanical Properties and Sol Content Measurements
To determine the effect of chain length of the diol monomer and the degree ofacrylation (DA)on
the mechanical properties of the crosslinked elastomers, polymers listed in Table 3.3 were subjected to
tensile testing. Figure 3.5a shows that tensile testing of the photocrosslinked PDT elastomers produced
representative uniaxial tensile stress-strain curves which are characteristics of typical elastomeric
materials. Avemge values for Young's modulus (E), ultimate tensile stress (cr), cross-linking density
(Px), and maximum strain (c) are summarized in Table 3.3. The mechanical properties spanned from
elastic to brittle depending on the diol used and the degree of elastomer acrylation. No permanent
deformation was observed during the mechanical testing (Figure 3.5 b). The value of cr was as high as
0.25 MPa while the value of I: was as high as 238.28 %, under the synthesis condition. As reported in
Table 3.3, PHT elastomer has the highest cr and E values. This was attributed to the fact that PHT
possessed the lowest number of methylene groups in the chain of the diol used in the prepared
prepolymers. As the diol chain length of the prepolymers decreased, the Px of the polymer increased
--: :-~ - - - --
Figure 3.5. (a) stress-strain curves of poly(diol-tricarballylate) elastomers. (b) POT elastomer shows
100% recovery after being stretched to break.
Table 3.3. Mechanical properties and sol contentofpoly(diol-tricarballylate) elastomers.
Elastomer (MPa) (%)
E P, S
(MPa) (mole/m') (%)
DA*
(%) Description
PHT 0.2S±0.03 47.36±1.39 0.6S±0.OS 87.44±6.729.36±Z.96 0.87
POT 0.18±0.02 S3.30±3.6 0.44±0.025 59.19±3.36 8.0Z ± 3.11 0.86
POET 0.14 ± 0.02 61.23±S.83 0.33±0.023 44.39±3.09 1I.9S±5.69 0.91
PDDT 0.072±0.01272.35±6.4 0.11±0.016 14.79±2.IS 10.4Z ± 3.80 0.89
Hard,Brittle
PDDT~s 0.029±0.002238.2±6.11 0.012±0.002 1.6±0.26 59.06±11.O3 Very weak,
Elastic
*estimatedbyNMR
which resulted in the fonnation of a crosslinked elastomer that is stiffer and less extensible. On the other
hand, increase in the alkylene diol chain length decreased Pxand therefore, increased E of theelastomer.
Finally, it was also noted that the decrease in DA of PDDT prepolymer resulted in a decrease in the Px
which increased the elastomer stretchablility and elasticity (Figure 3.5a). The sol content for the
different PDT elastomers did not change appreciably as a function of the chain length of the
prepolymers; however, it was affected by varying the DA. The sol content represents the mass
difference after removal of the uncrosslinked prepolymer which is soluble in dichloromethane. As such,
the decrease in the number of terminal acrylated groups in the prepolymersdecreased thecrosslinking
during photocuring and increased the sol content in the prepared elastomer. Therefore, PDDTo.,
elastomer, with the lowest calculated degree ofacrylation (0.38),possessed the highest sol content
among all the prepared elastomers. Although stretchability will strongly improve as a result of
increasing the sol content ofPDDT elastomer, the relatively low sol content will help in maintaining the
mechanical properties after implantation.
3.3.3. In vitro Degradation
3.3.3.1. Influence ofchain length on in vitro degradation
In orderto-exarnine the influence of chain length on the degradation rate and the changes in the
mechanical properties of the elastomer during the in vitro degradation, four different PDT elastomers,
based on varying chain lengths of alkylene diol were prepared and tested. Figure 3.6 shows the weight
loss and water absorption data for the four prepared PDT elastomers. As can be seen, the water
absorption and weight loss of the elastomers were directly proportional to the chain length of the
alkylenediolusedandinverselyproportionaitotheelastomers'p.(fable3.3).Forexample, at the end
of the 12 weeks period, PHT elastomer, which had the lowest number of methylene groups in its chain
and the highest P., demonstrated the lowest weight loss with minimal water uptake rate. Such findings
were consistent with our previously reported results regarding the diffusion of water into the bulk of
elastomericpolyesters at temperatures above their glass transition. I Also, the results are in accordance
with the fact that water diffusion and mass loss are inversely proportional to the polymer's p•.49-50
3.3.3.2. Degradation behavior
It is well known that surface erosion occurs when the elastomer's degradation rate is faster than the
rate of water diffusion into theelastomer.51 •52 Conversely, bulk erosion occurs if degradation and weight
loss are correlated with the rate of water penetration into the bulk of the elastomers.51•52 As shown in
Figure 3.6, all the elastomers exhibited a two-stage water absorption and weight loss behavior.Inthe
fl1'St stage, which lasted up to 4 weeks, the water absorption and weight loss proceeded rapidly which
resulted in the changes in elastomer's morphology (Figure 3.7). However, in the second stage, the water
absorption and weight loss took place in a slower rate and exhibited little observablechangesinthe
dimensions of the prepared elastomer (Figure 3.7 d). The degradation of PDT elastomers proceeded as
follows: after the immersion of the elastomers in the phosphate buffers saline, water diffusion and
absorption into the elastomer mass took place and resulted in thehydrolysisofthepolymerchains.This
process was not limited to the surface but mainly took place in the bulk of the elastomer. The firststage
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Figure 3.6. Degradation results ofpoly(diol-tricarballylate) elastomers in PBS at 37 ·C. (a) percentage
weight loss versus time. (b) percentage water absorption versus time. Error bars represent the standard
deviation of the mean of measurements from three samples.
Figure 3.7. Images of the PDDT elastomers during in vitro degradation after: (a) 0, (b) I, (c) 4, and (d)
12 weeks.
of degradation was also accelerated by the diffuse out of the hydrolysis products from the s01 phase of
the polymer which further contributed in the formation of oligo carboxylic acids within the polymer
mass which auto-catalyzed the degradation rate further and increased the hydrophilic character 0 fthe
polymer due to the formation of free -COOH and -OH moieties within the elastomer bulk. As such, the
elastomers became more susceptible to water absorption and therefore swelling in the matrix and
changes in elastomers from flat shape to a bloated convex shape occurred. In addition, the surface
became smooth and translucent (Figure 3.7c) and further mass loss took place with water absorption.At
the end of the first 4 weeks period, the rate of production of short chain fragments decreased
significantly which resulted in a much lower internal pressure or driving force that enables those
fragments to diffuse into the surrounding medium. As a result of that, the weight loss in the tested
samples proceeded in a much slower fashion after the initial 4 weeks period. The above degradation
behavior confirms that all matrices underwent bulk erosion similar to other previously reported
polyesters.1.0.51
3.3.3.3. Changes in the mechanicalproperties during in vitro degradation
Figure 3.8 shows the changes in the mechanical properties of the elastomers withrespecttotime
during the in vitro hydrolytic degradation study. Although the elastomers showed a decrease in their
mechanical strength with time, they maintained their shape and extensibility over the testing period.
BothEand cr decreased in a linear fashion with time as indicative of zero-order degradation mechanism.
This linear decrease was observed regardless of the network composition, the crosslinking density and
the initial E and " of the elastomers. Figure 3.8 C shows that the change in I: was less sensitive to the
degradation of those elastomers. No significant change in I: was found up to 12 weeks of the in vitro
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Figure 3.8. Change in tensile properties of the elastomers during degradation in PBS at 37°C. (a)
Young'smoduius,(b)ultimatestressand(c)ultimatestrain,linesarefitted curves to equation (I) and
(2). Error bars represent the standard deviation of the mean of measurements from three samples.
degradation time. These results confirmed that the hydrolytic degradation of these elastomers followeda
bulk erosion mechanism, resembling the behavior of biodegradable polyesters reported previously.49 It is
only with surface erosion degradation pattern that the elastomers can maintain their mechanical
propertiesunchanged13. Additionally, Figures 8aandb,showthatEandaforalitheeiastomerslinearly
decreased with time.
Through a linear regression of the zero-order degradation kinetics of the data in Figure 3.8 aandb
usingequations(I)&(2),therateconstantswerecalcuiatedandarelistedinTable3.4.
(I)
(2)
In equations I and 2, t denoted the immersion time (in weeks) in PBS. The values of Eo and 0()
corresponded to the intercepts obtained from extrapolating the zero-order fitted line. Kaand KE
represented the zero-orderdegradationconstants for Young's modulus and the ultimate tensile stress,
respectively. The decrease in the alkylene diol chain length in the elastomer was accompanied by an
increase in KEand K•. As seen, the KE and~ for PHT were 0.0441 and 0.0154 MPa/week, respectively,
while KE and Ka for PDDT were 0.0080 and 0.0018 MPa/week, respectively. We previously reported
that Young's modulus of the elastomers depended mainly on the crosslinkingdensity and the ultimate
tensile stress depended on the distribution of end to end distances between crosslink points within the
matrix. I•49 As well, it is well known that degradation occurred by the hydrolysis of the ester bond in the
end to end distance between crosslinks. As such, lower molecular weight PDT elastomers demonstrated
faster decline in their mechanical strength compared to higher molecular weight PDT elastomers.
Furthermore, it was previously reported that the mechanical parameters decrease in a much faster rate as
the molecular weight between cross-links decreases.49 By the end of the 12 weeks study period in PBS,
Table 3.4. The linear regression coefficients values for PDT elastomers during in vitro degradation in
PBS (pH 7.4).
the degradation study was stopped. At that stage, the elastomers maintained their original shape and did
not degrade completely.
3.3.4. In vitro Cytocompatibility with Fibroblast CeU
In order to determine if there was a dose dependant effect of the elastomer on cytotoxicity we treated
fibroblasts were treated with three different masses of PDT elastomers (100, 200 and 300 mg), for 24
hrs. After 24 hrs of culturing, all wells incubated with elastomer were examined and results indicated
growth and morphology as an objective measure of cytotoxicity of each formulation of PDT elastomer.
The density of treated cells was measured and compared to that of control cells, arbitrarily set at 100"/0
(Figure 3.10). The relative cell density/well of 100 mg was found to range from 101 % ± 7% (pHl) to
97 % ± 5% (pOOl), demonstrating 100 mg of all elastomer formulations is biocompatible and exhibited
no adverse effect on cell viability. The elastomer pieces weighing greater than 100 mg exhibited only
slightly lower cell densities, with 200 mg and 300 mg samples of the four different elastomers on
fibroblast cell viability. The relative densities shown with 200 mg ranged from 95 % ± 4% (PH]) to
91.4 % ± 4% (pOOl). For 300 mg, the same trend in cell density was found ranging from 97.6 % ± 4%
(pHl) to 91.4 % ± 8% (POOl). However, there was no statistical significance found between the cell
densities of control or any of the elastomer treatments independent of the mass of elastomer used. The
small differences in cell density between samples of different mass may be related to the fact that a
larger piece of elastomer was placed in each well potentially scraping different amount of cells from the
well as it settled to the bottom. In all, these results show that PDT is cytocompatible and could function
as biomaterial for controlled drug delivery and for tissue engineering applications without causing
adverse cellular effects.
(A) POT (B) Polystyrene plate (control).
Figure 3.9. Phase contrast images ofhwnan fibroblasts cells with POT elastomeric films and
polystyrene plate control after 24 hrofculturing.
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Figure 3.10. Hwnan fibroblasts cell density after 24 hr incubation with different weight of different
PDTelastomeric films, relative to control polystyrene plate.
The PDT elastomers studied were found to possess a few advantages which possibly make them
good candidates for controlled drug delivery applications. First, the polymers are degradable by bulk
hydrolysisoftheesterbondsandnoneoftheirbuildingblocksaretoxic.Second,a1teringthechain
length of the a1kylenediol can vary the hydrophilic and hydrophobic properties of theeIastomers. Thus,
the elastomers can be tailored to satisfy a particular purpose. Additionally, all the prepared elastomers
were amorphous with glass transition temperatures below physiological body temperature, so they are
suitable as elastomeric implants in vivo. Moreover, PDT elastomers used visible light in their
crosslinking, avoiding some of the drawbacks associated with using UV photocuring.14 The
polymerization conditions were also sufficiently mild to be carried out in the presence of other
biological materials. (e.g., forencapsulationofcellsandproteins,indrugscreening,orinbiosensing
applications). Additionally, visible light penetrates deeper through tissues than UV light (less scattering
and less absorption). This property may limit the need for invasive surgical procedures by allowing
trans-tissue polymerizations, whereby the material is injected subcutaneously or even subdermally and
irradiatedthroughtheskintopolymerizethematerialinsifU.
3.4. CONCLUSIONS
This study demonstrated the preparation of a new family of elastomeric thermoset biomaterials
which are crosslinked at room temperature using visible light photopolymerization technique. It was also
shown that the physical properties of these elastomers can be controlled through manipulations of the
chain length of the used diol and the degree ofpolymeracrylation. All the obtained elastomers were
rubbery and their mechanical properties ranged from hard brittle to very weak and elastic and their
Young's modulus, the ultirnate tensile strength and % strain depended on the degree ofacrylationand
the length of the diol chain used. As well, the sol content of the prepared elastomers significantly
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dependedonthedegreeofacrylation.Additionally,theinvitrodegradationofpoly(diol-tricarballylate)
elastomers was determined. All the elastomers underwent bulk erosion similar to that of the previously
investigated biodegradable polyester elastomers. A linear decrease was observed in the Young's
modulus and the ultimate stress with time that was also accompanied with an increase in water
absorption and weight loss. The PDT networks degraded relatively slowly after a period of 12 weeks
with no appreciable dimension changes. The exploration of visible light crosslinking, the solventless
preparation process, and the controllable mechanical properties of these biodegradable polymers make
them excellent candidates for use in controlled drug delivery, particularly for thermosensitive
therapeutic proteins and peptides. Solid particles of such drugs can be mixed with the pure acrylated
prepolymers which are then rapidly crosslinked using visible light at room temperature to be formulated
as drug delivery systems (implants or microspheres) that will undergo biodegradation in thebody.
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CHAPTER 4
Osmotic-Driven Release of Papaverine
Hydrochloride from Novel Biodegradable
Poly(decane-co-tricarballylate) Elastomeric Matrices
The content of this chapter was published in the Journal of Thempeutic Delivery I, 1,37-50 (2010).
Mohamed A. Shaker and Husam M. Younes
ABSTRACT
We have recently reported on the synthesis, characterization and biocompatibility ofa noveI family
of visible-light photocrosslinked poly(diol-co-tricarballylate) elastomers intended for use in drug
delivery and tissue engineering applications. In this work, the osmotic-driven-controlled release of the
water soluble drug, papaverine hydrochloride, from poly(decane-co-tricarballylate) elastomeric
cylindrical monoliths is reported. We also examined the influence of various parameters such as the
degreeofprepolymeracrylation,crosslinkingdensity,andtheincorporationofosmoticexcipientslike
trehalose on the release kinetics of the drug. The release rate of papaverine hydrochloride was found to
decrease in dissolution media of higher osmotic activity as an indication of the predominant involvement
of the osmotic-driven release mechanism from the elastomeric devices. The drug release rate was also
found to be dependent on the degree of macromer acrylation. Furthermore, it was found that co-
formulating papaverine hydrochloride with trehalose increases the release rate without alteringthelinear
nature of the drug release kinetics. A new delivery vehicle composed of biodegradable poly(decane-co-
tricarballylate) elastomers demonstrated to be a promising and effective matrix for linear,constantand
controllable osmotic-drivenrelease ofdrugs.
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4.1. INTRODUCTION
The development and use of biodegradable polymers with elastomeric properties in tissue
engineeringl•3 and implantable drug deliveryH have recently gained considerable attention in the
biomedical and pharmaceutical fields. Elastomers can be regarded as one of the best biomaterials for
such applications as they can offer many advantages over the other fabricated tough materials. Their
mechanical properties can be manipulated in a manner that makes them as soft as body tissues. They
have the ability to recover and withstand the mechanical challenges upon implantation inamobile part
ofthebody,7 and they are also proven to be well suited for controlled drug delivery applications.4.'
Therapeutically, elastomers utilized in controlled delivery of drugs such as paclitaxel,l dexamethasone,9
levonorgestrel lO and colindine hydrochlorideII have been extensively investigated for use in many
clinical applications which include but are not restricted to cancer therapy, hormonal contraceptionand
inflammation therapy. 1·11
"'One strategy of controlling the release of water soluble drugs and therapeutic proteins (e.g.,
interferons, interleukins and growth factors) from implantable elastomeric monoliths is achieved by
dispersing the active drug mixed with osmotic excipients and relying on the osmotic rupture as the
predominant mechanism for achieving constant zero-order release" Osmotically-driven delivery of
water soluble drugs from elastomeric polymers has been the focus of many previous studies. 12•11 Several
reports have investigated the different drug and elastomer physicochemical and mechanical factors that
affect the rate and mode of release from those systems. 12•IS Others have focused on the development of
different mathematical models that describe the release profiles from such systems. 16.17
The generally accepted view of drug release from an elastomeric monolith is as follows: When the
volumetric loadings of the drug are below a critical volume fraction called the percolation threshold (30-
35 % v/v), the drug particles will not be appreciably interconnected to each other. The drug particles
located on the surface dissolve and produce an initial burst effect, accounting for 5 to 15% of the
initially loaded drug, followed by a slow release period.lbis slow release depends on the rate of
degradation of the polymer when the polymer is degradable and/or the rate of formation of cracks and
interconnected pores resulting from water imbibition into the polymer. The rate of this water imbibition
is proportional to the porosity of the polymer and the osmotic activity of the loaded drug. 19 When the
elastomer degradation rate is slow enough to maintain the implant's geometry and mechanical properties
(extension ratio) during the release period, the osmotic-driven mechanism will dominate the linear
controlled-release and polymer degradation will play only a minor role in the overall release pattern:
A description for the release of drugs via an osmotic mechanism is illustrated in Figure 4.1. As
shown in the figure, the drug release by osmotic rupture starts by the diffusion of water vapor through
the polymer to the first layer of drug particles. The saturated drug solution formed creates an osmotic
gradient that drags more water into the drug compartment, exerting a pressure which acts radially
outwllr~usingittoswell.Ifthegeneratedosmoticpressurewashighenoughtoexceedtheinward
resisting pressure caused by the polymer elasticity, the drug compartment will rupture, releasing its
contents upon relaxation of the elastomer to the outside medium through the generated microcracks. The
same process is repeated for the following layers of dispersed drug particles (i.e., in a serial fashion)
towards the center of the device, creating a network of microcracks that leads to the externalmedium.
Traditionally, osmotic-driven controlled release offer distinct and practical advantagesoverother
means of delivery. First, the drug release is essentially constant as long as the osmotic gradientremains
Figure 4.1. Schematic representation of osmotic swelling, rupture and release mechanism. (A) Water
vapor diffuses to the inside of the elastomer. (B) The water dissolves the solid drug and exert osmotic
pressure on the inside wall. (C) The pressure causes micro-cracks in the elastomer and the drug content
is then released upon polymer relaxation. (D) The process occurs in a serial fashion towards the center
of the cylinder as each cross-sectional layer of compartments rupture.
constant, and typically gives a zero-order release profile with a high degree of in vitro and inviva
correlation. I2,IS Second, the release panem is well characterized and understood and may be delayed or
pulsed if desired. 13 Finally, the rationale for this approach is that the presence of water in the extemal
release environment is relatively constant, at least in terms of the amount required for initiation and
controlling osmotically base theory.
In our recent study on the preparation ofa polymeric carrier for proteins andpeptides, we succeeded
in preparing and characterizing a novel family of visible light photocrosslinked poly(diol-co-
tricarballylate) elastomers.20.21 These newly synthesized elastomers offer many advantages over other
previously reported polymers. First, they are amorphous thermoset polymers that degrade by bulk and
surface erosion, which often results in the retention of their three dimensional structure throughoutthe
hydrolytic period. Second, altering the chain length of the a1kylenediol used in their preparationcanvary
the hydrophilic and hydrophobic properties of the elastomers. Thus, these elastomers can be tailored to
satisfy a particular application and need. Third, drugs can be dispersed into the prepolymer in a
solventless manner and further photocrosslinked using visible light at temperatures near the
physiological range. Thus, it would avoid many of the drawbacks associated with using organic solvents
and UV photocrosslinking upon dealing with biologically thermo-sensitive therapeuticslikeproteinsand
otherheat-sensitivedrugs?O.2 I FinaIly,thecuringprocessproceedsrapidly,ontheorderofminutes.
The purpose of the present study, therefore, is to demonstrate the osmotic-driven release from these
newly synthesized photo-cured biodegradable elastomers. Poly(decane-co-tricarballylate) (pDEn was
used as a representative for this new family of biodegradable elastomers. We also chose papaverine
hydrochloride(pH)asamodelforadrugwithareasonablymoderateosmoticactivity,reasonablewater
solubility (lg in 30 ml), and good candidacy for extended-release delivery. PH is a pharmacologically
potent vasodilating agent that is used for the treatment and prevention of symptomatic cerebral
vasospasm after hemorrhage caused by aneurysm rupture.22 Since PH therapeutic effects are very short-
lived, it is typically administered by continuous systemic or localized infusion (intra-arterial,
intravenous, intrathecal or intracisternal). This delivery mode has its inherent technical problems,
involves risks of infection and usually results in severe PH side effects and toxicity.23 As such,
developing a prolonged-release elastomeric device that can be implanted intracranially at the time of
surgery for aneurysm clipping is expected to prevent vasospasm significantly, while maintainingan
appropriate safe and effective concentration of papaverine in the cistem.24
4.2. EXPERIMENTAL
Tricarballylicacid,I,10-decanediol,stannous2-ethylhexanoate,4-dimethylaminopyridine,acryloyl
chloride, triethyl amine, sodium sulphate, amaranth trisodium, triethanol amine, champhore-quinone,
and papaverine HCI were purchased from Aldrich-Sigma chemical company (Canada). Acetone and
chloroform were purchased from Caledone chemical company (Canada). The osmolality standards of
100, 290 and 1000 mmollkg were all purchased from Wescor Company. All chemicals were used as
received without any further purification.
4.2.2. Synthesis and Characterization of Acrylated Poly(decane-co-tricarballylate) Prepolymer
Acrylated PDET was synthesized according to the previously described method in chapter 3 (section
3.2.2.) which is illustrated in Figure 4.2 A.21
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Figure 4.2. Schematic illustration of the synthesis, acrylation and photocuring of poly(decane-
tricarballylate). (A) The step-reaction polymerization of tricarballylic acid and decane diol was
catalyzed by stannous2-ethylhexanoate. The acrylationwas carried out using acryloyl chloride in the
presenceoftriethylarnine. To photo-crosslink, acrylated prepolymer was mixed withcarnphorquinone
(the photoinitiator)and crosslinked under visible light (40mW/cm2).(B) Schematic representation of
the method ofpreparing PH loaded elastomeric cylindrical monoliths.
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The final purified product was characterized using proton nuclear magnetic resonance eH-NMR) to
confinnthe final product's purity. The signal intensity of the methylene groups ofdiol (1.3-1.7 ppm)
and the acrylate groups' intensities (5.8-6.4 ppm) were used to calculate the degree ofacrylationinthe
prepolymers.21
4.2.3. Elutomeric Matrices Preparation and Characterization
The photocuring process was carried out in a dark fume hood equipped with a sodium lamp. On a
watch glass, 5 j!1 of 10 % ethanolic solution of both camphorquinone and triethanolamine (equivalent to
0.01 % (w/w») photoinitiator was added to 5 grams of the acrylated prepolymer. The mix was then left at
40°C under vacuum for I hr to ensure complete removal of any traces of alcohol from the photoinitiator
solutions. The mix was then poured into the bottom of a sealed cylindrical silanized glass mould of I cm
in length and 0.5 cm in diameter. The mould was then exposed to a visible-light source (450-550 nm at a
40 mW/cm2) filtered from a 50 Watt tungsten-halogen lamp (Taewoo Co., Korea) for 10 minutes at a
distance of 10 cm to form the elastomer which was then removed from the mould for further testing. The
tensile mechanical properties of elastomeric cylinders (1.5 cm in length and 0.5 cm in diameter) were
tested using an Instronmodel In-Spec2200testerequippedwith500N load cells and run by Merlin
Data Management Software. The sample was pulled at a rate of 1.0 mm1sec and elongated to failure.
Values were converted to stress-strain and plotted. Young's modulus was calculated from the initial
slope of the stress-strain curve. Finally, the obtained elastomers were subjected to solid-state carbon 13
nuclear magnetic resonance (13C_NMR) to confinn full crosslinking of the acrylated moieties and
complete consumption of the C=C terminal bonds in the free radical photoinitiated reaction.
I
4.2.4. Fabrication of PH loaded Elastomeric Cylinden
As illustrated in Figure 4.2 B, PH was first ground into fine powder using a glass mortar and a pestle
and then sieved througb a 45 j1IIl mesh using esc sieve shaker. The sieved powder was then intimately
mixed with the acrylated PDET prepolymer to achieve a total of 10% v/v loading of the drug. The
resulting mixture wasphotocrosslinked in a cylindrical glass mouldofl em in length and 0.5 em in
diameter under the procedure described above. Each prepared drug-loaded cylinder was weigbed and the
amount of PH in each was calculated. The final loading of PH in each cylinder was found to be
equivalent to 14.5 ± 0.5 mg.
When a mixture of PH and TH was used to load the cylinder, both were co-lyophilized to obtain an
intimately mixed powder which was further passed througb a 45 j1IIl mesh size sieve to obtain the fina1
micronized mixture. A 10% v/v volumetric loading of the lyophilized mixture was also used in all of the
prepared cylinders. The total loaded amount of PH was equivalent to 6.5 ± 0.1 mg and 4.5 ± 0.2 mg in
the 1:1 and 1:2 PH to TH weigbtratio loaded cylinders, respectively.
A similar procedure was followed in loading PDETlOo elastomeric cylinders with 10% v/v amaranth
trisodium (An powder. A mixture of AT and TH (weigbt ratio 1:2 ATITH) was co-lyophilized and
further passed througb a45 j1IIl mesh size sieve to obtain the fina1 micronized mixture.
4.2.5. Osmotic Activity Measurements
The osmolality of 10/11 of triplicate samples of saturated solutions of PH, TH, distilled water, 3%
w/v NaCI and PBS of pH 7.4 was measured using a Wescor vapour pressure osmometer which was
previously calibrated using 100, 290 and 1000 mmoUkg (NaCl) standards at 37°C.
The prepared monolithic cylinders were subjected to in vitro release studies using distilled water
(DW), phosphate buffer saline (PBS) of pH 7.4 and 3% w/v NaCI as release media Four samples of
each cylinder were put into 40 m1 scintillation vials and filled with 30 m1 of release medium. The vials
were attached to a Glas-Col rugged culture rotator. The rotator was set at 20% rotation speed and placed
in an oven at 37± 0.5 DC. To ensure sink conditions and constant osmotic pressure driving force, the
receptor release medium was replaced with fresh medium over the release period or until 100 %
cumulative release was achieved. Solutions withdrawn were filtered and PH concentrations were
determined using a Beckman Du-70 UVNIS scanning spectrophotometer at 245 nm.2S Results reported
were the mean ± standard deviation from three independent experiments. Similar procedure was
followed upon testing the release of AT from PDET\oo elastomeric cylinders in PBS over a period of 3
4.2.7. In vitro Degradation Study
PDET cylinders, with different degrees ofacrylation (50, 70 and 100%), of initial known weights
(WI) were subjected to a degradation study in PBS at 37"C. Conditions were similar to those applied in
the release study. The buffer was replaced daily to ensure a constant pH of 7.4. At different time
intervals, the swollen weight (W2) and dried weight (W3) were measured after wiping the surface water
with filter paper and aftervacuum-<!rying at 45°C for 2 days, respectively.
The water absorption and weight loss of cylinders were calculated as follows:
Water absorption % = [(W2-W3) I W3] X 100.
Weight loss % = [(Wi-W3) I Wi] X 100.
The results were reported as the mean of three measurements.
4.2.8.ScanningEledronMicroscopy
Scanning electron microscope (SEM) was utilized to investigate the changes in the surface and the
interior of the PDETlOo elastomer after PH release in terms of surface pores and micro-crack formation.
PHITH (weight ratio I :2) loaded matrices of both newly fabricated and after complete release, were
vacuum dried for 24 hours. The cylinders were mounted on a conductive carbon adhesive, attached to
aluminum stubs and then sputter-coated with gold palladium. Gold was evaporated onto the specimen to
a thickness of approximately 15 om. Samples were examined using a Hitachi model S-570 scanning
electron microscope. The microscope was interfaced with electron backscatter diffraction (EBD) system
and an energy dispersive X-ray (EDX) analytical system from Tracor Northern. The electron gun was a
tungsten hairpin type filament and the sample images were digitally captured using a digital imaging
system.
4.3. RESULTS AND DISCUSSION
In the following discussion, the abbreviated POET refers to poly(I,IO decane-co-tricarballylate)
while the subscripted number following this abbreviation referstoitstheoreticaldegreeofacrylation.
4.3.1. Elastomer Preparation and Charaderization
As shown in Figures 4.3 A and 4.3 B, IH_NMR analysis confirmed the purity and the chemical
structure of the POET prepolymer and also confirmed the formation of acryloyl moieties following the
acrylation at the terminals of the formed chains. The calculated degree of prepolymer acrylation as
estimated via IH_NMR (Figure 4.3 B) are listed in Table 4.1. The full interpretation of each individual
peak of the two IH_NMR spectra is reported on the figures. Figure 4.3 C which reports the solid-state
13C_NMR spectrum of the elastomer, shows peaks at 25,60 and 170 ppm which are attributed to -eHz-,
O-CH2- and -e=O groups, respectively. The spectrum also confirmed that there are no peaks
corresponding to -CH=CH2 terminal groups in the prepared elastomer. These observations form
constituted evidence that the acrylated groups were fully consumed during the photopolymerization
The obtained photocrosslinked POET elastomers were stretchable and rubbery and swelled but did
not dissolve in most of organic solvents. The mechanical properties spanned from tough to elastic
depending on the degree ofacrylation. Figure 4.4 shows that tensile testing ofthephotocrosslinked
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Figure 4.3. NMR spectra ofPDET (A) 'H-NMR ofPDET prepolymer before acrylation (B) 'H-NMR of
PDET prepolymer after acrylation. (C) Solid-state '3C-NMR spectrum ofPDETlOO elastomer.
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Figure 4.4. Stress-strain curves ofPDET elastomers of different degrees of acrylation.
Table 4.1. Mechanicalpropertiesandsolcontentofpoly(decane-co-tricarballylate)elastomers.
·Degree ofacrylation estimated by NMR.
POET elastomers produced representative uniaxial tensile stress-strain curves which are characteristics
of typical elastomeric materials. No permanent deformation was observed during the mechanical testing.
Average values for Young's modulus (E), ultimate tensile stress (cr), cross-linking density (p,.), and
maximum strain (&) are summarized in Table 4.1. The elastomers exhibited controllable mechanical
properties. The value of cr was as high as 0.45 MPa while the value of E was as high as 200 %, under the
synthesiscondition.Young'smodulusvaluesrangedbetweenO.54andO.06MPa.
The crosslink density (Px) was calculated according to the theory of rubber elasticity following the
equation: Px = E/ 3RT, where Px represents the number of active network chain segments per unit
volume (mole I m\ E represents Young's modulus in Pascal (pa), R is the universal gas constant
(8.3144 J/mol K) and T is the absolute temperature (K). The crosslinking density changes appreciably as
a function of the degree ofacrylation. As such, the decrease in the number of terminal acrylated groups
in the prepolymers resulted in a decrease in the linking anchors between the polymer chains during
photocuring which resulted in an increase in the elastomers' stretchability and elasticity.
Manipulation of elastomers' sol content was also found to depend mainly on the degree of
acrylation. The sol content represents the mass difference after removal of the un-erosslinked
prepolymer which is soluble in dichloromethane. Therefore, POETso elastomer, with the lowest
calculated degree of acrylation (0.47), possessed the highest sol content among all the prepared
elastomers (59%). Although stretchability will strongly improve as a result of increasing the sol content
of elastomer, the relatively low sol content will help in maintaining the mechanical propertiesafter
implantation.
Table 4.2. Osmotic activity of saturated solutions of papaverine hydrochloride, trehalose and used
release media.
SOlution
SaturatedpapaverineHClsolution
Distilled water
Phosphate buffer saline ofpH 7.4
30/0 NaCI
*Averageofthreereadings.Valuesaremean±standarddeviation.
4.3.2. In vitro Release and Degradation Studies
In an attempt to demonstrate the osmotic-driven release of water soluble agents from this newly
synthesized photoset biodegradable elastomer, PH was used as a model compound because of its
moderate osmotic activity (Table 4.2) and the ease of determining its concentration inthereleasemedia
using a validated spectrophotometric method of analysis.2s The stability of PH in the release media was
tested by monitoring the changes in the concentration of PH in prepared stock solutions (n=5) over a
period of one week. The study showed that there was no statistical significant difference (p>O.OI) in PH
from its initial concentration in each medium over the tested period. Also, the UV spectra of PH in the
stock solution coincided with those of the freshly prepared PH solution.
The release of the PH from PDET lOo elastomer in different dissolution media is illustrated in Figure
4.5. In all cases, the cumulative release profile showed an initial rapid release period which extended up
to almost 3 weeks followed by a slower linear release phase that extended up to 33 weeks. Generally, the
release pattern of PH can be described as follows: After the immersion of the PH loaded cylinders in the
release media, water started to diffuse into the matrix mass and typical osmotic-driven release started.
The durnpiness in the release which occurred at the beginning can be explained by the combination of
osmosis mechanism in the outside layers of the cylindrical matrix as well as emancipation of those
particles located on the surface of the cylinder and those incorporated in theun-crosslinked part (sol
content) of the outermost layer of the cylinder. Thisinitialhighreleaseperiodwasthenfollowedbya
period of constant but slow release. This slower release rate can be attributed to the fact that the initial
polymer swelling and gelling which took place in the outermost layer of the elastomeric cylinder
resulted in the formation of a boundary layer that slowed down further penetration of water into the
Figure 4.5. Cumulative percent of PH released from PDETlOo elastomers in different release media.
Error bars represent the standard deviation of the mean of measurements from four samples.
Figure 4.6. Release of amaranth trisodiwn dye from PDETlOo elastomeric cylinders and the change in
the cylinders geometry in PBS release mediwn. (A) A representative image of amaranth trisodiwn
loaded elastomeric cylinders before the start of the release study. (B) A representative image of
amaranth trisodiwn loaded cylinders after 3 months of the start of the release study. (C) A representative
image of a blank elastomeric cylinder before the start of the degradation study. (D) The image of the
same cylinder at the conclusion of the release study.
subsequent matrix layers with subsequent delay in drug dissolution. Insuchcircumstances, it is expected
thatthedeportofthesoliddrugparticlesfromthesuccessionallayertotheadjacent outer layers and
then to the surface of the matrix is also retarded. To demonstrate the formation of such a boundary layer,
the release of amaranth trisodium dye from cylinders over a period of 3 months was examined (Figure
4.6). As shown in Figure 4.6B, the arrows point to the limits of the formed boundary gel layer which
also confirms that osmotic-driven release mechanism is taking place in a serial fashion towards the
center of the device as has been also reported in Figure 4.JD.
4.J.2.1.1mpact ofpoiymer degradation on drug release
A detailed long-term degradation study using dog-bone-shaped elastomeric samples in PBS was
carriedoutpreviously.21 In that study, it was demonstrated that the degradation rate, water absorption
and weight loss of the elastomers were directly proportional to the chain length of the alkylenedioland
inversely proportional to the elastomers' P.. The elastomers were also found to follow slow zero-order
degradation rate kinetics and exhibited the ability to maintain their shape and extensibility over the
studied period.
Water absorption and change in weight of blank elastomeric cylinders over the drug release period
was further investigated in this study to assess the exact possible contribution of degradation on the
device geometry and the overall drug release mechanism. As seen in Figure 4.7, by the end of the 100%
release period, the average cumulative water absorption was equivalent to 67%, 56% and 48% in the
PDETso, PDET7S• and PDETloo respectively. Such fmdings were consistent with our previously reported
results regarding the diffusion ofwater into the bulkofelastomeric polyesters attemperaturesabove
Time (days)
Figure 4.7. Percentage water absorption versus time ofPDET elastomeric cylinders of different degrees
of acrylation in PBS at 37"C. Error bars represent the standard deviation of the mean of measurements
from tbree samples.
--
their glass transition. I Also, the results are in accordance with the fact that water diffusion and mass loss
are inversely proportional to the polymer'sp•. In addition, it is clear from Figure 4.7 that all the
cylinders exhibited a two-stage water absorption behavior. In the first stage, which lasted up to 2-3
weeks, the water absorption preceded rapidly in a manner that matches the observationsreportedinthe
release study. However, in the second stage, the water absorption took place in a much slower rate and
resulted in almost no changes in the dimensions of the prepared cylinders (Figure 4.6 C &4.6 D). This
is also consistent with our previous findings with dog-boned-shaped elastomers.21 0 n the other hand, the
mean weight loss of the tested cylinders at the end of the release period was found to beequivalentto
28%,21% and 16% in cylinders made using PDETso, PDET7S. and PDETlOo respectively. The above
dataconfinn that degradation played only a limited role in the overall release of the PH from the
cylindrical devices. In addition, since PH is a weak basic drug (pKa =5.9), it could have also contributed
in the reduction of the autocatalytic hydrolysis of the polymer chains which might have lead to a further
decrease in the rate of elastomer degradation. It is also obvious that none of the reported drug release
profiles exhibited a distinct release phase that can be clearly attributed to the polymer degradation.
Finally, there was no evidence ofmajor degradation or loss in the geometry of the cylinders at the end of
the release studies (Figure 4.6 D) which is important in having the osmotic-driven mechanism
predominate the overall drug release profile.
4.3.2.2. Impact ofthe osmolality ofthe release media
In order to assess the role of the osmotic-driven mechanism, the effect of osmolality of the release
medium on the rate and extent of PH release was examined. The release of PH from a 10 % v/v loaded
PDETIOO elastomeric cylinders in three release media (OW, PBS and 3% NaCl) of different osmotic
activities was investigated. Figure 4.5 shows the release kinetics of the PH as influenced by the
difference in the osmolalities of the release media It is shown that the relative PH release rate
significantly decreased upon increasing the osmolality of the release medium. However, the same
pattern of release has taken place irrespective of the release medium used. IS The above observations can
be attributed mainly to the decrease in the water penetration rate into the matrix upon decreasing the
difference in the osmotic gradient (Le. between PH inside the capsule formed in the matrix and the
outside release medium) which lead to delayed drug dissolution, less micro-cracks formation and
subsequently, less drug forcing out of the cylinder.
To elucidate on the constant release profile through the PDET lOo elastomer, a linear regression of the
release data after the first 3 weeks until the completion of release was carried out. As shown in Figure
4.8,the linear release over this period resulting from the osmotic-driven delivery mechanismcanbe
described as zero-order release kinetics with constant daily release. IS The linear regression correlation
coefficient was found to be equal to 0.999 for the release of PH in phosphate buffer and 3% NaC!. On
theotherhand,itwasequaltoO.996 for the release in distilled water. In addition, the linear controlled
release of PH in PBS was maintained overaperiodof232 days with an average daily release of 0.35 %
per day.
4.3.2.3. Effeet ofdegree ofprepo/ymer aery/ation
In order to investigate the effect of manipulating the elastomers' physicochemical properties on drug
release rate, we examined the effect of varying the prepolymer degree ofacrylation on the release
kinetics of PH from these elastomeric matrices. PH loaded cylinders using prepolymers of different
Time (days)
Figure 4.8. Linear regression of release data of PH from PDETlOo elastomeric cylinders in different
release media. Error bars represent the standard deviation of the mean of measurements from four
samples.
Time (days)
Figure 4.9. Cumulative percent of PH released in phosphate saline buffer from PDET cylinders with
different degrees ofacrylation(DA). Errorbarsrepresentthestandarddeviation of the mean from four
measurements. Where error bars are not shown when the standard deviation is smaller than the symbol.
degrees ofacrylation (100,75 and 50%), were prepared and the release of PH from these cylinders was
examined. Figure 4.9 shows the release of PH from the prepared cylinders in PBS at pH 7.4. The
resulting release data showed a significant dependence of the drug release on the prepolymerdegree of
acrylation and the correspondingcrosslinking density as reported in Table 4.1. It is also apparent that the
same release pattern was followed in all cases with the highest release rate achieved from the elastomer
of the least crosslinking density as a result of its lowest degree of acrylation. The release of PH from
POETso and POET7S 10010 v/v loaded cylinders was completed within 13 and 24 weeks, respectively. On
the other hand, the release of PH from POETlOo cylinders reached 100% only after 33 weeks. This
expected release behavior can be explained by the fact that waterdifIusion is inverselyproportionalto
the degree of prepolymer acrylation. I,20 This observation is consistent with our previously reported
results regarding the effect of degree ofacrylation on the difIusionofwater into the elastomericmatrices
at temperatures above their glass transition temperatures. I In addition, the decrease in the crosslinking
density would result in increasing the void volumes between each crosslink in the elastomer which
increase the possibility of formation of inter-connected networks and channels betweentheencapsulated
drugparticles.2l Theaboveresultsdemonstratedtheabilitytocontrolthedrugreleaseratebychanging
the structure nature of the POET matrix which confirms its potential use in controlled drug delivery.
4.3.2.4. Effect ofosmotic excipient
One goal of the development of this system was the delivery of therapeutic protein drugs such as
Interleukin-2 and Endostatin for cancer immunotherapy. Since most proteins cannot be loaded at high
volume fractions, pore-forming agents of high osmotic activity have been used in many cases when the
protein does not have enough osmotic activity to elicit the required capsule fracture orwhen a complete
release of the loaded fraction was needed. In addition, in order to be incorporated as solidparticles,most
proteins need to be lyophilized with cryoprotectants and other stabilizing agents like sugars(e.g.,
mannitol, trehalose) which also possess high osmotic activity. As such, and to better understand the
impact of intimately mixing such agents with the drug on the osmotic-driven release rate,weexamined
the effect of loading the elastomeric cylinders with aco-crystallized mixture composed of different
weight ratios of TH: PH while maintaining the 10% v/v overall particles loading in the device. Figure
4.10 shows the release kinetics of PH in PBS using different drug to TH intimately mixed ratios loaded
into PDETlOo elastomeric cylinders. As shown, when no TH was incorporated, PH was released in a
tardy declining manner, at an average rate ofI.1 o/oldayduringthe first phase (22 days) and later
dropped to 0.35o/olday during the second phase of release. On the other hand, the cylinders which
conlained a I: I PHI trehalose ratio released the drug at a rate of 0.6 %/day (?=O.9957) over a period of
20 weeks while when trehalose concentration was increased to two third of the particles content (PHI
trehalose 1:2), the release rate was increased to 0.8 %/day (?=O.9891) over a period of I3 weeks.Itis
evident that the high loading of trehalose has accelerated the uptake of water into the elastomer matrix
and generated a greater solution osmotic activity and subsequently increased the release rate. 12•1S The
results also confirm that the mechanism of PH release from the PDET elastomer can be also controlled
by varying in the mixture the weight ratio of osmotic excipient to the drug while maintaining the same
overall volumetric loading of the incorporated mixture in the device.
Although the release of PH from loaded elastomeric cylinders with different ratios of TH might
serveasareasonableestimateforassessingthereleasebehaviorofproteindrugs,itcannotbe
overlooked that the aberrant geometrical and physicochemical properties ofpeptides (three dimensional
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Figure 4.10. Effectofincorporatingdifferentweightratiosoftrehalose to papaverine hydrochloride on
the osmotic-driven release rate from PDETlOo elastomeric cylinders. Error bars represent the standard
deviation of the mean from four measurements. Where error bars are not shown when the standard
deviation is smaller than the symbol.
structure nature, relative large molecular weight and isoelectricpoint) might affect the release rate from
the PDET matrices. From a practical standpoint, the obtained results in this study is useful in terms of
suggesting that the mechanism of protein release from such similar elastomeric cylinders would be
controlled mainly by the amount ofTH incorporated with the loaded drug.
4.3.3 Scanning electron microscopy
In order to further investigate and demonstrate the proposed theory of the osmotic-driven release
mechanism, the changes in the surface and interior architecture of the loaded cylinders before andafter
the release was examined. Figure 4.11 shows the SEM images of the PH/trehalose (molar ratio 1:2)
loaded PDETlOo cylinder before and after the conduction of release studies. As shown, the cylinders
before the conduction of release showed a smooth surface without any channels. However,afterthe
osmotic drug release, the surface and cross-section images showed cracks and pores correspondingto
the routes which the drug took for release in concordance with the proposed osmotic-driven drug
released mechanism.
4.4. CONCLUSIONS
The osmotic-driven release mechanism of PH of 10% v/v loadings from monolithic cylinders of
newly synthesized elastomer was demonstrated. The results revealed that the drug release profiles
possessed linear zet'lKlrder release and were influenced by the osmolality of the release medium. It has
also been shown that the rate of PH release can be controlled through manipulations in the elastomer's
degree ofacrylationand co-formulationwithosmotic diluents like trehalose. In all situations,osmotic-
Figure 4.11. Scanning electron microscopy photographs ofPHffH (weight ratio 1:2) loaded PDET lOo
cylinders. (A) Surface image before the start of the release study. (B) Surfaceimageaftertheconclusion
of the release study. (C) Cross-sectional view of the cylinder at the conclusionofthe release study.
driven release mechanism was the dominant mechanism that contributed to that enhancement in the drug
release. These novel photocrosslinked elastomeric matrices constitute a promising delivery system for
water soluble proteins andpeptides. In particular, their planned use in long-term irnplantable cytokines
delivery for treatment of a variety of solid tumors. The incorporation of therapeutic proteins with
osmotic pharmaceutical excipients as well as the selection of the properprepolymer degree 0 facrylation
can be efficiently used to achieve desired release rates. Finally, as they are degradable, 0 nceintroduced
to the diseased lesions into the body they require no retrieval or further manipulation and are degraded
into soluble, non toxicby-products.21
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CHAPTERS
Biocompatibility and Biodegradability of
Implantable Drug Delivery Matrices Based on Novel
Poly(decane-co-tricarbaUylate) Photocured
Elastomers
The content of this chapter is submitted to the Journal of Bioactive and Compatible Polymers.
Mohamed A. Shaker, Norilm Daneshtalab, Jules J.E. Dore and Husam M. Younes
ABSTRACT
Visible-light photocrosslinked biodegradable amorphous elastomers based on poly(decane-w-
tricarballylate) [pDET] of varying crosslinking densities were synthesized and their cytotoxicity,
biocompatibility and biodegradability were reported. Cytotoxicity of PDET extracts of the elastomers
were assessed for mitochondrial succinate dehydrogenase activity by 3-(4,5-dimethylthiazol-2-y1)-2,5-
diphenyltetrazolium bromide (MIT assay) and inhibition of eHlthymidine incorporation into DNA of
epithelial cells. Toassessinvivobiocompatibilityandbiodegradability,subcutaneousimplantationof
PDET micro-cylinders was undertaken in twenty five male Sprague-Dawley rats over a period of 12
weeks. Biodegradablepoly(lactic-co-g1ycolic acid) sutures served as controls. The in vivo changes in
physical and mechanical parameters of implants were compared to those observed in vitro. The treated
epithelial cells revealed no signs of cytotoxicity and the elastomers degradation products caused a slight
stimulation to both mitochondrial activity and DNA replication. The implantation results showed that no
macroscopic signs of inflammation or adverse tissue reactions were observed at implant retrieval sites.
Moreover, the retrieved implanted micro-cylinders were found to maintain their original geometry and
extensibility in a manner similar to those observed in vitro. The findings confinned that these new
elastomers have good biocompatibility and are expected to be useful as biodegradable and
biocompatible biomaterials for controlled drug delivery and tissue engineering applications.
5.1. INTRODUCTION
Biodegradablepolymerswithelastomericpropertieshavelatelyattractedspecialattention for their
uses in controlled-drug delivery systems I~ and tissue engineering.7-16 Elastomers can be regarded as one
of the best biomaterials for such applications as they can offer many advantages over the other
fabricated tough materials. Their mechanical properties can be manipulated in a manner that makes them
as soft as body tissues. They have the ability to recover and withstand the mechanical challenges upon
implantation in a mobile part of the body, IS and they are also proven to be well suited for controlled-
drug release applications. 6,17
Biodegradable elastomers reported in the literature have been synthesized as one of two types:
thermoplastic 8,9,12 or thermoset elastomers.1,7,10 While thermoplastics offer the advantage of ease of
fabrication,theydegradeheterogeneouslyduetotheirsemi-crystallinenature.This leads to rapid non-
linear loss of mechanical properties as well as large deformations as the material degrades. Conversely,
although thermoset polymers are not easily fabricated, they outperform thermoplastics in a number of
areas,includinguniformbiodegradation, better mechanical properties, and overall increased durability.
This makes thermoset elastomers better suited for most biomedical applications.
As one of the techniques utilized in preparing suchelastomeric polymers, the use oflight-activated
curing approaches in preparing photoset elastomers have recently gained considerable attentionasit
would offer a number of advantages over the conventional thermal or solution crosslinking techniques in
preparing biodegradable thermoset elastomers. IS First, the process excludes the use of thermal energy,
in other words, the polymers can be formulated at temperatures near physiological range even once
loaded with biologically thenno-sensitive thempeutics like proteins and other heat-sensitive drugs.
Second, the process proceeds mpidly, on the order of minutes. Third,the process can be carried out in
situ. Finally the degree of crosslinking and mechanical propertiesofthephotocured elastomer can be
tailored by changing the density ofphotosensitive termini in the prepolymer. 16
We have recently reported on the synthesis, chamcterization and cytocompatibility of a novel family
ofamorphousphotosetpoly(diol-co-tricarbailylate)elastomersls.16andtheiruse in controlled-release of
small- molecule pharmaceuticals and protein drugs. 6,IS.17 These newly synthesized elastomers utilized a
prepamtion process which involved using visible light photoinitiated polymerization and a solventless
stmtegy of drug loading.6,17 The elastomers were optically tmnsparenl, exhibited controllable
mechanical properties and proven to be amorphous with glass tmnsition tempemtures below
physiological body tempemture, which make them suitable as elastomeric implants in vivo. It was also
ilIustmted that altering the chain length of the alkylenediol can vary the hydrophilic and hydrophobic
properties of the elastomers that can be tailored to satisfy a particular purpose. 16
The newly prepared elastomers also demonstmted to be a promising biomaterial for protein drug
delivery and other tissue engineering applications. Specifically, the use of visible lightcrosslinking
helped in eliminating many of the dmwbacks associated with using UV photocuring by making the
polymerization conditions sufficiently mild to be carried out in the presence ofotherbiologicalmaterials
i.e. for encapsulation of viable cells, in drug screening, orin biosensing applications. 18 Additionally,
visible light was able to penetmte deeper through tissues than UV light (less scattering and less
absorption). This property may limit the need for invasive surgical procedures by allowing tmns-tissue
polymerizations, whereby the material is injected subcutaneously or even subdennally and irmdiated
through the skin to polymerize the material in situ. In the most recent study conducted in our lab, we
have demonstrated that therapeutic proteins such as Interleukin-2 (IL-2) have retained almost 100% of
their stability during drug loading and after its release form the elastomers. The cell based bioactivity
studies on the released IL-2 showed that more than 94% of its original activity was retained over a28
days release period.17 In addition, it was shown that osmotic-driven controlled release of drugs from
these new elastomeric matrices is linear, constant and controllable.6
In this study, we have focused on determining the in vitro cytotoxicity of these biodegradable
elastomers and evaluating their biological performance after long term contact with soft tissue in vivo.
We have also examined the in vivo changes in the physical and mechanical properties of these
elastomers and the influence of changing the polymer crosslinking density on those properties.
Furthermore, we have attempted to compare the in vivo degradation changes to those observed in vitro
as a mean of establishing an in vitrolinvivo comparison for the changes in elastomers' physical and
mechanical properties during the degradation.
5.2. EXPERIMENTAL
The chemicals used for the preparation of elastomers were tricarballylic acid (99%), I,IO-decanediol
(98%),stannous2-ethylhexanoate(95%),4-dirnethylamino pyridine (99%),acryloyl chioride(96%),
triethylamine (TEA; 99.5%), sodium sulphate (99"/0), triethanolamine (99%), and camphorquinone
(96%) and were purchased from the Aldrich-Sigma chemical company. Acetone (99"/0) and chloroform
(99%) were purchased from the Caledon chemical company. All chemicals were used as received
without any further purification.
5.2.2. Preparation of Prepolymen and Elutomen
The detailed method of preparation was described in chapter 3 (section 3.2.2.),16 outlined in Figure
5.1 and summarized herein. First, POET prepolymer was prepared by solvent-free step growth
polymerization. Briefly, 11.33 gofl,lO-decanediol(O.065 mole) and 7.05 g oftricarballylic acid (0.04
mole) was added into a three-neck flask in the presence of stannous 2-ethylhexanoate as a catalyst. The
mixture was heated to 140·C under nitrogen with continuous stirring for 20 minutes and for an extra 10
minutes under vacuum. Molecular weights and molecular weight distributions of the resulting
prepolymer were determined using a Waters GPC system (Waters, Milford, CT) equipped with 410
Waters differential refractometer and an on-line multi-angle laser light scattering (MALLS) detector (pO
2000 OLS, precision detectors, MA). The column configurations consisted of an HP guard column
attached to a phenogel (2) linear 51ffil column (300 x 7.8 mm2). The mobile phase consisted of
anhydrous tetrahydrofuran at a flow rate of I mllmin at 35 ·C. The sample concentration was 20 mglml
and the injected volume was 75 ~1. The absolute MWs were determined by MALLS using a dn/dc value
ofO.I72m11g.0atawerecoliectedandhandledusingPrecisionAcquirelDiscoverysoftwarepackage.
A 100% acrylation of the prepared prepolymers (POETlOo) was carried out by reacting acryloyl
chloride (ACRL) with the terminal hydroxyl groups of the prepolymers. Into a flask, 10 g of the
prepared prepolymer was dissolved with 60 ml of acetone, to which 10 mg of 4-dimethyl arninopyridine
was added as a catalyst. The flask was seaIed, flushed with argon and then imrnersed in aO·C ice bath.
A stepwise addition of 2.35 ml ofACRL (29 mmol) with 4.02 ml of TEA (equimolar amounts) to the I
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Figure 5.1. A schematic illustration of the synthesis, acrylation and photocuring of poly(diol-
tricarballylate) elastomers. The step growth polymerization of tricarballylic acid and alkylene diol was
catalyzed by stannous-2-ethylhexanoate. The acrylation was carried out usingacryloyl chloride in the
presence of triethylamine. To photo-crosslink, the acrylated prepolymer was mixed with the
photoinitiator, camphorquinone and triethanolamine and crosslinked undervisiblelight.
prepolymer solution was carried out over a period of 12 h. The reaction was later continued at room
temperature for another 12 hrs. The 75 % and 50 % acrylated PDET prepolymers (PDET7s and PDETso
respectively) were prepared by following the same procedure as described above but using 75 % and 50
% of ACRL and TEA molar amounts. The final product's purity was confirmed by a proton nuclear
magnetic resonance eH-NMR) spectroscopic analysis in chloroform-dusing a BTUker Avance-500 MHz
NMR spectrometer. The signal intensity of the methylene groups of diol (1.3-1.7 ppm) and the acrylate
groups'intensities(5.8-6.4ppm)werethenusedtocalculatethedegreeofacrylation in the prepolymers.
The following describes the procedure followed in preparing the final elastomers. Briefly, in a dark
fume hood equipped with a sodium lamp, 5 III of 10 % ethanolic solution of both camphorquinone and
triethanolamine [equivalent to 0.01% (w/w)photoinitiator] were added to 5 grams of the acrylated
prepolymer. The mixture was then left under vacuum for 4 hrs at 40 ·C to ensure complete removal of
any traces of alcohol from the photoinitiator solutions. The dried sample of the prepolymer that was
mixed with the initiator was then poured into the glass mould using a spatula The mould was exposed to
a visible light source (450-550 nm at a 40 mW/cm2) filtered from a 50 Watt tungsten-halogen lamp
(Taewoo Co., Korea) for 10 minutes at a distance of 10 cm to form the microcylinder specimens which
were removed from the mould by breaking and pealing the glass. The thermal properties of the PDETlOo
elastomer were characterized using Q200 DSC at a heating rate of 10 ·CI min. The samples were heated
from room temperature to 150 ·C and rapidly cooled down to -100 ·C. The DSC scan was recorded as
the sample was being reheated from -100 to 150 ·C.
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5.2.3. In vitro Cytotoxicity and Proliferation Assays
5.2.3.1. Preparation ofdegradation aliquots
The POET elastomers were subjected to degradation in sterile phosphate buffered saline (PBS) of
pH=7.4 to test the cytotoxicity of the degradation products. Photocured POET films, with different
degrees of acrylation (50, 75 and 100%), were prepared by visible light polymerization on 22 mm cover-
glasses. Three different preparations of each elastomer were used. The elastomer films were cut into
pieces of approximately 300 mg and sterilized by autoclaving. The degradation media were prepared by
incubating these pieces in 600 f!I of PBS for I, 7,14 and 28 days at 37°C, in sealed sterile plastic
eppendorftubes. Samples were done in triplicate from each elastomer preparation. PBS incubated under
the same conditions but without the addition of the elastomer was used as a negative control. Aliquots
from each elastomer degradation buffer solution were added directly to the cell culture medium, to test
for cytotoxic effects.
Mink lung epithelial cell line (MvILu, American Type Culture Collection, Manasas, VA, USA) was
used for in vitro toxicity assessment. The cells were grown in Oelbecco's Modified Eagle Medium
(DMEM; Invitrogen, Carlsbad, CA) supplemented with 10% (v/v) fetal bovine serum (Growth Medium;
PAA Laborntories, Etobicoke, ON), at 37°C in an atmosphere of 5% COv'air and 100% relative
humidity. For assays, cells were trypsinized to remove them from the T-75 flasks they were grown in
and re-suspended in growth medium. Cell density was determined by manual counting using a
hemocytometer. Cells were then diluted in growth medium to the appropriate density and plated as
described for the specific assay.
5.1.3.3. The MIT 3-(4,5-dimethylthillzol-l-yl)-1,5-diphenyltetrazolium bromide assay
MvlLu cells were seeded in 96-well plates (Falcon) at a density of 5x10· cells/well in a volume of
200 III culture media, and incubated in a humidified atmosphere (5% C~/air), at 37 ·C. After 24 hrs, 20
IliIwell of each sterile degradation sample or the appropriate PBS control was added into duplicate of
three wells. This resulted in a dilution of elastomer degradation supernatant equivalent to 45 mg
elastomer/mi. After another 24 hrs, 20 III of MIT labeling reagent (final concentration 0.5 mglml) was
added to each well and incubated for 4 hrs in humidified atmosphere at 37 ·C. Unreacted dye was then
removed by aspiration and the insoluble formazan crystals were dissolved in 200 IlVwell solubilization
buffer (10% sodium dodecyl sulphate in O.OIM HCI) and incubated over night and then measured
spectrophotometrically at ).,= 580 nm, using a Polarstar, Optima plate reader (BMO Lab technologies,
Durham, NC USA). Results were recorded as percentage absorbance relative to untreated control cells.
The cytotoxicity assay results were used to calculate cell viability after incubation with elastomer as
Cell viability (%) = [A]/ [A]c x 100
Where [A] is the absorbance in a well containing the elastomer degradation sample and [A]c is the
mean absorbance for untreated control cells. Results reported as the mean ± SO from three different
elastomer preparations of each degree ofacrylation.
5.1.3.!: J1!.-Thymidine incorporation assayfor DNA synthesis
MvlLu cells were plated in 24-well plates (Falcon) at a density of 40,000 cells/well in I mI of
growth medium and allowed to attach in a humidified atmosphere (5% CWair), at 37 ·C for 24 hours
prior to the initiation of experiment. One hundred III of each elastomer degradation sample (45 mg
--I
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elastomer/mJ equivalent), or time-matched PBS, was added to duplicate wells and incubated for 18 hrs.
As a positive control, transforming growth factor ~ (2nglmJ) was added to duplicate wells to
demonstrate responsiveness to growth inhibitors, and sterile saline treated wells served as anegative
controI. After the incubation period, I I1Ci 3H-thymidine was added to each well and incubated for I hr.
Medla was aspirated and the radioactivity incorporated into macromolecules was precipitated by
washing each well twice with I mJ of 10% ice cold trichloroacetic acid solution added to each well for
10 min at room temperature. The solution was aspirated and the precipitated radioactivity was then
dissolved in 0.25 mJ of solubilization buffer (0.2M NaOH, 0.25mglmJ sheared DNA) by shaking for 30
minutes at room temperature. Solubilized radioactivity was added to 5 mI of scintillation cocktail and
the amount of radioactivity determined using a 6500LS liquid scintillation counter (Beckman Coulter
Inc., Brea, CA, USA). The incorporated radioactivity results were used to calculate percentage of DNA
synthesis after incubation as follows:
DNA synthesis (%) = [R]/ [R]c x 100
Where [R] is the measured radioactivity in a well containing the elastomer degradation sample and [R]c
is the mean measured radioactivity for untreated control cells. Results reported are the mean ± SD from
three independent elastomer preparations.
S.2.4./n vivo Biocompatibility and Degradation Studies
5.2.4.1. Animal preparation and subcutaneous implantation
The study was carried out following the guidelines set by the Canadian Council on Animal Care,
outl~gthecodeofethicsgoveminganimalexperimentationandwithapprovaloftheprotocoIby the
Memorial University Animal Care and Use Committee. Twenty five adult male Sprague-Dawley rats,
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16-20 weeks of age and 200-250 g in weight, obtained from the Vivarium at Memorial University
Health Sciences Center (St John's, NL, Canada) were utilized for this research. The rats were housed in
Macrolon IV polycarbonate cages in a thermostatically controlled room, and were given normal tap
water and regular Purina rodent diet (Prolab RMH 3000, PMI Mills Inc, Brentwood, MO, USA). To
allow acclimatization of the animals to the lab environment and to minimize stress prior to experimental
procedures, all animals were housed for at least 24 hrs prior to surgery under 12/12 h light/dark cycles
with-free access to regular purina chow and water.
The implantation surgery was carried out under aseptic conditions and performed under general
anesthesia of 2.5% isofluorane (PPC Richmond Hill, ON, Canada) and 70% 02. At the surgical
anesthesia level (indicated by the lack of tail and corneal reflexes),thehairwas shavedfromthedorsal
nape and back region (around the implantation sites) and disinfected by brushing with iodine solution.
This area was chosen so as to minimize the possibility of rats chewing on the implant site
postoperatively, hence, minimizing lossofsarnple and the risk of infections (Figure 5.2). 0 n each side
of the vertebral column, two paravertebral incisions of approximately 10 mm were made. Lateral to
these incisions, small subcutaneous pockets were created by blunt hemostats to allow the subcutaneous
implantation. A "sham" surgery was used to examine the prejudicial scar tissue formation due to the
surgical procedure itself.
The rats were divided into five groups with each group containing five randomly chosen rats
(n=5/group). From each of the five groups ofanimals, two rats were implanted with two sarnpleseachof
PDETlOo and PDETso autoclaved microcylinder specimens (I cm in length and 2 mm in diameter), n=2
of specimen/rat. The third rat, again from each of the five groups was implanted with two PDETlOo and
one PDETso microcylinder and one PLGA suture of I cm length and 0.3 mm diameter (2-0 CL-811 3
Metric Polysorb®, Covidien Syneture, Norwalk, CT, USA). The fourth one was fixed with one PDETlOo
Site 4
Figure 5.2. A diagrammatic illustration of the implantation sites for the specimens in each rat.
and two PDETso microcylinders and one PLGA suture. The fifth rat was implanted with one PLGA
suture, one PDETlOo and one PDETso samples in addition to the sham surgery. Hence, a total of 95
implants consisting of 15 PLGA sutures, 40 PDETIOO, and 40 PDETso were inserted subcutaneously.
Aftertheinsertionoftheimplants,thesurgicalcutswereclosedusingskinstaples(Agraves®;lnstruVet
C.V., Cuijk, the Netherlands) as well as 50,000 1U of Duplicillin (Intervet Canada Ltd.-Whitby, ON,
Canada) was injected in the hind leg to minirnize risk of infection. Following implantation, eachgroup
of rats was selected randomly at weeks 1,2,4,8,and 12 and the rats were euthanized using intra-
peritoneal injection of 32.5 mg Phenobarbital (Somnotol", MTC pharmaceuticals, Cambridge, ON,
Canada). The implants were dissected along with soft tissue and skin around the sample.
5.2.4.2. Implant retrieval and histological preparations.
For each of the above implantation periods, a total of five PDETlOo and PDETso tissue-covered
implants from different rats were retrieved. As well, three of PLGA suture and one sham specimen were
recovered. The tissue specimens were fixed in 10% buffered formalin for at least 24 hrs. Subsequently,
the specimens were routinely processed and embed into methyl methacrylate embedding. The block was
then cut precisely perpendicular to the longitudinal axis of the implant site using Leica RM 2165 rotary
microtome (Meyer Instruments, Inc. Houston, TX, USA). Several 4-j.UIl sections were cut from each
sample block perpendicular to the long axis of the tissue at the midsagittal site of the implant. The
sections were stained with hematoxylin/eosin for cellular identification and routine histological
examination to observe the interface between implant and surrounding tissue. In addition, VanGieson's
stain was used for differential staining of collagen and connective tissue.
5.2.4.3. Macroscopic and histological evaluation.
For each implantation period, the tissue samples were visually checked for any abnormalities such as
discoloration or marks of macroscopic corrosion. General morphologic and histological observations of
stained sections were performed and digital phase contrast photomicrographs were captured using
Olympus FV 300 microscope (Olympus Canada, Inc., Markham, ON, Canada) coupled with SPOT Rf[
slider camera (Diagnostic Instruments, Inc., Sterling Heights, MI, USA) with complete image analysis
software (Image Pro Plus, version 4.1, Media Cybernetics, Inc., Bethesda, MD, USA). Special attention
was given to examining the connection of the implant to the surrounding tissue. Each tissue sample
received a score by the histopathologist, based on graded scales to assess the cellular response and
determine tissue reaction to implant. All samples were compared to tissue which was obtained by sham
surgery. An inflammatory cell infiltrate score for each implant was determined using a grading scale.
The scale was graded as follows: 0 = no difference from normal control tissue, no presence of
macrophages, giant cells, lymphocytes, eosinophils, or neutrophils at or around implant site; 1=
presenceofafewlymphocytesormacrophages,nopresenceofgiantcells,eosinophil,orneutrophils;2
= presence of several lymphocytes, macrophages, with a few giant cells and a small foci of neutrophils;
3 = presence of large numbers of lymphocytes, macrophages, and giant cells, with notable presence of
eosinophils and neutrophils; 4= severe cellular infiltrate response to implant followed by tissue necrosis
at oraroUitd the implant site. Each cell type was identified separately using an arbitrary scale of+ to
++++, denoting the range from few cells to dense infiltrate, respectively, with - denoting no observed
cells. Inadgiti!!l).,.the fibrous capsule membrane thickness around each implant was measured and
expressed as the mean value of four readings per slide out of five slides at each time point. All
histological preparations were assessed by the pathologist (P.W), who was blinded to the identity of
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5.2.4.4. Physical characterizJJtion ofexcised cylinders
Three of the PDETlOo and PDETso cylinders shaped samples, each of known weight (Wl), were
retrieved from different rats after each implantation period for physical and mechanical measurements.
Immediately after excision to remove attached tissue, the elastomer cylinders were weighed after wiping
the surface with filter paper to determine the swollen weight (W2). The mechanical properties of the
freshly excised elastomers were measured by uniaxial tension using an Instron model In-Spec 2200
tester with Marlin PDA Data Management Software (Instron Corporation, Norwood, MA, USA). At
room temperature, each sample was pulled longitudinally at a rate of 1.0 mm/sec and elongated to
failure. Values were converted to stress-strain and Young's modulus was calculated from the initial
slope of the stress-strain curve. The results reported are the mean ± SD of four measurements. The
crosslinkdensity(p') was calculated according to the theory of rubber elasticity following the equation:
P. = El3RT , where p. represents the number of active network chain segments per unit volume
(mol/ml), E represents Young's modulus in Pascal (Fa), R is the universal gas constant (8.3144 J/mol K)
and T is the absolute temperature (K). The samples from the tensile measurement were collected and
dried under vacuum at room temperature in the presence of a desiccant for 48 hrs, the dried mass (W3)
was then measured. The weight loss was calculated as follows:
Weight loss % = [(Wl-W3) I WI] X 100.
5.2.4.J.,Illvitrodegradation.
Fifteen of known weight (Wi) PDETlOo and PDETso autoclaved cylinder-shaped samples, were
placed in 2~~.sc~tillationvials containing 15 mI PBS (pH=7.4) and 0.01% of sodium azide. The vials
were placed in an oven at 37 ·C for up to 12 weeks. The buffer was replaced daily to ensure a constant
pH of 7.4. After 1,2, 4, 8 and 12 weeks, the cylinders were removed, blotted dry, weighed after wiping
the surface water with filter paper to determine the swollen weight (W2). The samples were then
subjected to a uniaxial tensile measurement while hydrated. The samples from the tensile measurement
were dried as above and the dried mass (W3) was then measured. The weight loss was calculated as
5.2.5. Statistical analysis.
Statistical analyses of data were performed using Graphpad Prism software (version 5.02) by using
2-way ANaVA followed by the Bonferroni post-tests. Oata reported as means ± standard deviation
(SO). Statistical differences between the groups were considered significant if the p value was < 0.05
unless otherwise reported.
5.3. RESULTS
The POET prepolymer molecular weight and polydispersity index were measured to be 1366 Oa and
1.25, respectively. There was no IH_NMR evidence of unreacted monomers in the prepolymer analysis
and the incorporation of the terminal acrylated groups in the prepolymer was confirmed by the
appearance of three peaks at 5.8, 6.1 and 6.4 ppm. Table 5.1 provides a short summary of the
mechanical properties of the prepared elastomers, their crosslink densities and the corresponding
estimated degrees of prepolymer acrylation based on NMR analysis. The POETloo elastomer was
amorphous and exhibited only one glass transition temperature, at - 24°C, with no melting point.
5.3.1./nvitroCytotoxicity
This study evaluated the cytotoxicity of POET elastomers in vitro using MIT test and 3H_Thymidine I
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Table 5.1. Mechanical proprties and sol content ofPDET prepared elastomers.
* EstimatedbyNMR
biomaterials with each test reflecting not only cell number but also cellular metabolic status (MTD and
replication (thymidine incorporation).
5.J.1.1.MITassay
The MIT assay measures mitochondrial dehydrogenase activity and thus indicates cell viability and
metabolic function. The results of the assay on the PDET elastomers with different degrees of acrylation
(50,75 and 100 %) are shown in Figure 5.3. The differences in mitochondrial function associated with
each PDET elastomer were expressed as a percentage relative to that from control PBS treated cells
(arIlttratIlysetatIOO%),wherehigherabsorbancevaluesindicateincreasedmetabolicactivityofviable
cells. Exposure of epithelial cells to the PDET elastomer degradation products with different degrees of
acrylationresulted in a maintenance of high metabolic rate independent of degradation period or degree
of acrylation. This assay therefore provides confinnation of the biocompatible nature of these
5.3.1.2. JH-Thymidine incorporation assay
The 3H-thymidine incorporation assay was used to measure DNA synthesis of cells as a second
measure of cell viability and function. The relative degree of thymidine incorporation into cells, after
incubation with different elastomer degradation aliquots is shown in Figure 5.4. These results are
calculated as a percentage of incorporation of 3H-thymidine, relative to the incorporationrateofthe
appropriate time related PBS treated cells, using the positive and negative controls to define limits of
replication effects. No statistical significant difference was seen in incorporation of 3H-thymidineinto
replicating DNA for PDET degradation aliquot treated cells, regardless of elastomer's degree of
acrylation or time of degradation.
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Figure 5.3. The effect of PDET elastomers of different degrees of acrylation on the MvlLu epithelial
cell viability estimated by MIT assay after 1,7, 14 and 28 days of elastomer degradation. Results are
expressed as the percentage of viable cells compared with phosphate buffer saline (PBS) treated controls
(mean ± SD, n = 6). The significance of the results was determined by comparison with control value
using 2-way ANOVA; • p<O.05.
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Figure 5.4. The effect of POET elastomers of different degrees of acrylation on MvlLu epithelial cells
proliferation and DNA synthesis using lH-thymidine incorporation assay after I, 7, 14 and 28 days of
elastomer degradation in comparison to control. Results are expressed as thepercentageof 3H-thymidine
incorporation relative to that of PBS-treated controls (mean ± SO, n = 6). Transforming growth factor P
(2nglml) was used as a positive control (+vecontrol) and sterile saline treatedwells served as a negative
control (-ve control). The significance of the results was determined by comparison with control value
using 2-way ANOVA; • P<O.05.
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S.3.2./nvivoBiocompatibility
Evaluation of the local pathological effects was carried out at both the gross level and the
microscopic level. Gross evaluations of the rats were conducted daily for 12 weeks. These evaluations
showed no exudative inflammatory reaction on the dermis, even though the implants could be palpated.
The rats were recorded as being healthy and active throughout the study, with no abnormal behavior
noted in any of the animals. Daily weights did not reveal any abnormalities in food consumption. There
was no abnormal swelling, skin irritation/infection or discoloration of the tissue around the implant, as
shown in Figure 5.5.
5.J.2.1.Biologicalresponsesandhistology
Practically, our fundamental aspects of the tissue response in this study included inflammatory and
foreign body reactions as well as ultimately fibrous encapsulation. Therefore,twodifferentcrosslinked
densities of the elastomer (pDETlOo and PDETso) were implanted to assess the in vivo biocompatibility
and to investigate the influence of the degradation rate on the magnitude of the biologicalreaction.
Table 5.2 provides an overview of the nature and extent of observed tissue reactions after each
implantation period. Based on the histological evaluation, the various cellularresponses were rated as
shown in the table. The sections were also examined for the presence of fibrin, the induction of
vascularization, and the formation ofa fibrous capsule around the implant.
As shown in Figure 5.6 (B, E, H) and Table 5.2, up to the second week of implantation, high
concentrations of macrophages surrounded the implants and were clearly seen at 20x magnification and
their amount was relatively high compared to that of sham surgery. As well, no significant difference in
Figure 5.5. Elastomer implants as dissected along with soft tissue and skin around them. Images (A) and
(B) show representative PDETIOO implants at 4 and 12 weeks respectively. Images (C) and (0) show
representative PDETso implants at 4 and 12 weeks respectively. No necrosis, granulomas, or sign of
dystrophic soft tissue calcification can be seen around any of the implants.
Table 5.2. Tissue reactions to PDET implanted samples of different degrees of acrylation and PLGA
sutures.
Time
"So (Week)
8
Jl
Macro Lympho- Eosino- Neutro- Giant tInfiammatory "Fibrous
-phages cytes phils phlils cells cell score Capsule
Thickness
(I'm)
~ 35±5.0~ __-..-.... ,.-;";'";..... r-;o;-o"'Ilr--........Ir--~I~o-;-'"ll-.....~-l,...,~",....
tScaleforinflammatorycellinfiltrate=O-4.
- Not present; + to ++++ = sporadic to severe.
* Fibrous capsule tbickness was measured intbe tbickest part as tbe tbickness around tbeimplant
was not uniform. The measurements represent mean ± standard deviation (n=5 for botb PDETso
& PDETlOo and =3 for PLGA suture).
PDET100 PDETso PLGA
Figure 5.6. Representative histological images of the tissue surrounding cylindrical POET elastomeric
implants and PLGA sutures (control) showing macrophages (black arrows) and fibrin layer (white
arrows) at the implantation site. POET lOo implants after (A) 2 weeks at 4x magnification (B) 2 weeks at
20 x magnification and (C) 12 weeks at 20x magnification. POETso implants after (0) 2 weeks at 4x
magnification (E) 2 weeks at 20 x magnification and (F) 12 weeks at 20x magnification. PLGA implants
after (G) 2 weeks at 4x magnification (II) 2 weeks at 20 x magnification and (1) 12 weeks at 20x
magnification.
the number of macrophages could be found between the various implants. In the surrounding tissue of
all implants, leukocytes such as eosinophils, neutrophils and lymphocytes were also detected in
comparable levels to sham surgery, but the neutrophils were higher in the POET implants than the
PLGA samples. Basically, the presence of high concentration ofleukocytes (predominantly neutrophils)
indicates the presence of an acute inflammatory response to the tissues injury occurred during the
surgical process of implantation. Neutrophils were chemotaxically emigrated or moved from the blood
vessels to the perivascular tissues and the injury (implant) site, depending on the extent of injury and the
size of implanted material. Thus, more neutrophils in the POET than the PLGA might be attributed to
the foreign material response as the major role of the neutrophils in acute inflammation is to
phagocytose foreign materials. This is considered the normal wound healing response to implanted
biomaterials. The acute inflammation was of relatively short duration and started to resolve after 2
weeks, as neutrophils have short lifetimes (hours to days) and disappearrapidiy.
Following the localization of leukocytes at the implant site, in particular neutrophils, phagocytosis
and the release of leukocyte enzymes started to occur in an attempt to phagocytose foreign materials.
Although implants were not generaIly phagocytosed by neutrophils or macrophages because of the size
disparity (Le. the surface of the implant is greater than the size of the cell), frustratedphagocytosismight
have occurred. This process did not involve engulfment of the implants but caused the increase of
lymphocytes and macrophages as well as the extracellular release of leukocyte products in an attempt to
degrade the implant. The accumulation of macrophages was the most important feature for foreign body
giant cell formation. These giant cells most likely originated from fused macrophages and were an
indication ofnormal foreign body reaction (Table 5.2).
At weeks 4 and 8,macrophages still surrounded all of the implants, however, the densityofthe
macrophages started to diminish with PDETlllO samples showing lower macrophage density when
compared with PDETso and PLGA. This relatively high number ofmacrophages seen in PDETso was not
likely due to leachable products from the elastomers since their aliquots did not show any inhibition of
cellular functions in vitro (Figures 5.3 and 5.4). A possible explanation might be the reiativefasterrate
of PDETso degradation when compared to PDET1oo, keeping high numbers of macrophages around the
implant site in an attempt to phagocytose the degradation products. Neutrophils and eosinophilsstarted
to disappear which were mostly replaced by monocytes that differentiate into macrophages. The giant
cells also started to decrease in number with the implanted elastomers at week 4 and reached to the same
density or below that of sham surgery, nonetheless, in case of implanted PLGA sutures they continued
to stay at high levels. By week 8 and 12, the giant cells had virtually disappeared around PDETso and
PDETlOo implants, respectively.
By 12 weeks (Figure 6 C, F, I), the PLGA suture was completely absorbed and couldn't be detected,
nonetheless, macrophages and giant cells were present in the area where originally the PLGA suture had
been implanted. All of the PDET implants were still surrounded by macrophages compared to sham
surgery but less than the PLGA suture implant site. All implanted samples showed considerably lower
leukocytes density at week 12 compared to 1 or2 weeks post implantation, although, there was no
considerable number of eosinophils or neutrophils observed in all implants. There were very few
numbers of lymphocytes, compared to 4 weeks, in the vicinity of implanted elastomer specimens, an
amount which is quite similar to that of the PLGA suture. These remaining lymphocytes and
macrophages were an indictor of chronic inflammatory or immune response due to persistent
inflammatory stimuli confined to the implant site.
Within one week following implantation, the healing response, initiated by the action of
macrophages, was followed by proliferation of fibroblasts and vascularendothelialcellsattheimplant
site. Mature fibroblasts were found to forrn similar distinct fibrous capsules (vascular collagenlayer)
around both PDET elastomers and the PLGA suture within the first week. As the capsule thickness was
unequalaroundtheimplant,measurementsweretakenatthethickestpartofthecapsule.Actua1IY,the
foreign body reaction with granulation tissue development is considered the norrnal wound healing
responsetoimplantedbiomaterials(i.e.thenorrnalforeignbodyreaction).
5.3.5. In vitro and In vivo Degradation
The in vitro and in vivo percentage weight loss of the elastomers versus degradation time is shown in
Figure 5.7. As can be seen, the percentage weight loss of the elastomers reported both in vitro and in
vivo was inversely proportional to the crosslink density of the prepared elastomers (Table 5.1). 16
The PDETso elastomers underwent weight loss at a faster rate (3.20 %/day and 2.47%/day in vivo
and in vitro, respectively) than the PDETlOo elastomers (1.85%1day and 1.22%/day in vivo and in vitro,
respectively),indicatingthatthecrosslinkdensityoftheelastomercontributesto its degradation rate and
behavior. For both crosslink densities, a significant increase in the degradation ratewasfoundtotake
place in vivo when compared to that observed in vitro. By 12 weeks, the in vivo experiments showed that
mass loss was approximately 38.4±3.9 % and 22.1±3.6 % for PDETso and PDETIOO, respectively.
However in the in vitro system, elastomer degradation appeared to be slower, having only lost 29.6±0.8
To deterrnine the kinetics of the changes in the mechanical properties of the elastomers(Young's
PDET elastomers were investigated (Figure 5.8 and Table 5.3). The results revealed that for both in vitro
modulus,E,-tensile stress at break, a,andstrainatbreak, e),the in vitro and in vivo degradations of the
% and 14.6±0.6 % of their initial mass for PDETso and PDETIOO, respectively.
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Figure 5.7. Degradation studies of PDET elastomers of different degrees of acrylation. (A) In vitro and
in vivo percentage weight loss versus time. (B) In vitro and in vivo percentage water absorption versus
time. Each point represents mean ± SD (n = 3).
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Figure 5.8. Changes in mechanical properties ofPDETlOoand PDETso elastomers during in vivo and in
vitro degradation. (A) Young's modulus at time t, Et (B) Ultimate tensile stress at time t, crt (C) Ultimate
tensile strain at time t, Et.• Lines on the figures are fitted curves to zero-order degradation kinetics
equation. Each point represents mean ± SD (n = 3). Kinetics parameters and linear regression
coefficients are reported in table 2.
Table 5.3. Zero-order kinetic parameters and linearregressioncoeffecients of the changes in the
mechanical data for POET elastomers during in vitro and in vivo degradation studies.
E.(MPa) KE(MPalWeek) If u.(MPa) K.(MPalWeek) If
and in vivo degradation, the changes in the mechanical properties with respect to time followed the same
pattern of degradation and were significantly dependent (p<0.001) on the degree ofacrylationofthe
PDET elastomer. Although the elastomers showed a decrease in their mechanical strength with time,
theymaintainedtheiroriginalshapeandextensibilityoverthetestingperiod,invivoasweII as in vitro.
In both in vivo and in vitro studies, the measured values of E (Figure 5.8A) as well as (J (Figure 5.8
B) decreased with time in a linear fashion as an indicative ofa zero-order degradation mechanism. This
linear decrease was observed regard1ess of the network composition, the crosslinking density and the
initial E and lJ of the elastomers. Ontheotherhand,thechangeine was less sensitive to the degradation
of those elastomers and no significantchangesine values during the in vivo and in vitro degradation
period were observed (Figure 5.8 C). These results confinnedthat the in vivo hydrolytic degradation of
these elastomers followed a bulk erosion mechanism resembling the in vitro behavior, as we reported
previously. 16 It is only with a surface erosion degradation pattern that the elastomers can maintain their
mechanical properties unchanged. 16
Through a linear regression of the zero-order degradation kinetics of the data in Fig. 5.8 A &5.8B
using equations (I) & (2),the rate constants were calculated and are listed in Table 5.3.
(I)
(2)
In equations I & 2, t denoted the degradation time (in weeks). The values of Eo and lJ() corresponded to
theinterceptsobtainedfromextrapolatingthezero-orderfittedline.~andK£representedthezero-order
degradation constants for Young's modulus and the ultimate tensile stress, respectively.
For the in vivo degradation of PDETIOO, E as well as (J decreased linearly with time (correlation
coefficient, R2, of 0.981 and 0.969, respectively). The rate constants for the decrease in E (K£) and (J
(K.) were 0.0942 and 0.0122 MPalWeek, respectively. PDETso in vivo degradation also exhibited a
linear decrease in E and a with time (R2 = 0.978 and 0.979, respectively). The rate constants for the
decrease in a was nearly the same as PDETlOo (K. = 0.0117 MPalWeek), while the decrease rate
constants in E was slower than that ofPDETlOo (KE = 0.0162 MPalWeek).
5.4. DISCUSSION
We have previously conducted a preliminary cytocompatibility study by incubating intact elastomers
with fibroblast cells for 24 hrs and examined cell morphology and density for any signs of
cytotoxicity.\6 Those results showed that PDT elastomers could function without causing adverse
cellular effects, but those results only indicated cytocompatibility with a cell line after short term contact
time. Therefore, one of the objectives of this study was to assess the effects on cell viability and
proliferation ability in the presence of elastomer degradation products, to furtherinvestigate the in vitro
cytotoxicityprofileofthePDETelastomers.
While the choice of the cell line used for cytotoxicity testing remains controversial and a vast
number of cell lines have been used, we chose a phenotypically normal cell line, MvlLu, because of its
high sensitivity to replication inhibitors and stimulators\9 and its relevance as a non-transformed
epithelial cell, thereby serving as a useful model system for the study of cytotoxicity on cell
proliferation.2o The MTT assay was chosen because it measures the metabolic activity of cells, although
it has been extrapolated for use as a measure of cellular proliferation. This assay has alsobeenrecently
developed as an effective method for preliminary screening of in vitro cytotoxicity of polymeric
biomaterials. 2\ To measure effects on DNA replication of cells after exposure to polymer degradation
products, we chose to use 3H-thymidine incorporation assay, one of the most common methods to
determine cell viability or cytotoxicity. The method is as sensitive as the 5-bromo-2-deoxyuridine
(BrdU) incorporation assay and traditionally used as a sensitive screening for in vitro toxicity of new
biomaterials.22 As the results clearly illustrate (Figures 5.3 and 5.4), the response of epithelial cells
treated with the degradation product of POET elastomers, with different degrees of acrylation,
demonstrate the ability of the cells to interact favorably with this new biomaterial as verified by
maintenance of metabolic activity and proliferation when compared to control cells.
From a practical perspective, the in vivo assessment of tissue compatibility is carried out to
investigate the possible biological and/or immunological events, indicating an adverse tissue response to
the presence of the implant, that could accompany the in vivo application and result inimplantfailure.
Elastomermicrocylinders were implanted subcutaneously into rats, with the main intentto identify any
local responses of the living tissue to these implants, as well as the response of the implants to the Iiving
system by evaluations under conditions simulating clinical use. Inthisstudy,biodegradablePLGA(poly
L1actide-co-30%glycolide)waschosenasacontrol biomaterial for in vivo biocompatibility because of
its ubiquitous uses in a variety of Food and Orug Administration (FOA) approved therapeutic devices
and due to its well reportedbiocompatibility.
As shown in Figure 5.5, the mild local tissue responses were confirmed by the lack of necrosis,
granulomas, or signs of dystrophic soft tissue calcification around any of the investigated specimens
when observed daily throughout the study. A mild to moderate inflammatory response characterized by
an initial increase of leukocytes was localized to the vicinity of the implants, a response that isexpected
and consiste~ with the introduction of a foreign material into the body. Usually, the normal foreign
body reaction is consisting mainly of macrophages and/or foreign body giant cells that maypersist at the
tissue-implant interface for the lifetime of the implant. Therefore, leukocytes (predominantly
macrophages,neutrophils, lymphocytes and giant cells) were the predorninantinflanunatory cell type
present as an indicative marker of acute inflanunatory response. They were found to be very close to all
of the implant-tissue interfaces and were most notable during the first 1-4 weeks post-implantation and
remained up to week 12 of the study. However, their densities were reduced considerably for POETlllO
by 4 weeks, while for POETlll, the macrophage density had diminished by 8 weeks compared to the
PLGAimplant.
This above discussion indicates that implantation of POET elastomers was associated with an acute
inflanunatory response as shown by the high amount of leukocytes followed by a chronic inflanunation
as indicated by the remaining cells through the 12 weeks of the test.23.24 Our observations are sirnilarto
the immune reactions seen with other absorbable materials, such as crosslinked dermal sheepcollagen 2S,
tyrosine-derived polymers 26 and matrices of polylacticacid andpolyglycolic acid. In those models, the
severity ofinflanunationdecreased upon decreasing degradation rate.27
illS known that the formation of the multinucleated giant cells occurs as a common response
towards a biodegradable material as these cells participate in the overall biodegradation process and
oftencontail!.C?d,!!a~entsofthedegradationproducts.A1thoughthenatureoftheinitialtissueresponse
for the POET elastomers and that of the PLGA control was quite similar, the giant cells were
considerably less around POET elastomer implants during the 2nd to 8th week of implantation. This
observation can be attributed to the fact that POET elastomers appeared to remain stable in vivo for a
much longer time than the PLGA suture which was found to be completely absorbed by the week 12 of
the implantation period. At 12 week post-implantation, giant cells had disappeared from all implants but
not from control samples (pLGA suture), even though a complete absorption of the PLGA suture had
occurred. Such a response was also observed previously with polylactic and polyglycolicacidmatrices.27
In part, the body reaction to POET elastomers and PLGA produced thin vascularized fibrous
capsules within the first week of implantation. The overall thickness of these capsules appeared to
become thinner over time as reported in Table 5.2. This is similar to the response observed with 0 ther
polymeric absorbable materials upon implantation.2l-27 Some newly formed blood vessels and capillaries
were seen located between the capsule layer and soft tissue, regardless of the implant type. The number
of these blood capillaries as well as the leukocyte number diminished over the implantation time. There
was, however, a significant decrease in thickness with PLGA suture at 12 weeks as the suture was
completely absorbed. Therefore,itisexpectedthatthecompletedisappearanceofcollagenlayeratthe
implant site would restore its histological architecture after complete absorption of POET elastomers
implant, as a classical end-stage of fibrous capsules. 21 All of these observed tissue responsesindicated
that the POET elastomers are able to coexist with subcutaneous tissues without causing harm, regardless
of the time period of implantation and therefore can be consideredbiocompatible. In addition, there
were not any qualitative differences in histology between POET,oo and POET,o specimens that could be
detected under the light microscope and differential staining methods.
The examined in vivo and in vitro changes in the physical and mechanical properties of the POET
have revealed the following. First, a marked increase in the in vivo degradation rate has been noticed
when compared to that observed in vitro over the twelve week of implantation. This is likely due to the
acute1nflammatoryresponse in vivo and reasonably to a greater degree of solubility of the degradation
products present at the surface in the invivoaqueousenvironment.24 Second,theelastomersdidnot
absorb as much water during the in vivo degradation period as in the in vitro period, but rather shrun.k
slightly or remained at their nearly initial weight and volume. This observed behavior was independent
of the crosslink density used. This is a useful finding as it indicates that the elastomers maintained their
geometry and stability in vivo during the degradation period, a factor which is important fortheirusein
drug delivery and mechanically challenged implantable devices. Third, although the implants were
encapsulated by fibrous tissue in vivo, thepattem of the changes in the mechanical propertieswithtime
was'essentially the same in vivo as in vitro. These results were consistent with what has been reported
earlier for uncrosslinked 29 and crosslinked 30 aliphatic polyesters. The mechanical properties of the
elastomers decreased at the same rate and to the same extent in vivo as was observed in vitro, and were
mainly dependent on the crosslink density of the elastomer (Figure 5.8 and Table 5.3). We have
previously reported that Young's modulus of the elastomers depended mainly on the crosslinking
density while the ultimate tensile stress depended on the distribution of end to end distances between
crosslink points within the matrix. 16 As well, it is well known that biodegradation (either in vivo or in
vitro) occurred by the hydrolysis of the ester bond in the end to end distance betweencrosslinks.As
such, PDET,oo with higher crosslinking density demonstrated faster decline in the Young's modulus
compared to PDETso with lower crosslinking density, while, the ultimate tensile stress for both decline
Finally, it cannot be overlooked that neither the in vitro nor the in vivo degradationconditionsinthis
study represent a perfect sink for dissolving or absorbing the elastomer degradation products and
removing them from the site of degradation, As well, the structure and nature of the degradation
products are likely to be different between in vivo and in vitro as well as for each degree of acrylationas
a result of their different crosslinking density, However, from a practical standpoint, this close
correlation between in vitro and in vivo degradation is useful in tenns of designing long-tennresorbable
matrices using these elastomers, for controlled drug delivery and tissue engineering applications.
5.6. CONCLUSIONS
InthisstudY,wereportedontheresultsofthecytotoxicity,biocompatibilityandbiodegradabilityof
POETelastomers,oneofourpreviouslydevelopedandcharacteriudnoveibiodegradablepolyesters,as
determined in an in vitro and in vivo system. We have demonstrated that POET elastomers, with
differentdegreesofacrylation,showedpromisingcytotoxicityresultswithMvlLucellsandreceived
reasonably consistent results between the two common cell viability assays (MIT and thymidine
incorporation). We also have shown in vivo justification to confinn the potential of these elastomers as
soft-tissue friendly materials as well as the candidacy of these elastomers as biodegradablebiomaterials
on long run. We have also demonstrated that POET elastomers, with different degrees of acrylation
degrade at different rates within the body and therefore elastomer selection can be tailored to achievethe
desired irnplantationperiod and release rates. All the collected data are enabling properties for POET
elastomers, which make them potentially suitable as a developed resorbable matrix for medical devices
use iI4ong-tenn phannaceutical delivery. Promising results regarding osmotic-driven controlled release
and stability of papaverine hydrochloride from POET matrices have already been achieved.6
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CHAPTER 6
Sustained Interleukin-2 Delivery from
Photocrosslinked Biodegradable Poly(decane-co-
tricarbaUylate) Elastomer
The content of this chapter is to be submitted to the Journal of Controlled Release
ABSTRACT
One of the main challenges in interleukin-2 (IL-2) cancer immunotherapy is achieving localized and
efficientdeliveryoverasustainedperiodoftimewithpropermaintenanceofitsstabilityandbioactivity.
In the present study, new biodegradable elastomeric poly(decane-co-tricarballylate) [pOET] matrices
which utilize the osmotic-driven-controlled release mechanism were designed in an attempt to overcome
these stability and bioactivity challenges facing lL-2 delivery. Elastomer synthesis was achieved by
polycondensationreaction between tricarballylic acid and a1kylene diols, followed by acrylation and
photo-curing. lL-210aded micro-cylinder and disk-shaped elastomers were prepared by intimately
mixing lyophilized lL-2 powder with the acrylated prepolymer prior to photocrosslinking. lL-2 release
was analyzed using 11-2 enzyme-linked immunosorbent assay method and the in vitro bioactivity of
released lL-2 was assessed using C57BU6 mouse cytotoxic T lymphocyte. The influence of various
parameters such as the elastomer crosslinking density, the volumetric loading percentage and the
incorporation of osmotic excipients like trehalose on the release kinetics of the drug was also examined.
The disk-shaped specimens showed faster controlled 11-2 release profiles than microcylinders, with
drug release proceeding via typical zero-orderrelease kinetics. The increase in the device's surface area
and the incorporation of trehalose in the loaded lyophilized mix increased the lL-2 release rate.Aswell,
it was shown that the decrease in the degree of prepolymer acrylation of the prepared devices increased
thelL-2releaserate.CellbasedbioactivityassayforlL-2overareleaseperiodof28daysshowedthat
the released lL-2 retained more than 94% of its initial activity. The new PDET elastomers demonstrated
to be promising as a protein drug delivery vehicle for localized and sustained 11-2 immunotherapy.
6.1. INTRODUCTION
Interleukin-2(IL-2)isacytokinemessengerproteinthatplaysanimportantroleintheactivationof
cell-mediated immunotherapy against cancer. I,2IL-2 is currently indicated for systemic administration
via multiple injection regimens to treat a number of different types of cancer diseases such as metastatic
melanoma,3 kidney carcinoma,4as well as surgical minimal residual tumor disease after cancer resection
surgery,5 0r the use ofchemotherapy.6 Systemic IL-2 therapy has always been associated with rapid
clearance and life-threatening toxicities that restrict its full clinical relevance.7 Loco-regional IL-2
delivery, however, is used to localize IL-2 actions and activities into the vicinity of tumors and can
result in an improved therapeutic outcome with much less side effects ortoxicity.8 Although, the
effectiveness of local IL-2 delivery system has been extensively investigated and approved for the use in
the treatment of a broad range of solid tumors,B.9 IL-2 still possesses many stability problems that
challenge its bioactivity with the formulation approaches. Firstly, IL-2 molecule is sensitive to acidic
conditions (pH ~ 2.1) as it contains one intramolecular critical disulphide bridge linkage between
cysteine amino acid at positions 58 and 105, that is essential for maintaining the stability 0fthetertiary
structure and subsequently the biological activity. 10.1 1Secondly, as with many othertherapeuticproteins,
IL-2 is heat sensitive and undergoes irreversible thermal denaturation and aggregation in solution at
temperature exceeding 44oC. 12 Furthermore, IL-2 is subject to unfolding and formation of compact
denaturated hydrophobic clusters (aggregation) with subsequent loss of activity when present fora
relatively long time and in high concentrations in aqueous solution. 11
In spite of the aforementioned challenges, extensive research has focused on the developmentof
drug delivery systems capable of achieving sustained and localized deliveryofIL-2. Such delivery
systems include but are not restricted to the use of liposomes,13 hydrogels,14 polymeric
microsphereslnanospheres,IS,16 thermo responsive synthetic polymers (ReGel~,17 and injectable
polymeric controlled release systems (Medusa II*),18 An extensive evaluation of the different routes of
administration and formulation approaches utilized for the delivery ofIL-2 has recently beenreviewed
and the reader is strongly advised to refer to that review for detailed discussionrelated to advantages and
limitations of each of those IL-2 delivery systems. 19 One of the most recently used strategies for
localized therapeutic protein delivery was achieved by dispersing the protein mixed with osmotic
excipients inside implantable biodegradable polymers and relying on the osmotic-rupture mechanism as
the predominant mechanism for achieving constant zero-order release.2O-11 These polymeric devices
were prepared by UV photo-crosslinking of an acrylated star-poly(&-caprolactone-co-D,L-lactide)
prepolymers,2° acrylated poly(octane- tartarate)23 or trimethylene carbonate copolymerized with D,L-
lactide and &-caprolactone based elastomer.24 Although the mechanism of osmotic-driven release
offered distinct and practical advantages over other means of delivery, there were a number of issues
which have an impact on the stability and activity profiles of loaded proteins. Mainly,theuseoforganic
solvent during the formulation may change the protein conformation.2S,26 In addition, the use of ultra-
violet radiation during the photocuring was reported to denature proteins and consequently result in loss
oftheirbiologicalactivity.2s
We have recently reported on the synthesis, characterization, biodegradation and biocompatibilityof
a no'<d f.aJnily of amorphous photoset poly(diol-co-tricarballylate) elastomers26 and their use in the
controlled-release of smaIl molecule drugs.27 These newly synthesized elastomers also exhibited many
characteristics which make them a promising matrix to overcome the aforementioned stability and
activity ch~;;-facing the delivery of therapeutic proteins.26,27 Firstly, protein drug loading was
achieved in a solventless manner which helped in preventing possible drug denaturation and
precipitation due to its exposure to organic solvents and disruption ofprotein hydrophobicinteractions.26
Secondly, the use of visible-light crosslinking helped in eliminating many of the drawbacks associated
with using UV photocuring by making the polymerization conditions sufficiently mild to be carried out
in the presence of sensitive biological materials like proteins.2S,26 Additionally, visible light was able to
penetrate deeper through tissues than UV light (less scattering and less absorption). This property may
limit the need for invasive surgical procedures by allowing trans-tissue polymerizations, whereby the
material is injected subcutaneously or even subdermally and irradiated through the skin to polymerize
the material in situ.26 Thirdly, it was shown that osmotic-driven controlled release of drugs from these
new elastomeric matrices is linear, constant and controllable.27 Finally, the use ofaslowly hydrolysable
copolymer such as poly(decane-co-tricarballylate) [pDET] would reduce or eliminate the production of
acidic monomersloligomers within the elastomers until the vast majority of the loaded protein is
released, via the osmotic-rupture mechanism, before any significant reduction in the mechanical
properties of the elastomer occurs due to its hydrolysis.26,28 A description for the proposed controlled
release of IL-2 via the osmotic-rupture mechanism is illustrated in Figure 6.1 and described as follows:
The drug particles located on the surface dissolve and produce an initial burst effect, accounting for up
to 15% of the initially loaded drug, followed by a slow release period, predominant osmotic driven
mechanism. This slow release depends on the rate of degradation of the polymer when the polymer is
degradable and/or the rate of formation of cracks and interconnected pores resulting from water
imbibition into the polymer.22,27 When the elastomer degradation rate is slow enough to maintain the
implant's geometry and mechanical properties (extension ratio) during the release period, the osmotic-
driven mechanism will dominate the linear controlled-release and polymer degradation will play 0 n1ya
minor role in the overall releasepattem.21,27
DiI
Figure 6.1. Schematic representation of osmotic swelling, rupture and release mechanism A) water
diffusion through the elastomer reach to the first layer of encapsulated drug particles. B) the imbibed
water dissolves the solid drug at solid polymer interface, creating a saturated solution surrounding
elastomer, causes it to swell and exert pressure on the inside wall. C) the pressure causes micro-cracks to
form in the elastomer and the dissolved protein/excipients content is then released. The process is
repeated with the subsequent layer of particle which leads to interconnected network formation. D) the
osmotic release from a cylinder shape elastomer.
The purpose of the present study, therefore, is to further investigate the use of this new family of
synthesized photo-cured PDET biodegradable elastomers as controlled release matrices for therapeutic
proteins and their ability to maintain the stability and bioactivity of loaded IL-2 during loading and
preparation stages and after drug release.
6.2. EXPERIMENTAL
Chemicals used in elastomer synthesis and purification include tricarballylic acid (99%),1,10-
decanediol(98%),stannous2-ethylhexanoate(95%),4-dimethylaminopyridine(99%),acryloylchloride
(96%), triethyl amine (99%), sodium sulphate ~99 %) and champhore-quinone( 97%) were purchased
from Aldrich-Sigma chemical company, Canada. Solvents used in the purification of the synthesized
prepolymers and acrylated prepolymers include ethyl ether (99%) acetone (99%) and chloroform (99%)
were purchased from Caledone chemical company, Canada. For the release study, recombinant murine
interleukin 2 (rmIL-2) and rmIL-2 ELISA kit were purchased from Peprotech Inc., Canada. Trehalose
dihydrate, bovine serum albumin and ABTs liquid substrate system for ELISA were obtained from
Sigma, Canada. Chemicals used in calorimetric assays include phenol (99%),sulfuricacid (95-98%)
obtained from Fischer, Canada, and Pierce BCA protein assay kit was obtained from thermo scientific,
Canada. For the bioactivity assay, Dulbecco's phosphate buffer saline, GIBCO® RPMI medium 1640,
penicillin and streptomycin were obtained from Invetrogen, Canada and Rat T-STIM with Concanavalin
A was purchase from BD biosciences, Canada. MIT cell Proliferation Kit was purchased from Roche,
Canada. All chemicals were used as received without any further purification.
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Figure 6.2. Schematic illustration of the synthesis, acrylation and photocuring of poly(decane-
tricarbailylate). The step-reaction polymerization oftricarbailylic acid and decane diol was catalyzed by
stannous2-ethylhexanoate. Theacrylation was done by reacting with acryloyl chloride in the presence
of triethylamine. To photo-crosslink, acrylated prepolymer was mixed with the photoinitiator, poured
into a seaied glass mold and crosslinked under visible light (40mW/cm2).
6.2.2. Synthesis and Characterization of Acrylated Poly(decane-co-tricarballylate) Prepolymer
Acrylated POET was synthesized according to the previously described method in chapter 3 (section
3.2.2.) which is illustrated in Figure 6.2.26 The final purified product was characterized using proton
nuclear magnetic resonance ('H-NMR) to confirm the fmal product's purity and the signal intensity of
themethylenegroupsofdiol(1.3-1.7ppm)andtheacrylategroup'intensities(5.8-6.4 ppm) were used
to calculate the degree ofacrylation in the prepolyrners.26
6.2.3. Elastomeric Matrices Preparation and Characterization
The photocuring process was carried out in a dark fume hood equipped with sodium lamp. On a
watch glass, 5 III of 10 % ethanolic solution of both camphorquinone and triethanolamine (equivalent to
0.01 % (w!w» photoinitiator was added to 5 grams of the acrylated prepolyrner. The mix was then left at
40°C under vacuum for I hr to ensure complete removal of any traces of alcohol from the photoinitiator
solutions. The mix was then poured into the bottom of a sealed cylindrical silanized glass mould of I cm
in length and 2 mm in diameter. The mould was then exposed to a visible light source (450-550 om at a
40 mW!cm2) filtered from a 50 Watt tungsten-halogen lamp (Taewoo Co., Korea) for 10 minutes at a
distance of 10 cm to form the elastomer which was then removed from the mould for further testing. The
tensile mechanical properties of elastomeric cylinders (1.5 cm in length and 2 mm in diameter) were
tested using an Instronmodel In-Spec 2200 tester equipped with 500N load cells and run by Merlin
Data Management Software. The sample was pulled at a rate of 1.0 mm1sec and elongated to failure.
Values were converted to stress-strain and plotted. Young's modulus was calculated from the initial
slope of the stress-strain curve.
For in vitro degradation, PDETlOo and PDETIO cylinder-shaped samples (I cm in length and 2 mm in
diameter) of known weight (WI) were placed in 20 m1 scintillation vials containing IS m1 PBS (pH=7.4)
and 0.01% of sodium azide. The vials were placed in an oven at 37 °C for up to 12 weeks. The buffer
was replaced daily to ensure a constant pH of 7.4. After 1,2,4 and 8 weeks,thecylinderswere
removed, blotted dry, weighed after wiping the surface water with filter paper to determine the swollen
weight (W2). The samples were dried at room temperature for a week and the dried mass (W3) was then
measured. The water absorption & weight loss were calculated as follows:
Weight loss % = [(WI-W3) I WI] X 100.
Water absorption % = [(W2-W3) I W3] X 100.
6.2.4. PrepmtioDofIL-2 Loaded Elastomeric Delivery Systems
Recombinant murine IL-2 (rmIL-2) was first co-Iyophilized with different ratios of trehalose (TH)
and bovine serum albumin (BSA) in 10 mM sodium citrate, pH=4. Various amounts of rmIL-2,
trehalose and BSA were used, while keeping the ratio of rmIL-2 to the total ofTH and BSA I: I0, unless
otherwise stated. The formulation solution was lyophilized and the obtained solid was ground into fine
powder using a glass mortar and a pestle and then sieved through a 45 lUll mesh using CSC sieve shaker.
The sieved protein particles were intimately mixed with the acrylated PDET prepolymer by gently
'vortexing and photocrosslinked as per the procedure described above. For the micro-cylinder samples,
the photocrosslinking was carried out in a cylindrical glass mould of I cm in length and 2 mm in
diameter. On the other hand, disk sample photocrosslinking was carried out in disk shape teflon moulds
of I cm in diameter and I mm in the thickness. Each prepared IL-210aded cylinder was weighed and the
amount ofIL-2, albumin and trehalose in each were calculated. Cylindrical devices had an average
weight of 20 ±1.2 mg, while the disk-shaped devices had an average weight of 40.0±2.7 mg. The
volumetric loading of the lyophilized protein/excipient was 2, 10 and 20010 of the elastomer volume to
ensure that the drug loading was below the percolation threshold.
6.2.5. Effect of Formulation Conditions on the IL-2 Bioactivity
To determine whether IL-2 maintained its bioactivity during the formulation and analysis condition,
in triplicate, known amount of 11-2 solid particles with different THlBSA mass ratio where dissolved in
PBS and the solutions of each THlBSA mass ratio were divided into three equal a1iqouts. To examine
the pl!ot~uring effect, in the first part 10 % ethanolic solution of both camphorquinone and
triethanolamine (equivalent to 0.01% (w/v»was added and the solution exposed to avisible light source
(450-550 nm at a 40 mW/cm2) at a distance of 10 cm for 10 minutes. To see the lyophilization effect, the
second part-;;-asIYOPhilized and the obtained solidre-dissolved is sterile water. To access the freezing
andthawingcyclesonproteinstability,thethirdaliquotwasfrozenat-85°Cforsubsequent 24 hrand
then thawed at room temperature. These solutions were then added to a CTLL-2 cell culture to assess the
bioactivity of lL-2. CTLL-2 cell are T cell lymphocyte obtained from C57BU6 mouse and can
proliferate onIy in the presence ofbioactive IL-2.
6.2.6./nviJroReleaseStudies
The prepared monolithic micro-cylinders and disks loaded with lyophilized IL-2 were subjected to in
vitro release studies using phosphate buffer saline (PBS) of pH 7.4 as a release medium. Each of the
triplicate micro-cylinder samples was put into 200 J.l1 microcentrifuge vials filled with 100 J.l1 of release
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medium. As well, each of the disk samples was put into 2 mI microcentrifuge vials filled with 200 III of
release medium. The vials were attached to a Gias-Col rugged culture rotator. The rotator was set at
20% rotation speed and placed in an oven at 37± 0.5 ·C. To ensure sink conditions and constant osmotic
pressure driving force, the receptor release medium was replaced with fresh medium over the release
period..-~0Iutionscollectedweredividedintoaliquots,frozenat-85·CforsubsequentIL-2,albumin
and trehalose concentration analysis as well as IL-2 bioactivity assay using cytotoxic T-cell.
IL-2 concentration was analyzed using rmIL-2 enzyme-linked immunosorbent assay (ELISA) assay
system. A 100 III of capture antibody solution (2I1g/m1) was added to each well immediately after
dilution in Dulbecco's PBS. The plate was sealed and incubated overnight at room temperature. The
wells were then aspirated and washed 4 times using 300 III of wash buffer (0.05% Tween 20 in
Dulbecco's PBS), after the last wash, the plate was inverted to remove residual buffer and blotted on
paper towel. A 300111 of block buffer (1% bovine serum albumin in Dulbecco's PBS) was then added to
each well and incubated for I hr at room temperature, then aspirated and washed 4 times. A 10111 of the
released samples was added to each well in duplicate followed by 90 111 of PBS and incubated at room
temperature for another 2 hr. The wells were aspirated and washed 4 times and 100 111 of detection
antibody (0.25I1g/m1) was added to each well after dilution in diluent (0.05% Tween 20 and 0.1 % bovine
serum albumin in Dulbecco's PBS) and incubated at room temperature for 2 hr. The plate was then
aspirated and washed 4 times and 100 III ofavidin-HRP conjugate (1:2000 in diluent) was added in each
well and incubated for 30 minutes at room temperature. The plate was aspirated and washed 4 times and
100 111 of ABTS liquid substrate was added to each well and incubated at room temperature for color
development The developed color was measured at 405 nm with wave-length correction set at 650 nm
using Polarstar, Optima ELISA plate reader (BMG Scientific). The obtained optical densities were used
to detenninethe amountofIL-2 released using a calibration curve constructed with different
concentrations of IL-2 standard (0-3nglml) run at each measurement.
Total protein concentrations were detected using Pierce® BCA protein assay kit. A 5 ~I of the
released samples was added in duplicate into a microplate well and 200 ~l of BCA working reagent
[mixture of 50 parts of BCA reagent A (bicinchonic acid, Na2C03, NaHC03 and sodium tartrate in 0.1
M NaOH) and I part of BCA reagent B (4% cupper sulphate)] was added to each well and mixed
thoroughly on plate shaker for 30 second. The plate was covered and incubated at 37 °C for 30 minutes
and then left to cool to room temperature. The absorbance of each well was measured at 560 nm using
Polarstar, Optima ELISA plate reader and the amount of albumin in each sample was calculated using a
calibrationcurveconstructedwithdifferentconcentrationsofalbuminstandard(20-2000~glmI)runat
TH concentrations were analyzed by phenol-sulfuric acid method for carbohydrate assay.29 A 5 ~I of
the released samples was added in duplicate into a microplate well and 150 ~I of concentrated sulfuric
acid and 30 ~I of 5% phenol were added to each well. The plate was heated for 5 minutes at 90°C in a
water bath and then brought to room temperature for 5 min. It was then wiped dry and the absorbance
was measured at 492 nm using Polarstar, Optima plate reader.
6.2.7. CeU Line Culture and IL-2 Bioactivity Assay
The bioactivity of the released IL-2 was assessed through its ability to stimulate the proliferation of
the C57BU6 mouse cytotoxic T lymphocyte (CTLL_2).30 Proliferation of the CTLL-2 was measured
using the MIT cell proliferation assay. Using sterile cell culture flasks, the cells were cultured in
GrncO® RPMI-I640 medium supplemented with 2 mMIL glutamine, ImM sodium pyruvate, 10%
fetal bovine serum and 10% rat T-STIM with Concanavalin A in a humidified incubator in 5% CChat 37
°c. The cells were sub-cultured twice per week, before they have reached a cell density of 2xlOl
cellslml, to avoid the loss of cell viability. Before culturing into 96-well sterile culture plate, the cell was
centrifuged and re-suspended in GrnCO® RPMI-I640 medium supplemented with 2 mMIL glutamine,
ImM sodium pyruvate, 10% fetal bovine serum, 2.5 ~glml amphotercin B, and 50 gentamycin to a cell
densityoflxl06cellslml.Fromthisstockcellsuspension,100~lwastransferredintoeachweII, then, 5-
20'ii! of the standard or released IL-2 samples were added to each well in duplicate and incubated in a
humidified incubator in 5% CCh at 37°C. After 48 hrs incubation, 10 III of MIT labeling reagent was
added to each well and incubated for 4 hrs in humidified atmosphere at 37°C. The formed insoluble
formazan crystals were dissolved in 100 ~lIwell solubilization buffer (10% sodium dodecyl sulphate in
O.OIM HCI) and incubated over night and then measured spectrophotometrically at A= 544 nm with
wave length correction set at 650 nm using Polarstar, Optima ELISA plate reader.
IL-2 bioactivity results of released samples were recorded as percentage absorbance relative to
absorbanceofIL-2standardasfollows:
IL-2 bioactivity (%)= [A]/[A]sx 100
Where [A] is the absorbance difference (at 544 nm and 650 nm) for cells incubated with released IL-
2 sample and [A]s is the absorbance difference for cells incubated with equivalent IL-2 standard.
6.2.8. Scanning Electron Microscopy
Scanning electron microscope (SEM) was utilized to investigate the change in the surface of the
PDETIOO elastomer after 1L-2 release in tenns of surface pores and micro-crack fonnation. Micro-
cylinder loaded matrices of both newly fabricated and after complete release, were vacuum dried for 24
hours. The cylinders were mounted on a conductive carbon adhesive attached to aluminum stubs and
then sputter-coated with gold palladium. Gold was evapomted onto the specimen to a thickness of
approximately IS om. Samples were examined on a Hitachi model S-570 scanning electron microscope.
The microscope was interfaced with an electron backscatter diffraction (EBD) system and energy
dispersive X-ray (EDX) analytical system from Tmcor Northern. The electron gun was a tungsten
hairpintYPe filament and the sample images were digitally captured using a digital imaging system.
6.2.9. Statistics Analysis
Statistical analyses of data were perfonned using Gmphpad Prism software (version 5.02) by using
2-way ANOVA followed by the Bonferroni post-tests. Unless otherwise stated, data reported as the
mean, and the error bars in the figures represent the standard deviation (SO) about the mean, of triplicate
samples. Statistical differences between the groups were considered significant if the p value was < 0.05
unless otherwise reported.
6.3. RESULTS AND DISCUSSION
In the following discussion, the abbreviated POET will refer to poly(decane-co-tricarballylate) while the
subscripted number following this abbreviation refers to its theoretical degreeofacrylation.
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6.3.1. Elastomer Preparation and Characterization
IH_NMR analysis confirmed the purity and the chemical structure of the POET prepolymer and also
confirmed the fonnation of acryloyl moieties following the acrylation at the tenninals of the fonned
chains. The calculated degree of prepolymer acrylation as estimated via IH_NMR are listed in Table 6.1.
The charts and the full interpretation of each individual peak of the two IH_NMR spectra was reported
previously.26 Solid-state I3C_NMR spectrum of the elastomer confirmed that there is no peaks
corresponding to -CH=CH2 tenninal groups in the prepared elastomer, reported previously.27 These
observations fonn constituted evidence that the acrylated groups were fully consumed during the
photopolymerizationprocess.
The obtained photocrosslinked POET elastomers were stretchable and rubbery and swelled but did
not dissolve in most of organic solvents. The mechanical properties spanned from tough to elastic
depending on the degree ofacrylation. Figure 6.3 shows that tensile testing of the photocrosslinked
POET microcylinders produced representative uniaxial tensile stress-strain curves which are
characteristic of typical elastomeric materials. No pennanent defonnation was observed during the
mechanical testing. Average values for Young's modulus (E),u1timatetensile stress (a},cross-linking
density (p,,), and maximum strain (&) are summarized in Table 6.1. The elastomers exhibited controllable
mechanical properties. The value of a was as high as 0.44 MPa while the value of & was as high as 120.4
%, under the synthesis condition. Young's modulus values ranged between 0.73 and 0.19 MPa
Table 6.1. Mechanical properties and sol content ofpoly(decane-co-tricarballylate) elastomers.
PDETso 0.24 ± 0.05 0.39± 0.01 53.0±0.4 59.11 ±9.03 0.47
*Degree ofaery/ation estimated by NMR
PDET100
PDET75
PDET50
a.
~0.3
~
~ 0.2
60 80 100
Tensilestrain(%)
0.01"-----,------,----.-----,-------.-----.----.-----'
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Figure 6.3. Stress-strain curves of different PDET elastomeric micro-cylinders
The crosslink density (p.) was calculated according to the theory of rubber elasticity following the
equation: Px = FJ 3RT, where px represents the number of active network chain segments per unit
volume (mole I m\ E represents Young's modulus in Pascal (pa), R is the universal gas constant
(8.3144 J/mol K) and T is the absolute temperature (K). The crosslinking density changes appreciably as
afunctionofthedegreeofacrylation.Assuch,thedecreaseinthenumberofterminalacrylatedgroups
in the prepolymers resulted in a decrease in the linking anchors between the polymer chains during
photocuring which resulted in an increase in the elastomers' stretchability and elasticity.
Manipulation of elastomers' sol content was also found to depend mainly on the degree of
acrylation. The sol content represents the mass difference after removal of the un-crosslinked
prepolymer which is soluble in dichloromethane. Therefore, PDETso elastomer, with the lowest
calculated degree of acrylation (0.47), possessed the highest sol content among all the prepared
elastomers (59%). Although stretchability will strongly improve as a result ofincreasing the sol content
of the elastomer, the relatively low sol content will help in maintaining the mechanica1propertiesafter
implantation.
For the different formulation parameters effect on the IL-2 bioactivity,the relativebioactivityresults
showed that there was no statistical significant difference (p<0.05) in the obtained IL-2 bioactivity from
its incipient bioactivity in each of the formulation and analysis condition tested, over the different
THlBSA mass ratio.
6.3.2./nvitroReleaseStudies
Our main aspect of the development of this biodegradable implantable system was to provide an
extended release of an active IL-2 for an established period of time that can be easily and fittingly
controlled. IL-2 as with most pharmaceutical proteins is usually co-lyophilized withcryoprotectantsin
order to be incorporated as solid particles in the POET elastomer. For this reason, TH was used as a
cryoprotectant for maintaining IL-2 native structure during freezing and frozen storage. TH
demonstrated to be an excellent stabilizer for various recombinant protein pharmaceuticals.31 On the
otherhand,sincemostoftherapeuticproteinsdonothaveenoughosmoticactivitytoelicittherequired
osmotic mechanistic action, pore-forming agents of high osmotic activity like TH have to be used in
order to load IL-2 at high volume fraction and to ensure the complete release of the loaded protein
fraction. We also selected BSA to protect 11-2 molecules from freezing damage due to its known effect
in preventing the drop in the pH that occurs during the lyophilization in buffer as well as its role in
preventing the protein adsorption to the surface.31 Consequently, to get IL-2 loaded networks conducted
in the study, THlBSA was first co-Iyophilized with 11-2 and the obtained solid particles were dispersed
in the acrylated macromer preceding photo-crosslinking. Different geometries of these elastomeric
networks were made from three different degrees of acrylated macromers, as well; different loading
percentage ratios and different THlBSA were also prepared. The release kinetics was performed in PBS
(pH 7.4) at 37 °C for 60 days and the results as well as the impact of different variables used on the
release, as depicted in Figures 6.4-6.8, are discussed in the following sections.
6.3.2.1. Effect ofdegree ofprepolymer acrylation
InordeJ:-toinvestigatetheeffectofmanipulatingtheelastomer'sphysicochemicalproperties on the
IL-2 release profile, we examined the effect of varying the prepolymer degree ofacrylation on the
release kinetics from these elastomeric matrices. Based on the chemical structure of the POET
elastomer, it is assumed that changing the elastomer's crosslinking density would change the void
volumes between each crosslink in the elastomer and consequently alters the network's water
permeability during the release process. In order to test this, prepolymers with three different degreesof
acylation·were prepared (pOETIOO, POET,s and POETso) and loaded with the same volumetric loading
ofIL-2IBSAlTIlparticlesduringphotocuring.
Figure 6.4A shows that in the three networks prepared, an initial small burst release, which
corresponds to approximately 6-7% of the loaded IL-2 contenl, was observed within the first4 days of
IL-2 release. This burst release was followed by a phase of linear and sustained release which steadfastly
continuedWltil the release of the loaded protein was completed. This release pattem ofIL-2 can be
described typically as follows: After the immersion of the loaded devices in the release medium, water
started to diffuse into the matrix mass and subsequent osmotic-driven release started. The occurred
celerity in the release in the first 4 days can be explained by the combination of osmotic mechanism in
the outside layers of the matrix as well as emancipation of those particles located on the surface of the
device and those incorpomted in the Wl-crosslinked part (sol content) of the outer mostlayerofthe
device. This initial high release period was then followed by a period of constant but slow reiease. This
slow release mte can be attributed to the fact that the initial polymer swelling and gelling which took
place in the outermost layer of the elastomeric cylinder resulted in the formation ofa boWldary layer that
slowed down further penetmtion of water into the subsequent matrix layers with subsequent delay in
protein dissolution. In such circumstances, it is expected that deport of the solid IL-2particles from the
succesional layer to the adjacent outer layers and then to the surface of the matrix is also retarded. The
formation of such a boWldary layer and the demonstmtion that osmotic-driven release mechanism to
Figure 6.4. Cumulative percent ofIL-2 released in phosphate saline buffer from 10% v/v Loaded PDET
micro-cylinders (A) disks (B) shape specimens, with different degrees of acrylation (DA). Each point
represents the mean of triplicate experiments, and the error bars represent onestanderdeviationabout
the mean. Error bars are not shown when the standard deviation is smaller than the symbol.
place in a serial fashion towards the center of the device have been reported in our Iatest study on the
release of amaranth trisodieurn dye form PDET elastomers.27
Figure 6.4A also shows that for the microcylinders, the same release pattern was followed in all
matrices with the highest release rate achieved from the elastomer of lowest degree ofacrylation.lnthe
fIrSt four days, the release behavior from the networks of different degrees of acrylation was
comparable. Following that period, the release from the elastomers of less degree of acrylation was
faster in comparison to the release from the networks with high degree ofacrylation. Thecurnulative
release data showed a significant dependence of the release on the prepolymer degree ofacrylationand
the corresponding crosslinking density as reported in table 6.1. The release of IL-2 from PDETso was
approximately completed within 60 days of the release study. While the release from PDET71 and
PDETlOo cylinders reached 69% and 48% of the loaded IL-2, respectively. In the same manner, Figure
6.48 shows that IL-2 is released faster from the less densely crosslinked disk-shaped networks and this
is in agreement with the release pattern obtained from micro-cylinders presented in figure 6.4A. Loaded
protein was released within 6 days from PDETso networks, while the PDET7S and PDETlOo networks
released its content within approximately 10 and 20 days, respectively.
The aforementioned discrepancy in the release rate may be attributed to the fact that water diffusion
is inversely proportional to the degree of prepolymer acrylation26,27 and this is in agreement with the
water-uptake values presented in the degradation study. Decrease in the crosslinking density would
result in increasing the voidvolurnes in the elastomer which increase the possibility of faster water
diffusion through the matrix. This observation is consistent with our previously reported results
regarding the effect of degree ofacrylation on the diffusion of water into theelastomeric matrices at
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temperatures above their glass transition temperatures.26 From these results, it can be revealed that IL-2 I
release can be tuned by adjusting the crosslinking density by cbanging the chemical structure nature 0 f
these networks.
To elucidate on the constant release profile, a linear regression of the release data from the micro-
cylinders after the first 4 days until the 60 days of release and from the disks during the 60 days of
release were carried out. The linear release over this period resulting from the osmotic-driven delivery
mechanism can be described as zenHlrder release kinetics with nearly constant daily release. The linear
regressioncorrelationcoefficientwasfoundtobeequaltoO.993,O.990andO.987 for the release from
PDETso, PDETn, and PDETIOO, respectively (Table 6.2).
6.3.1.1. Effect ofthe device shape on the release
Micro-cylindrical and disk-shaped specimens were used to study the influence ofdeviceshapeand
geometry on the release of entrapped IL-2. As shown in Figure 6.5, IL-2 loaded into PDET\oo disk
samples exhibited a rapid release of approximately 97 % within 20 days while approximately only 48 %
of loaded protein was released in 60 days from the microcylinder samples with the same degree of
acrylation. On the other band, lL-2 loaded into PDETso disk samples exhibit a faster release pattern in
the first six days with approximately 97 % oftheIL-2 released, showing an extremely rapid reiease,
while the microcylinder samples foUowed a typical sustained release pattern for approximately 94 % of
theIL-2overaperiodof60days.
This disparity in the release rate was in agreement with the osmotic release theory in that the
release rate depends on the device geometry including its surface area and thickness (the length of its
Table 6.2. The regression values of 1L-2 released from POET micro-cylinders and disks shape
specimens, with different degrees ofacrylation (OA).
50%OA 0.9855 0.9927 0.9330 0.9659
75%OA 0.9814 0.9906 0.9225 0.9604
100%DA 0.9746 0.9872 0.9112 0.9546
.96700.9833 0.98650.9932
0.97790.9889 0.98330.99162
Time (days)
Figure 6.5. Cumulative percent ofIL-2 released from 10% v/v Loaded PDET elastomers with different
degree ofacrylation (DA) and different device shape. Each point represents the mean of triplicate
experiments. The error bars represent the standered deviation about the mean. Error bars are not shown
when the standard deviation is smaller than the symbol.
smallest dimension). Device's surface area represents the outer boundary of the device with the release
medium, and thereby affecting the rate and extent of the water penetration into the elastomer.Having
said that, initiating the osmotic driven release is a matter of water diffusion into the system followed by
the formation of aqueous microcapsules from the dissolved embedded IL-2 particles. The larger the
surface area of the device, the more space/surface area through which water can diffuse, the higherthe
rate and extent of water imbibitions into the device. In addition, the device's thickness represents the
length of the distance required to transport by the IL-2 molecules to release from the device. The shorter
the length of this distances, the faster the release of the dissolved protein. Consequently, IL-2 release
through a I mrn thick disk film with a surface area of 188.5 mrn2 was sufficiently faster to enable
complete release within 6 and 20 days with half and full acrylated samples, respectively. While the
release from 2 mm diameter microcylinders, with a surface area of69.1 mm2, was much slower.
The results of this release experiment demonstrated that controlled delivery for IL-2 can be
constructed from this bio-resorbable elastomer at a rate manipulated by the device shape and geometry
and determined by the body needs over a specific period of time. The IL-2 release rate could be easily
tuned as needed; for example, increase the release rate by increasing the geometrical surface area of the
prepared device, or extend the required treatment period by increasing the thickness of the device.
6.3.2.3. Effect ofloading percentage
To assess the effect of IL-2 loading percentage used on the release properties, IL-2 was co-
lyophilized with BSA and TH and loaded with a 2, 10 and 20 volumetric loading percentage. These
loading percentages were chosen to ensure that the total loading was well below the particle percolation
threshold so that osmotic pressure would remain the dominant mechanism of release throughout the
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Figure 6.6. Release data of IL-2 from different loaded percentage POET micro-cylinders with 50%
degree of acrylation, (A) represent the percentage released and (B) represent the cumulative amount of
IL-2 release. Each point represents the mean of triplicate experiments. The error bars represent standard
deviation about the mean. Error bars are not shown when the standard deviation is smaller than the
symbol.
study. While three different loading percentage microcylinders were prepared, the amount of TIIlBSA
co-lyophilized with IL-2 was fixed during the fonnulation. Figure 6.6A shows the released IL-2 versus
time profiles from POETlo micro-cylinder samples. As shown, when IL-2/excepient was incorporated at
2 % loading, IL-2 was completely released over a period of 18 days while samples loaded with 10 % and
20 % showed a release of 93 % and 49 % of the loaded IL-2, respectively, after 60 days. On the other
hand the cumulative amount of the IL-2 released, from these different loaded samples is illustrated in
Figure6.6B. The Figure shows that there are no distinct differences in the amountoflL-2 reieased per
day among all the different loading percentage, in the first 10 days of the release study. It was interesting
tonotethatalthoughtherewasaslightdifferenceinthereleaseratebetweenthe2%and20%
volumetric loadings, after the first ten days, this difference was not significant. It seems Iikelythatthe
zero-order release rate is nearly kept constant and was not affected by the volumetric loading percentage
of the IL-2. These results show that the difference in volumetric loading does not affect the effluent rate
ofIL-2 from the POET elastomer once it is below the percolation threshold.
6.3.2.4. Effect ofBSA/TH mass ratio on IL-2 release
Albumin and trehalose are extremely different in their osmotic activities; the osmolarity ofsaturated
BSA and trehalose solution in water at 37°C is 142 and 1620 mmollkg, respectively, as measured using
vapour pressure osmometer.27 Therefore, the BSAffH ratio in the loaded elastomer might considerably
affectstheexertedosmoticpressurepropertyandproteinreleaseratefromthematrix.Inthisstudy,
elastomers with different BSAffH mass ratios were prepared by keeping IL-2 mass ratio constant. The
cumulative IL-2 release profiles are shown in Figure 6.7. When BSA was used alone without trehalose
in the particles, only 19% of the IL-2 incorporated in the 100% acrylated micro-cylinders was released
during the 60 days of release at an average rate of 6.4 nglday, and approximately 33 %0fthe
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Figure 6.7. (A) and (B) are cumulative percent ofIL-2 released from PDET micro-cylinders with 100%
and 50% degree of acrylation, respectively, in existence of different molar ratio of bovine serum
albumin (BSA) and trehalose (TH). (C) The release kinetic of TH (triangles), BSA(circles) and IL-2
(squares) from PDET micro-cylinders with 100% degree of acrylation. The solid symbols are for 50%
degreeofacrylation, the hollow symbols are for 100% degree ofacrylationandthelinescorrespondto
theIL-2release.
Each point represents the mean of triplicate experiments, and the error bars represent one stander
deviation about the mean. Where error bars are not shown when the standard deviation is smaller than
the symbol.
incorporated IL-2 was released from the 50% acrylated samples at an average rate of II nglday.
However, the IL-2 release rate significantly increased by the combination of TH to the BSA in all the
prepared samples regardless of their degree of acrylation. The total mass fraction of IL-2 released over
the time frame observed increased as the trehalose content on the co-lyophiJized particles increased; for
example, complete release occurred after 54 days for IL-2 containing BSA/fH (1:4 weight ratio) from
micro-cylinders prepared with POETso. Most importantly, the release profiles of BSA and TH were
superimposed on the IL-2 release data. Figure 6.7 C shows the release profiles of BSA, IL-2 and TH
from the POETlOo microcyliders containing I: I and 1:4 BSA/fH weight ratios. The data for 1:0 and 1:2
ratios are omitted for clarity. Within the 60 days of the study, the BSA and trehalose release rate were
absolutely equivalent to the rateofIL-2 release.
These results demonstrate that the mechanism of protein release from the POET elastomer matrices
is controlled by the amountofTH loaded. It is evident that the high loading of trehalose has accelerated
the uptake of water into the elastomer matrix and generated a greater solutionosmoticactivityand
subsequently increased the release rateYo The results also reveal that the mechanism of IL-2 release
from the POET elastomer can be also controlled by varying the volumetric loading of the incorporated
osmoticexcipients.
6.3.2.5. Impact ofelastonrer degradation on IL-2 release
We have previously reported on the long-term degradation of the studies elastomers usingdog-bone-
shaped elastomeric samples in PBS.26 In that study, the elastomers were found to follow slow zero-order
degradation rate kinetics and exhibited the ability to maintain their shape and extensibility over the
studied period. Water absorption and change in weight of blank POETso and POETlOo microcylinders
over a 12 week period was further investigated in this study to assess the exact possible contributionof
degradation on the device geometry and the overall drug release mechanism. As seen in Figure 6.8, the
samples exhibited a two-stage of water absorption and weight loss behavior. In the fIrSt stage (4 weeks)
the water absorption and weight loss proceeded rapidly due to the diffuse out of the sol phase from the
samples. However, in the second stage, the water absorption and weight loss took place in a slow rate.
By the end of the study period, the average cumulative water absorption was equivalent to 68 % and 45
% in the PDETsoand PDETlOo respectively. In addition, the mean weight loss at the end of the 12 weeks
was found to be equivalent to 29 % and 14 % in micro-cylinders in the PDETso and PDETlOo
respectively. Such results confirms that matrices underwent bulk erosion, similar to what we report
previously,andtheobataineddataareinaccordancewiththefactthatwaterdiffusionandmassloss are
inversely proportional to the polymer's crosslinking density.26
The data above revealed that degradation played only a limited role in the overall release oftheIL-2
from the cylindrical devices. In addition, it is also obvious that none of the reported IL-2 release profiles
exhibited a distinct release phase that can be c1early attributed to the polymer degradation. Finally,the
structure integrity of the matrices were maintained and there was no evidence of major degradation or
loss in the geometry of the cylinders at the end of the release and degradation studies(Figure 6.9) which
is important in having the osmotic-drivenmechanism predominate the overall drug release profile.
When the elastomer degradation rate is slow enough to maintain the implant's geometry and mechanical
properties(extensionratio)duringthereleaseperiod,theosmotic-drivenmechanismwilldominatethe
linear controlled-release and polymer degradation will play only a minor role in the overall release
panem.21.27
TIme (weeks)
Figure 6.8. Percentage water absorption and weigbt remain versus time of POET elastomeric micro-
cylinders of different degrees of acrylation (OA) in PBS at 3TC. Error bars represent tbe standard
deviation oftbe mean of measurements from tbree samples.
Figure 6.9. A, B and C are scanning electron photomicrographs of blank PDET lOo microcylinders at the
end of 12 week degradation. D, E and F are scanning electron photomicrographs ofIL-2 loaded (with
BSA:TH ratio 1:4). PDET lOo microcylinders at the end of 60 days release study. A and D are
microcylinders images at 20X magnification. B and E are surface images at 2000X magnification. C and
F Cross-sectional view of the microcylinders at 2000X magnification.
6.3.3. Bioactivity ofthe Released IL-2
To characterize the bioactivity of the released IL-Z, the released supematantwas collected, frozen and
stored at -8SoC until thawing immediately prior to the bioactivity assay. The percentage of IL-Z
bioactivity was calculated by dividing the CCTL cellular proliferation response to the bioactiveprotein
in the release medium and by the maximum cellular response of an equivalent concentration of freshly
reconstituted IL-Z. The bioactivity of the recovered IL-Z in the release media are shown in Figure 6.10.
Despite achieving a zero-order release, the released IL-Z shown, for each formula, over 94% of the IL-Z
releasedinthefirstZ8daysremainedbiologicallyactiveandasthereleasecontinued,thefractionof
bioactive IL-Z started to drop in the subsequent days. As shown in Figure 6.10A, for the IL-Z embedded
in the PDETlOo formulation, the decrease of bioactivity indicated that nearly all the IL-Z released from
10adeddisk-shapedspecimenswaskeptbioactiveduringthefrrstZOdaysofthereleaseperiod.Onthe
other hand, IL-Z released from the micro cylinders specimens started to loose fraction of its bioactivity
after the frrst Z8 days of the release. As such, there was no major influence for PDET matrices device
shape and degree of acrylation as well as IL-Z loading concentration and BSAITII ratio on the
bioactivities of IL-Z recovered in the release media. Although IL-Z release from PDETso showed more
decrease in its bioactivity compared to that released from PDETn and PDET lOo• devices, nonetheless,
this difference was not statistically significant.
KeepingthenativebioactivityofthereleasedlL-Zisconsideredthemainkeyforthesuccessofits
delivery system for potential therapeutic application. Having said that, a numerous approaches have
gone into the achievements of that but most of them have been associated with limited success in
keeping it bioactive enough for the clinical setting. Despite the observed reduction in the IL-Z
bioactivity after the first month of the release from our elastomeric rnatrices, these bioactivityresults
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Figure 6.10. Bioactivity profiles ofIL-2 released from PDET with Different, (A) shape ofreleasing
device (B) degree of acrylation (c) loading % (D) different weight ratio ofBSA and TH. Each point
represents the mean oftriplicateexperirnents. The error bars represent the siandereddeviationaboutthe
represent an improvement over the previously published results provided with aquantitativeanalysisof
the actual percentage ofbioactive IL-2 released during the study. Using a prepared poly(lactic acid)
(pLA) naospheres. Sharma et al., was able to control the release of IL-2 for 30 days with only
maintaining 40% of the post-release bioactivity.32 Inasimilarapproach,Egilmezetal.,also loadedIL-2
into PLA nanospheres that showed total IL-2 release process lasted for 7 days and the composite
bioactivity of all IL-2 released was approximately 50%.33 Thomas etal., using apreparedpoly(lactide-
co-glycolide) (pLG)(50/50) by the double emulsion (DE) and single emulsion (SE) methods
demonstrated the IL-2 sustained release ability over a period of almost 30 days. The bioactivity of IL-2
released from microspheres prepared by DE was around 80% for the first 5 days, and then rapidly
dropped to less than 40% by day 10. On the other hand, the bioactivity of IL-2 released from
microspheresprepared by SEwas around 85% for the first 4 days, and then rapidly dropped to less than
50% by day 7.34 Rhinesetal., encapulated IL-2 ingelatin-chondroitin-6-sulphatebasedmicrospheres.
The study revealed that the release profile was characterized with a rapid release rate (almost 80%)
within the first 7 days followed by avery slower release over a total period of approximately52 days.3s
The in vitro bioassay studies conducted by the same team in a previous study using the same
formulation approach demonstrated that IL-2 retained only a total of approximately 50% of its original
bioactivity over a total releaseperiodof2 weeks.36 In our elastomers, IL-2 bioactivity was greatly
maintained by the using the solventiess formulation strategy and visible light photocuring which are
protein and peptide friendly condition. In addition to using the osmotic pressure driven release which
allow/or IL-2 release before significant POET elastomer bulk hydrolytic degradation occurred.
6.3.4. Scanning Electron Microscopy
In order to further investigate and demonstrate the proposed theory of the osmotic-driven release
mechanism, the changes in the surface architecture of the loaded cylinder before and after the release
was.examined. Figure 9 (A, B and C) shows the SEM micrographs of the POETlIJo micro-cylinder, taken
after the conductance of the 12 weeks degradation study in PBS. It can be seen that, in the dry state, the
integrity of the microcylider was maintained. In addition, it exhibited a quite uniform surface and a
nonporous smooth crossectionview that revealed absence of any visible pore throughout the matrix,
when 2000 x magnification was used. Figure 10 (0, E and F), on the other hand, shows the SEM
micrographs of the IL-2 with BSAITII (weight ratio 1:2) loaded POETlIJo microcylinder, taken after the
conduction of release studies. As shown, after the 60 days release study, the images showed evident
cracks and pores in the range ofl to 15 jUIl on the surface corresponding to the routes the IL-2 took for
release. In the same manner, the cross section photomicrograph showed a formed channel owing to the
release process in concordance with the proposed osmotic-drivenreleased mechanism.
6.4. CONCLUSIONS
This study explored the potential of monolithic, photocrosslinked POET matrices as implantable
delivery system for protein and peptide based drug. An IL-2 loading up to 20% was incorporated in the
matrix with the utilization of visible light crosslinking and without using additional organic solvent.IL-2
release results shown that the release can be controlled through osmotic pressure of the core by adjusting
the TIl mass incorporated, shape of the formulated device, and degree of POET prepolymer acrylation.
At the same time the release was at a rate to be fairly independent of loaded IL-2 percentage. These
matrices can release slow, steady dose ofIL-2 over extended period with keeping the native bioactivity
after the release, that represent an improvement over the previously published study from any type of
formulation. The control release, biocompatibiJity and slow degradation properties of these elastomers
combine to make it an attraetive candidate for use in the preparation of implantable devices to provide
deliveryofa biological cargo for therapeutic protein with different molecular weights and physical
properties andlortemporarymechanical support for tissue regeneration without the need forsurgical
rem&viB%procedures.
6.5. REFERENCES
1- Morgan DA, Ruscetti FW, Gallo R. 1976. Selective in vitro growth ofT lymphocytes from
normal human bone marrows. Science 193: 1007-1008.
2- SmithKA. 1988. Interleukin-2: inception, impacl, and implications. Science 240: 1169-1176.
3- Radny P, Caroli UM, Bauer J, Paul T, Schlegel C, Eigentler TK, Weide B, Schwartz M,
Garbe C. 2003. Phase II trial of Intralesional therapy with interleukin-2 in soft tissue
melanoma metastases. Br J Cancer 89: 1620-1626.
4- Sosman JA, Kohler PC, and Hank J, Moore KH, Bechhofer R, Storer B, Sondel PM. 1988.
Repetitive weekly cycles of recombinant human interleukin- 2: Responses of renal carcinoma
with acceptable toxicity. JNatl CancerInst 80: 60-63.
5- Bubenik J, Mikyskova R, VoDka V, Mendoza L, Simova J, Smahel M, Indrova M. 2003.
Interleukin-2 and dendritic cells as adjuvants for surgical therapy of tumours associated with
humanpapillomavirustypeI6.Vaccine21:891-896.
6- Mikyskova R, Indrova M, Simova J, Jandlova T, Bieblova J, Jinoch P, Bubenik J, VoDka V.
2004. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying
HPVI6-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF. Int J Oncol
24:161-167.
7- Lotze MT, Matory YL, Rayner AA, Ettinghausen SE, Vello JT, Seipp CA, Rosenberg SA.
1986. Clinical effects and toxicity ofinterleukin-2 in patients with cancer. Cancer 58: 2764-
2772.
8- Den Otter W, Jacobs JJ, Battennann JJ, Hordijk OJ, Krastev Z, Moiseeva EV, Stewart RJ,
Ziekman PG, Koten JW. 2008. Local therapy of cancer with free IL-2. Cancer Immunol
Immunother57:931-50.
9- Thatcher N, Dazzi H, Johnson RJ, Russell S, Ghosh AI(, Moore M, Chadwick G, Craig RD.
1989. Recombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for
advanced malignant melanoma. A phase I and II study. BrJCancer60: 770-774.
10-Robb RJ, Kutny RM, Panico M, Morris HR, and Chowdhry V. 1984. Amino acid sequence
and post-translational modification of human interleukin 2. Proc Natl Acad Sci USA 81:
6486-6490.
11- Liang SM, Thatcher DR, Liang CM, AIIet B. 1986. Studies of Structure-Activity
Relationships of Human Interleukin-2. J BioI Chem 261: 334-337.
12-Gounili P. 1999. PhD Thesis: The effect of pH and temperature on the conformational
~ ~. stability of recombinant human interleukin-2. University of Connecticut, USA.
13- Johnston D, Reynolds SR, Bystryn JC. 2006. Interleukin-2IIiposomes potentiate immune
responses to a soluble protein cancer vaccine in mice. Cancer Immunol Immunother 55: 412-
419.
14-Qiao M, Chen D, Hao T, Zhao X, Hu H, Ma X. 2008. Injectable thennosensitive PLGA-
PEG-PLGA triblock copolymers-based hydrogels as carriers for interleukin-2. Phannazie 63:
27-30.
15- Rhines LD, Sampath P, Di-Meco F, Lawson HC, Tyler BM, Hanes J, Olivi A, Brem H. 2003.
Local immunotherapy with interleukin-2 delivered from biodegradable polymer
microspheres combined with interstitial chemotherapy: a novel treatment for experimental
malignant glioma Neurosurgery 52: 872-879.
16-Hsu W, Lesniak MS, Tyler B, Brem H. 2005. Local delivery ofinterleukin-2 and adriamycin
is synergistic in the treatment ofexperimental malignant glioma JNeurooncol 74: 135-140.
17- Samlowski WE, McGregor JR, Jurek M, Baudys M, Zentner GM, Fowers KD. 2006. ReGel
polymer-based delivery of interleukin-2 as a cancer treatment. J Immunother 29: 524-535.
18-Chan YP, Meyrueix R, KravtzoffR, Nicolas F, Lundstrom K. 2007. Review on Medusa: a
polymer-based sustained release technology for protein and peptide drugs. Expert Opin Drug
Deliv4:441-451.
19-5haker M, Younes HM. 2009. Interleukin-2: Evaluation of Routes of Administration and
Current Delivery Systems in Cancer Therapy. J Phann Science 98: 2268-2298.
20-Gu F, Younes HM, El-Kadi AO, Neufeld RJ, Amsden BG. 2005. Sustained interferon-
gamma delivery from a photocrosslinked biodegradable elastomer. J Control Rei 102: 607-
617.
21- Gu F, Neufeld R, Amsden B. 2007. Sustained release ofbioactive therapeutic proteins from a
biodegradable elastomeric device. J Control Release 117:80-89.
22- Younes H M: 2003. New biodegradable elastomers for interferon-gamma delivery, PhD
Thesis, Faculty ofPharmacy, University ofAlberta, Edmonton, AB.
23- Younes H M, Ellaboudy H, Shaker M A. Biodegradable elastomers prepared by the
condensation of an organic di-, tri-ortetra-carboxylic acid and an organic diol. International
PatentNo.I4488IAI,2008
24-Chapanian R, Amsden BG. 2010. Combined and sequential delivery ofbioactive VEGFI65
and HGF from poly(trimethylene carbonate) based photo-cross-linked elastomers. J Control
Release 143:53-63.
25-Glenn FV, Rex MT. 1995. OVA radiation-induced oxidative damage to lipids and proteins in
vitro and in human skin fibroblasts is dependent on iron and singlet oxygen. Free Radic Bioi
-. Med 18: 721-730.
26- Shaker MA, Dore JE, Younes HM. 2010. Synthesis, characterization and cytocompatibility
of poly(diol-tricarballylate) visible light photocrosslinked biodegradable elastomer. J.
Biomater Sci Polym Ed 21: 507-528.
27-Shaker M, Younes HM. 2010. Osmotic-Driven Release of Papaverine Hydrochloride from
Novel Biodegradable Poly(Decane-co-tricarbailylate) Elastomeric Matrices. Therapeutic
Delivery 1:37-50.
28-Shaker M, Daneshtalab N, Dore J, Younes HM. In vitro Cytotoxicity, In vivo
Biocompatibility and Biodegradability of Photocrosslinked Poly(Decane-co-Tricarballylate)
Elastomers. Journal of Bioactive and Compatible Polymers (accepted April 2011).
29- Masuko T , Minami A , Iwasaki N , Majima T , Nishimura S , Lee YC. 2005. Carbohydrate
analysis by a phenol-sulfuric acid method in microplate format. Analytical Biochemistry 339:
69-72.
30- Lyanne Weston, Andrew Geczy and Caroline Farrell. 1998. A convenient and reliable lL-2
bioassay using frozen CTLL-2 to improve the detection of helper T lymphocyte precursors.
ImmunologyandCellBiology76:19Q-192.
31-Wei Wang. 2000. Lyophilizationanddevelopmentofsolidproteinpharmaceuticals
International Journal of Pharmaceutics 203:1-60.
32- Sharma A, Harper CM, Hammer L, Nair RE, Mathiowitz E, Egilmez NK. 2004.
Characterizationofcytokine encapsulated controlled-releasemicrosphere adjuvants. Cancer
BiotherRadioI19:764-769.
33-Egilmez NK, Jong YS ,Iwanuma Y ,Jacob JS ,Santos CA, Chen FA, Mathiowitz E,
Bankert RB. 1998. Cytokine immunotherapy of cancer with controlled release biodegradable
microspheres in a human tumor xenograft/SCID mouse model. Cancer Immunollmmunother
46:21-24.
34- Thomas IT, Kohane OS, Wang A, Langer R. 2004. Mircoparticlulate formulations for the
controlled release ofinterleukin-2. J Pharm Sci 93: 1100-1109.
35- Rhines LO, Sampath P, Di-Meco F, Lawson HC, Tyler BM, Hanes J, Olivi A, Brem H. 2003.
Local immunotherapy with interleukin-2 delivered from biodegradable polymer
microspheres combined with interstitial chemotherapy: a novel treatment for experimental
malignant glioma Neurosurgery 52: 872-879.
36- Hanes J, Sills A, Zhao Z, Sub KW, Tyler B, DiMeco F, Brat OJ, Choti MA, Leong KW,
Pardoll OM, Brem H. 2001. Controlled local delivery of interleukin-2 by biodegradable
polymers protects animals from experimental brain tumors and liver tumors. Pharm Res 18:
899-906.
CHAPTER 7
General Discussion and Conclusions
In the past years as the number of people who diagnosed with cancer increased, with the
understanding of cytokines as a cancer immunotherapy, an extensive research has focused on the
development of drug delivery systems capable of achieving sustained and localized deliveryofIL-2.
Therefore, Chapter I of the thesis introduces the current status ofinterleukine-2 therapy with more
evaluation of the different routes of administration and formulation approaches utilizedforthedelivery
from two perspectives. The first included an assessment of the most efficient strategies used to deliver
IL-2 in a non-toxic, efficient, stable and safe manner. The second introduce the advantages and the
limitation of each of the current used delivery systems for this cytokines. It was shown, in chapter I, that
in most of the cancer immunotherapy cases it is desirable to have a site specific and continuousdelivery
ofIL-2inthevicinityoftheturnoursiteisadesirablemodeofdeliveryasitcloselyreflects the cytokine
natural release pattem and results ina more effective treatment with fewer side effects.Itisalsoindicted
that long-acting formulations such as PEGylation and protein fusion techniques, prolongs IL-2 action
but do not adapt with IL-2 localization concept.
Although an extensive research has been focused on the development of drug delivery systems
capable of achieving sustained and localized delivery oflL-2, keeping the native bioactivityis
considered the main key for the success of its delivery system for potential therapeuticapplication.Such
delivery systems include but not restricted to the use of liposomes, hydrogels, polymeric
microsphereslnanospheres, thermo responsive synthetic polymers (ReGel~, and injectable polymeric
con~led-release systems (Medusa II~. Of the examined release strategies, biodegradable polymeric
vehicles would be able to circumvent the problems associated with short-term stability of liposomes and
other simiJer. delivery systems. However the use of conventional degradable polymer such as
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poly(lactide-co-glycolide),have been demonstrated to change the tertiary structure and subsequentlythe
biological activity of protein drugs before they are released from the delivery systems. Controllingthe
microclimate pH of the delivery system and avoiding the use of organic solvents inthe preparation and
drug loading steps are among the biggest challenges that are faced to stabilize IL-2 in any biodegradable
pol~e~c carrier. Therefore, an area of future investigation is the investigation of novel biomaterials,
able to keep the stability and bioactivity of therapeutic proteins by utilizing solvent-free drug loading
and more protein friendly crosslinking techniques to overcome the limitations associated with the
preparation and useofUV photo-crosslinking in the star-poly(e-caprolactone co D,L-lactide).
Basically,biomaterials are synthetic substances contained in therapeutic or medical devices that are
in contact with biological tissue or fluids. Typically these materials involve the use of synthetic
polymers, at least in part. Biodegradable polyesters have significant potential for biomedical
applications including tissue engineering, drug delivery, and biosensors. The most commonly used
materialsfortheseapplicationshavebeenpolylacticacid,polyglycolicacid,poly-e-caprolactoneand
their copolymers. Many medical devices are implanted in dynamic environment of the body, which
require elastomeric materials that will respond to these stresses. The material must be soft and resilient
to Dlll'llIIl'uze' irritation of surrounding tissue, and have mechanical properties similar to the surrounding
tissue. Furthermore, biodegradable materials can be especially advantageous when only temporary
mechanical support is needed with the controlled released purpose. Photopolymerization techniques,
which have been used to prepare biodegradable drug delivery carriers for various biomedical
applications such ashydrogels, have been also utilized recently to preparephotoset elastomers. This
approach involved the preparation of prepolymers with various photosensitive termini which in the
presern:erofthe proper photoinatiator can undergo free radical polymerization once exposed to a
suitable light source. This photopolymerization approach would offer a number of advantages over the
~J
conventional techniques in preparing biomaterials. Firstly, the spatial and temporal control is easily
achievedduringthephotopolymerizationprocess. Through controlling the exposure area and the time of
light incidence, precise control of polymerization can be achieved. Secondly,photopolymerizationcan
take place very rapidly at room temperature, in a matter of few seconds to minutes. Thirdly, the process
can be conducted at a temperature and pH that resemble the physiological ranges during fabrication
which allows easy and rapid production of complex matrix devices. In addition to the above, the
bio~~tc;t2.als can be created in situ in a minimally invasive manner. Fabrication of polymers in situ is
attractive for a variety of biomedical applications because it allows one to form complex shapes that
adhere and conform to tissue structures. Consequently, the utilization of photopolymerized polymer
networks has been suggested in drug delivery system and other biomedical application.
Chapter 3 reported on the synthesis, characterization and in vitrocytocompatibility ofa new family
ofphotocrosslinked amorphouspoly(diol-tricarballylate) (pOl) biodegradable elastomericpolyesters.ln
these elastomeric biomaterials, we demonstrated the preparation of a new family of polymers which are
crosslinked at room temperature using visible light photopolymerization technique. The synthesis was
based on the polycondensationreaction betweentricarballylic acid and alkylene diols, followed by
acrylation. The prepared and acrylated poly(diol-tricarballylate) (APDl) was characterized by means of
IT-IR, IH_ NMR, GPC and DSC. Liquid to solid photo-curing were carried out by exposing the APDT
to visible light in the presence of camphorquinone as a photoinitiator. The thermal properties,
mechanical characteristics, the sol content, long-term in vitro degradation and cytocompatibilityofthe
prepared PDT elastomers were also reported. The results have shown that the physical properties of
these elastomers can be controlled through manipulations of the chain length of the used diol and the
degree of polymer acrylation. All the obtained elastomers were rubbery and their mechanical properties
ranged from hard brittle to very week and elastic and their Young's modulus, the ultimate tensile
strength and % strain, depended on the degree ofacrylationand the length of the diol chain used.As
well,the sol content of the prepared elastomers significantly depended on the degree ofacrylation. The
mechanical and degradation properties of this newphotocurable elastomer can be preciseIycontrolled
by varying the density of acrylate moieties in the matrix of the polymer, and through changes in the
prepolymer chain length. Additionally, we demonstrated the in vitro degradation of poly(diol-
tricarballylate) elastomers. All the elastomers underwent bulk erosion similar to that of the previously
investigated biodegradable polyester elastomers. A linear decrease was observed in the Young's
modulus and the ultimate stress with time that was also accompanied with an increase in water
ab5.9!Jlt!!!!t and weight loss. The PDT networks degraded relatively slowly after a period of 12 weeks
with no appreciable dimension changes.
The use of visible light crosslinking, possibility of solvent free drug loading, the controllable
mechanical properties and cytocompatibility of these new elastomers make them excellent candidates
for use in controlled implantable drug delivery systems of protein drugs and other biomedical
applications. Solid particles of such drugs can be mixed with the pureacrylated prepolymers which are
then rapidly crosslinked using visible light at room temperature to be formulated as drug delivery
systems (implants ormicrospheres) that will undergo biodegradation in the body.
Inchapter4,the osmotic-driven-controlledrelease of the water soluble drug, papaverinehydrochloride
(PH), from poly(decane-co-tricarballylate) elastomeric cylindrical monoliths is reported. A 10% v/v PH
mixed PH micronized powder and acrylated PDET macromers of varying degrees of acrylation (100%,
75% and 50%). We also exarnined the influence of various parameters such as the crosslinking density
loaded cylinder-shaped matrices were prepared by visible-lightphotocrosslinking of the intimately
andtheincorporationofosmoticexcipientsliketrehaloseonthereleasekineticsofthedrug.To assess
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the contribution of the osmotic-driven release mechanism, the loaded elastomeric devices were
subjected to long term release studies using vials filled with release media of different osmotic
activities. The release rate of papaverine hydrochloride was found to decrease in dissolution media of
higher osmotic activity as an indication of the predominant involvement of the osmotic-driven release
mechanism from the elastomeric devices. The PH release rate was also found to be dependent on the
degree ofPDET macromers acrylation. Decreasing the degree of acrylation of the prepolymers resulted
in reduction in the crosslinking density of the formed elastomeric matrices which was associated with
and increase in the void volumes between crosslinks in the elastomer. This has possibly resulted in an
increase in the polymer pores size and also increased the inter-connected networks and channels
between the encapsulated drug particles in the elastomer. Furthermore, it was found that co-formulating
papaverine hydrochloride with trehalose increases the release rate without altering the linear nature of
the drug release kinetics. These results indicated the great potential of using these elastomers for
controlled drug release, through changing the structure nature of the matrix as well as increase the
osmotic activity of the loaded drug.
Inchapter5,we reported on the results of the cytotoxicity,biocompatibilityandbiodegradabilityof
PDET elastomers, of varying crosslinking densities were synthesized and cytotoxicity of PDET extracts
of the elastomers were assessed for mitochondrial succinate dehydrogenase activity by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MIT assay) and inhibition of eHJthymidine
incorporation into DNA of epithelial cells. We have demonstrated that PDET elastomers, with different
degreesofacrylation, showed promising cytotoxicity results with MvlLu cells and receivedreasonably
consistent results between the two common cell viability assays (MIT and thymidine incorporation).
The treated epithelial cells revealed no signs of cytotoxicity and the elastomers degradation products
caused a slight stimulation to both mitochondrial activity and DNA replication. To assess in vivo
biocompatibility and biodegradability, subcutaneous implantation of PDET micro-cylinders was
undertaken in twenty five male Sprague-Dawley rats over a period of 12 weeks. Biodegradable
poly(lacti\l-co-glycolicacid) sutures served as controls. The in vivo changes in physical and mechanical
parameters of implants were compared to those observed in vitro. The implantation results showed that
no macroscopic signs of inflammation or adverse tissue reactions were observed at implant retrieval
sites. We ha-;;'ili~wn in vivo justification to confirm the potential of these elastomers as soft-tissue
friendly materials as well as the candidacy of these elastomers as biodegradable biomaterialsonlong
run. We have also demonstrated that PDET elastomers, with different degrees of acrylation degrade at
different rates within the body and therefore elastomer selection can be tailored to achievethedesired
implantation period and release rates. Moreover, the retrieved implanted micro-cylinders were found to
maintain their original geometry and extensibility in a manner similar to those observed in vitro. All the
collected data are enabling properties for PDET elastomers, which make them potentially suitable as a
developed resorbable matrix for medical devices use in long-term pharmaceuticals delivery. The
findings confirmed that these new elastomers have good biocompatibility and are expected to be useful
as biodegradable and biocompatible biomaterials for controlled drug delivery and tissue engineering
applications.
In chapter 6, poly(decane-co-tricarballylate) [pDET] matrices which utilize the osmotic-driven-
controlled release mechanism were designed in an attempt to overcome these stability and bioactivity
challenges facing IL-2 delivery. IL-210adedmicro-cylinderanddisk-shapedelastomerswereprepared
by intimately mixing lyophilized IL-2 powder with the acrylated prepolymer prior to photocrosslinking.
IL-2 release was analyzed using IL-2 enzyme-linked immunosorbent assay method and the in vitro
bioactivity of released IL-2 was assessed using C57BU6 mouse cytotoxic T lymphocyte. The influence
of various parameters such as the elastomercrosslinkingdensity,the volumetric loading percentageand
the incorporation of osmotic excipientslike trehalose on the release kinetics of the drug was also
examined. The disk-shaped specimens showed faster controlled 11-2 release profiles than
microcylinders, withdrugreleaseproceedingviatypicalzero-orderreleasekinetics. The increase in the
deviCC::ssurfaceareaandtheincorporationoftrehaloseintheloadedlyophilizedmixincreasedtheIL-2
release rate. As well, it was shown that the decrease in the degree of prepolymer acrylation of the
prepared devices increased the IL-2 release rate. Cell based bioactivity assay for IL-2 over a release
periodof28 days showed that the released IL-2 retained more than 94% of its initial activity.
Promising results regardingosmotic-driven controlled 11-2 release have been demonstrated using
novel PDET biodegradable elastomers. An area of future investigation is the use of these elastomers to
formulate and deliver other therapeutic protein drugs (ex.Endostatin) in a stable, efficient and active
manner benefiting from the protein friendly preparation and crosslinking environment that would avoid
the drawbacks of using harsh preparation and crosslinking conditions like organic solvents 0 rUVphoto-
polymerization.
As mentioned before, the reported biodegradable elastomers in the literature have been synthesized
as either thermoplastic·-) or thermoset elastomersH . The undesirable heterogenous degradation of
thermoplastics restrictaed their uses for biomedical purposes particularly in the drug delivery
applications. One of the common approaches reported earlier to prepare thermoset elastomers is to first
prepare multi-arm star condensation polymers by subjecting biodegradable monomers to ring opening
polymerization in the presence of polyols as initiators. Some of the most common biodegradable
monomers used in that approach included lactides,&-caprolactone, g1ycolides, 5-valerolactone, urethane,
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para-dioxanone, dioexepanone and trimethylene carbonate. The most commonly used polyol initiators
included glycerol, lauryl alcohol, pentaerytbritol, and inositoI.2.6-IO The prepared star shaped
condensation polymers were then crosslinked using thermal or non-thermal approaches.4,11
Although the elastomers made ofE-caprolactone and dl-lactide polymers can be described as
absorbable, they have hydrophobic character that contributes to their Iongand slow bioabsorptionand
decreased biocompatibility. It is known that highly hydrophobic polymer surfaces have very high
contact angles with water and are more susceptible to protein adsorption. 12-14 0n the other hand the
acrylated UV crosslinked version of the sarne reported polymers involved the use oforganicsolvents
liketetrabydrofuran and dicbloromethane to incorporate the drug into the precrosslinked mass. This
iss_raises theconcem with regard to compatibility and even stability of loaded bioactiveagents. IS
Finally, the steps involved in preparing the above elastomers require higher heat and takesatleast3days
to obtain the final preparation.6•16
Another approach to prepare elastomeric polymers was also reported through polycondensation
reactions between di- and tricarboxylic acids and diols which were further subjected to thermal
crosslinking. Elastomers based on citric acid, tartaric acid, and sehacic acid monomers were reported
earlier. 17-21 These elastomers either required long curing times ranging from a few days to weeks with
inconsistency in the final physical and mechanical properties or the elastomers prepared were tough and
brittle. Inaddition,highcrosslinkingtemperatureswereneededfortheircrosslinkingwhichrestricted
their use in drug delivery of thermally sensitive therapeutic agents and other heat sensitivedrugs. There
remains a need for bioabsorbable and biocompatible elastomeric polymers. Accordingly, the reported
PDT elastomers possessed few advantages over the reported biodegradable elastomers in the literature,
which possibly make them good candidates for controlled drug and therapeutic protein delivery
applications. First, the polymers are degradable by bulk hydrolysis of the ester bonds and none of their
building blocks are toxic. Second,alteringthe chain length of the aikylenediol can vary the hydrophilic
and hydrophobic properties of the elastomers. Differentdegreesofacrylationdegradeatdifferentrates
within the body and release the loaded drug at different rate, thus, the elastomers can be tailoredto
satisfy a particular purpose. Third, bioactivity of the loaded IL-2 was greatly maintained by using
solvent-free formulation strategy and protein and peptide friendlyphotocuring condition. In addition to
using the osmotic pressure driven release which allows for IL-2 release before significant PDET
elastomer bulk hydrolytic degradation occurred.
Moreover, we put also more emphasis here on the usage of visible light photopolymerization rather
than UV photocuring. Visible light is much less destructive to the protein drugs and other material
compared to UV. The polymerization conditions are also sufficiently mild to be carried out in the
presence of other biological materials. (e.g., for encapsulation of cells and proteins,indrugscreening,or
in biosensing applications). Visible light penetrates deeper through tissuesthanUVlight(lessscattering
and less absorption). 1bis property may limit the need for invasive surgical proceduresbyallowing
trans-tissue polymerizations, whereby the material is injected subcutaneously or even subdermally and
irradiated through the skin to polymerize the material in situ. Much efficient photocrosslinking is
achieved upon using visible light. Most polymeric materials absorb the UV light, which hampers the
penetrationofUVlightintothedeepersurfaceregionoroftenresultsinnobondingbetweenphoto-
cured polymers and the surface if the coated layer is thick. Inaddition,aprocedureinvolving UV light
irradiation through the external side of the prepared device is not applicable because UV light is
completely adsorbed by the external surface before it reaches the intemal surface to be modified.In
other words, visible light can pass through even thick transparent polymeric material. Finally, UV has a
strong chemical action against the human body and causes danger at work. In addition, UV ray
apparatus must have facilities such as a specialized power supply and exhausting duct. This will require
much cost and make the scale of the facilities bigger and high cost of production. Visible light
photopolymerization is safer and uses simpler light source (easier to use).
In addition, the bioactivity results obtained from PDET elastmer represent an improvement over the
previously published polymers provided with a quantitative analysis of the actual percentage of
bioactive IL-2 released during the study. Using a prepared poly(1actic acid) (PLA) nanospheresresulted
in controlling the release ofIL-2 for 30 days with maintaining only 40% of the post-release bioactivity.22
In a similar approach, loaded IL-2 into PLA nanospheres that showed total IL-2 release process lasted
for 7 days and the composite bioactivity of the released IL-2 was approximately 50%.23 Using a
prepared PLG (50/50) by DE and SE methods demonstrated the IL-2 sustained release ability over a
perio<!. of_almost 30 days. The bioactivity of IL-2 released from microspheres prepared by DE was
around80%forthefust5days,andthenrapidlydroppedtolessthan40%bydayI0.Ontheotherhand,
the bioactivity of IL-2 released from microspheres prepared by SE was around 85% for the first 4 days,
and then r3pi(lIf(Iropped to less than 50% by day 7.24 Another research group encapulated IL-2 in
gelatin-chondroitin-6-sulphate based microspheres. The study revealed that the release profile was
characterized with a rapid release rate (almost 80%) within the fust 7 days followed by a very slower
release over a total period of approximately 52 days.2 l The in vitro bioassay studies conducted by the
same team in a previous study using the same formulation approach demonstrated that IL-2 retained
only a total of approximately 50% of its original bioactivity over a total release period of 2weeks.26
Another promising perspective for these elastomers is their use as a new carrier to deliver
J)NA/siRNA into targeted cells in therapy of cancer or genetic diseases. The DNA can be incorporated
with a chemically surface modified acrylated prepolymer which possess a targeting moiety and
photocuredto fonn nanospheres that can effectively target and enter the cell and degradeviahydrolytic
cleavage of the back bone ester group. Nonetheless, the proposed application requires efficient and
reliable in vilro testing of DNA activity and binding ability, nanospheres intracellularuptake and finally,
the in vivo protein expression forexarnining the transfer of genes to target cell or tumor model. These
elastomer-based new vectors can offer a new incitation to gene therapy because they are less toxic than
viral vectors and possess many previously discussed advantages (no endogenous recombination,fewer
or no immunological reactions, easy production, and delivery oflarge-sizedplasmid).
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